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Summary 
Pulmonary hypertension (PHT) is a chronic and progressive condition, which can 
result in right ventricular failure, and, eventually death. There are two main 
categories of PHT: primary and secondary PHT. Primary PHT is idiopathic in origin, 
however, recent studies have suggested a genetic basis for the condition. Secondary 
PHT occurs as a result of pre-existing lung or heart disease, such as chronic 
obstructive pulmonary disease or chronic heart failure due to left ventricular 
dysfunction. PHT, regardless of aetiology, is resistant to commonly used 
antihypertensive therapies which successfully manage systemic hypertension. This 
lack of therapeutic effect of existing treatments results from the differences between 
the pulmonary and systemic circulations. These variations account for the differences 
in mean arterial pressures, total peripheral resistances, and responses to hypoxia 
observed in the pulmonary and systemic resistances. Investigation into the unique 
properties of pulmonary arteries could provide the focus for novel antihypertensive 
treatments which would be therapeutically beneficial in the pulmonary circulation 
without causing hypotension of the systemic circulation. As the pulmonary resistance 
arteries (PRAs) are the primary site of increased peripheral resistance through 
vascular remodelling, these are the vessels studied throughout this thesis using the 
small vessel technique of wire myography. Therefore, this thesis investigates the 
response to, the receptors mediating, and signalling pathways involved in the effect of 
various endogenous vasoactive substances found in the pulmonary circulation in the 
PRAs of various species using an in vitro pharmacological approach, and also 
investigated whether these parameters change in the presence of secondary PHT of 
different aetiologies. 
xiv 
The vasodilator response to acetylcholine (ACh) was investigated in the hypobaric 
chronic hypoxic rat model of secondary PHT. The maximum vasodilator response to 
ACh was significantly increased in the PRAs of chronic hypoxic rats when compared 
to normoxic control rats. The presence of hypoxia-induced PHT influenced the 
mediator profile responsible for the ACh-induced vasodilatation. In control rat PRAs, 
the ACh-induced vasodilator response appears to be mediated by endothelium-derived 
hyperpolarising factor (EDHF) via small and large Ca2+-activated K+ channels (SKca 
and BKca, respectively). In chronic hypoxic rat PRAs, the ACh-induced 
vasodilatation was mediated by nitric oxide (NO), prostacyclin (PGh), and EDHF. 
However, the involvement of EDHF in the ACh-induced vasodilator response 
requires confirmation through the use of electrophysiology. 
The novel vasoconstrictor peptide human urotensin-II (hU-II) was shown to only 
elicit vasoconstriction in 30% of human PRAs in the presence of the NO synthase 
(NOS) inhibitor, L-NAME. However, hU-II was revealed as a vasodilator of human 
pulmonary and systemic resistance arteries (SRAs) which was equipotent with 
another potent endogenous vasodilator peptide, adrenomedullin. The hU-II-induced 
vasodilatation was shown to be mediated by PGh and EDHF via BKca and SKca 
channels. Again, the involvement ofEDHF in the hU-II-induced vasodilator response 
awaits confirmation through electrophysiological studies. 
The in vivo and in vitro response to endothelin-1 (ET -1) was investigated in the PRAs 
of patients with different severities of left ventricular dysfunction (L VD), using PRAs 
from patients undergoing lung resection for bronchial carcinoma as controls. The 
L VD patients groups were classified according to their ejection fraction, as assessed 
xv 
by echocardiographic assessment. The patients were divided into the following 
groups: an ejection fraction (EF) of >40% = good L VD; an EF of 30-40% = moderate 
L VD; and an EF of <30% = poor L YD. The in vivo experiments (which were not 
conducted by myself) showed a significant increase in the baseline measurement of 
pulmonary vascular resistance (PVR) between the good and poor groups, 
demonstrating the development of PHT as a consequence of severe L VD. The in 
vitro experiments revealed no significant increase in the potency of, or maximum 
contractile response to, ET -1 as the severity of L VD progressed. Three novel mixed 
ET,JET B antagonists significantly decreased the potency of, and attenuated the 
maximum contractile response to, ET -1 in all patient groups. Therefore, the mixed 
ETAIET B antagonists could prove to be therapeutically beneficial in the treatment of 
PHT secondary to chronic heart failure. 
The response to ET -1 was investigated in the presence and absence of three novel 
mixed ETAIET B antagonists in the hypobaric chronic hypoxic rat model. The 
maximum contractile response to, and potency of, ET -1 was significantly increased in 
the PRAs from the chronic hypoxic rat when compared to control rat PRAs. 
The three mixed ET,JET B antagonists significantly decreased the potency of ET -1 in 
the chronic hypoxic rat PRAs, but had no effect on control rat PRAs. Therefore, the 
mixed ETAIET B antagonists could be an effective treatment for hypoxia-induced PHT. 
xvi 
These studies show that PHT of different aetiologies results in an increase in 
pulmonary vascular tone due, in part, to an imbalance of endogenous vasoconstrictor 
(ET-I) and vasodilator (hU-II and ACh) action. Therefore, readdressing this balance 
may result in the development of new treatments for PHT of different aetiologies. 
xvii 

1.1. The need for research: 
Pulmonary hypertension is a chronic condition, existing most commonly as a 
secondary condition resulting from pre-existing lung and heart disease, but can also 
exist as a primary disease. Pulmonary hypertension (PHT) is a condition for which 
there is no effective cure as yet. Existing treatments are of little therapeutic value as 
they fail to exploit the differences between the pulmonary and systemic circulations. 
These variations result in treatment for PHT being of limited clinical use in the 
pulmonary circulation and the creation of side effects in the systemic circulation. 
1.2. Histology of blood vessels: 
Arteries are the blood vessels that carry oxygenated blood to peripheral tissues from 
the heart via the systemic circulation. However, the arteries of the pulmonary 
circulation differ from the systemic arteries as they deliver deoxygenated blood from 
the heart to the lungs where gaseous exchange occurs to re-oxygenate the blood. 
Despite this major difference in the oxygen content of the blood carried by systemic 
and pulmonary arteries, their general structural composition is similar, although the 
pulmonary arteries are structurally and functionally adapted to their specific role 
(Tortora, 1992; Ross & Rommel, 1989). 
Arterial walls are comprised of three distinct layers of tissues, the composition and 
relative thickness of these layers determine the class of artery being studied. The 
three distinct layers of an arterial wall are the tunica intima; the tunica media; and the 
tunica adventitia. Arteries are generally classed as large elastic arteries; medium 
muscular arteries; or small non-muscular arteries and arterioles. This classification is 
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rather general and, as will be demonstrated later, does not suffice when classifying 
pulmonary arteries. 
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Figure 1.1: Diagram of the structure of a classic elastic artery. Illustration adapted 
from the Principles of human anatomy, sixth edition, Tortora G. J., Harper Collins, 
1992. 
The tunica intima is the innermost layer of the arterial wall with its surface forming 
the wall of the arterial lumen. This coat is further subdivided into three layers: the 
endothelium; the basement membrane; and the internal elastic lamina. The 
endothelium is the innermost layer of the tunica intima and is comprised of simple 
squamous epithelium joined by the zona occludens (tight junctions) and gap junctions. 
The endothelial cell is the site of receptor for many vasoactive substances such as 
3 
nitric oxide and endothelin. The tight junctions between the endothelial cells act as a 
barrier to substances in the blood which must diffuse through the endothelial cell or 
be moved via active transport by the pinocytotic vesicles within the cell in order to 
affect surrounding extravascular tissues. The middle layer of the tunica intima is the 
basal lamina consists of a thin layer of connective tissue which helps the endothelium 
perform its barrier function to substances in the blood. The outer layer of the tunica 
intima is the internal lamina which is comprised of elastic fibres (Tortora, 1992; Ross 
& Rommel, 1989). 
The tunica media is the middle layer of the arterial wall. This layer is comprised of 
vascular smooth muscle cells and connective tissue cells in the form of collagenous 
and elastic fibres. The relative amounts of these two tissue types within the tunica 
media depends on the class of the artery that is being studied. The vascular smooth 
muscle cells in this layer are arranged in a spiral orientation, often with each muscle 
layer being separated by an elastic lamina. The smooth muscle cells are joined by gap 
junctions and the elastic laminae have fenestrations along their length. Both of these 
features contribute to the transport of substances by diffusion through the arterial 
wall. Sometimes, there is an external elastic lamina separating the tunica media from 
the tunica adventitia (Tortora, 1992; Ross & Rommel, 1989). 
The tunica adventitia is the outermost layer of the arterial wall. This layer is 
comprised of connective tissue, especially collagenous and elastic fibres. The relative 
amounts of collagenous and elastic fibres is again dependent on the class of artery, but 
the tunica adventitia is usually principally comprised of collagenous fibres; 
fibroblasts; and macrophages. The tunica adventitia is itself supplied by small blood 
4 
vessels called the vasa vasorum, whereas the tunica adventitia is also the site of the 
arterial nerve innervation called the nervi vascularis (Tortora, 1992; and Ross & 
Rommel, 1989). 
1.3. Classification of arteries: 
The general composition of an artery has been discussed above. However, such a 
general look at the arterial wall structure is too simplistic as different sizes of arteries 
at different locations within the pulmonary arterial tree have subtle variations. The 
studies described in this thesis are conducted in rat and human vessels so all further 
discussion of arterial histology will be with regards to these pulmonary arteries. It is 
currently thought that there are six structurally distinct subtypes of pulmonary artery 
within two main categories, and that these structural differences form the basis of the 
varied response to numerous stimuli and their effect on pulmonary pressure (Brenner, 
1935; and Sasaki et al., 1995). 
The first main category is the elastic artery, of which there are two subtypes. Both of 
these subtypes have a great mass of extracellular matrix consisting of collagenous and 
elastic fibres, interspersed with vascular smooth muscle cells and numerous elastic 
laminae in their tunica media's. The phenotype of the vascular smooth muscle cells 
in this type of artery have copious amounts of cytoplasmic organelles and sparse actin 
filaments which would result in a weak smooth muscle cell contraction. The tunica 
adventitia of both subtypes of elastic artery is densely packed with collagenous and 
elastic fibres and was more substantial in width than the tunica media (Brenner, 1935; 
and Sasaki et al., 1995). 
5 
The first of the elastic artery subtypes is known as the classic elastic artery (CE). 
The concentric interleaved elastic laminae of the tunica media are very prominent and 
the vascular smooth muscle cell layers that they separate are arranged away from the 
circumferential axis, each layer with a slightly different orientation from the next 
layer. The internal and external laminae are also very pronounced in these arteries. 
The pulmonary arteries with CE morphology are the main pulmonary arteries; the left 
and right pulmonary artery branches; and the main interlobar arteries (Sasaki et al., 
1995). 
The second of the elastic artery subtypes shares much of its morphology with the CE 
segments and is known as the transitional elastic artery (TE). The TE segment 
differs from the CE segment in two ways. While the TE artery has many prominent 
elastic laminae in its tunica media, they are not interleaved and the vascular smooth 
muscle cell layers are orientated around the circumferential axis. The pulmonary 
arteries with TE morphology are the proximal half of the branches that come off of 
the interlobar artery (Sasaki et al., 1995). 
The second main category is the muscular artery, of which there are four SUbtypes. 
All of these subtypes have vascular smooth muscle cells which are densely packed 
with actin filament bundles to allow a strong contraction compared to the elastic 
arteries, and the smooth muscle cells are orientated around the circumferential axis 
(Brenner, 1935; and Sasaki et al., 1995). 
The first of the muscular artery subtypes is known as the thick muscular artery (TM). 
The vascular smooth muscle cells of the TM segment often contain glycogen 
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aggregates to provide extra energy for contraction if needed. The tunica media of the 
TM segment is very thick as it is comprised of up to ten layers of densely packed 
vascular smooth muscle cells which are very sparsely interspersed by extracellular 
matrix. The tunica adventitia is not very substantial. The pulmonary arteries with 
TM morphology are the distal half of the branches of the interlobar artery in the rat 
and human lung biopsies. These are the type of vessels used in the rat and human 
studies in this thesis (l00 - 250llM i.d.) (Sasaki et al., 1995). 
The second of the muscular artery subtypes is known as the ordinary muscular artery 
(OM). The tunica media of the OM segment is comprised of one or two layers of 
vascular smooth muscle cells with very little extracellular matrix interspersing the 
cells. The pulmonary arteries with OM morphology are very small arteries that 
branch off from the branches of the interlobar artery (Sasaki et al., 1995). 
The third of the muscular artery subtypes is known as the partially muscular artery 
(PM). The tunica media of the PM segment consists of one discontinuous layer of 
vascular smooth muscle cells. Where the tunica media of the PM segment has no 
smooth muscle cells, the internal and external laminae fuse and appear as one single 
elastic lamina. As the circumference of the PM artery decreases, the amount of 
vascular smooth muscle cell coverage decreases resulting in larger patches of non-
muscular tunica media. The tunica adventitia of the PM segment is very thin. The 
pulmonary arteries with PM morphology are arterioles (Sasaki et al., 1995). 
The fourth and final muscular artery subtype is known as the non-muscular artery 
(NM). The tunica media of the NM segment does not contain any vascular smooth 
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muscle cells at all, the tunica media is comprised of immature smooth muscle cells 
(pericytes) instead. The tunica adventitia of the NM segment is so thin as to be 
virtually non-existent. The pulmonary arteries with NM morphology are the alveolar 
capillaries (Sasaki et al., 1995). 
The internal elastic lamina disappears gradually as we travel down the pulmonary 
arterial tree. The external elastic lamina also disappears gradually as you move down 
the tree, but there is a large attenuation in the extent of the external lamina between 
the TE and the TM segments and is virtually non-existent by the PM segment 
(Brenner, 1935; and Sasaki et al., 1995). 
1.4. Vascular smooth muscle cell phenotypes: 
Studies have revealed four phenotypically distinct cell subpopulations simultaneously 
exist in the medial smooth muscle cell (SMC) layer of arteries from both the 
pulmonary and systemic circulations in vivo and in vitro (Frid et al., 1994; Frid et al., 
1997). These cell subpopulations were isolated and characterised according to their 
expression of smooth muscle (SM) and cytoskeletal proteins, cell morphology, 
immunobiochemical characteristics, and responses to various growth-promoting 
stimuli and hypoxia (Frid et al., 1994; Frid et al., 1997). The four cell subpopulations 
can be separated into two broad categories: two smooth muscle cell subpopulations 
and two nonmuscle-like cell populations. These phenotypically distinct cell 
subpopulations are from specific layers of the tunica media: L I-cells were isolated 
from the subendothelial layer of the media, L2-SMCs were isolated from the middle 
layer, while L3-"s" SMCs and L3-"R" cells were isolated from the outer layer of the 
media. The two SMC subpopulations (L2 and L3-"S" cells) were characterised by 
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their expression of the SMC contractile proteins -SM-actin and SM-myosin, slow 
growth in 10% serum and no growth in 10% plasma, no proliferation in response to 
hypoxia, and do not secrete mitogenic factors. The L3-"S" SMCs also expressed the 
cytoskeletal contractile protein, metavinculin. The two nonmuscle-like 
subpopulations (LI and L3-"R" cells) were characterised by their lack of expression 
of SMC contractile proteins, exhibit fast growth in 10% serum and growth in 10% 
plasma, exhibit growth in response to hypoxia, and secrete mitogenic factors (Frid et 
al., 1994; Frid et al., 1997). However, despite the morphological and phenotypic 
differences between these four cell subpopulations, they all expressed the SMC 
contractile protein -SM -actin during their development, revealing them as being 
SMCs. The cells then differentiate into the four distinct phenotypes, which suggests 
that these cells have distinct cell lineages (Frid et aI., 1994; Frid et al., 1997). These 
findings suggest that these four cell subpopulations contribute in their own ways to 
vascular wall homeostasis in normal physiological and pathophysiological conditions. 
It is unclear whether all of the cell subpopulations are equally involved in the 
pathobiology of human vascular diseases such as arteriosclerosis and hypertension, or 
if only specific subpopulations are involved in these pathophysiological processes. It 
has been postulated that the subpopulations of nonmuscle-like cells which exhibit 
increased proliferation in response to pathological stimuli, such as hypoxia and 
mitogenic factors may be involved in the intimal thickening which occurs during 
several vascular diseases (Frid et al., 1997). It has been demonstrated that heparin 
inhibited the serum-stimulated growth of Ll cells. As a heparin-like substance has 
been shown to be released from endothelial and SMCs, the L1 cells are quiescent 
under normal physiological conditions. However, should vascular injury occur which 
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results in the decreased release of the heparin-like substance, the L1 cell 
subpopulation which exhibit increased proliferation in response to hypoxia and 
secretes mitogens, could be activated (Frid et ai., 1997). Therefore, the existence of 
four distinct cell subpopulations could allow the continuation of the normal 
contractile function of the media in response to pathophysiological stimuli while other 
subpopulations contribute to the pathophysiological process by undergoing increased 
proliferation (Frid et ai., 1997). 
The distinct morphological diversity within the arteries of the pulmonary circulation 
probably account for the observed variations in the response to various physiological 
stimuli and in the potency and efficacy of numerous vasoactive substances. These 
observations substantiate the practice of viewing the pulmonary circulation as a series 
of unique arteries rather than as a whole uniform entity. 
The rat vessels used in this study are rat and human pulmonary resistance arteries. 
These vessels have an internal diameter in the range of 100-250!ID1 and have TM 
morphology. 
1.5. Diversity in the pulmonary and systemic circulations: 
The pulmonary circulatory system is a unique and integral part of the body. Its 
importance is born from the fact that without it, the cardiovascular system ceases to 
implement its functional role of oxygenated perfusion of blood to all body tissues 
resulting in brain-stem death from oxygen and glucose starvation (Goerke & Mines, 
1988). The uniqueness of the pulmonary circulation system is due to the differences 
that exist between it and the systemic circulation both functionally and 
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pharmacologically. The pulmonary system is a low pressure system with a mean 
arterial pressure of 12-15mmHg while the systemic system has a mean arterial 
pressure of 95mmHg. Therefore, the pulmonary system is also a low resistance 
system compared to the systemic system. This functional difference is a result of the 
fact that pulmonary arteries have very little endogenous tone and are almost fully 
dilated in their resting state while the systemic arteries and arterioles are always 
slightly constricted and provide much of the total systemic resistance (Fishman, 1988; 
Goerke & Mines; 1988; MacLean, 1998). One of the most striking distinctions 
between the two circulatory systems is their response to hypoxia. The systemic 
arteries will dilate in low POz causing a decrease in mean arterial pressure while the 
pulmonary arteries will constrict in response to low POz resulting in an increase in 
mean arterial pressure and is known as hypoxia-induced pulmonary vasoconstriction 
(HPV) (Heath et al., 1973; Fishman, 1976; Fishman, 1988; Dominiczak & Bohr, 
1995; MacLean, 1998). HPV is a beneficial mechanism in healthy lungs that allows 
the alveoli that are being ventilated to selectively receive an increased blood supply in 
order to ensure maximisation of ventilation-perfusion matching in times of hypoxia. 
However, in lungs that already have compromised ventilation-perfusion matching due 
to pre-existing lung disease such as cystic fibrosis; lung cancer; or emphysema, the 
HPV mechanism only serves to exacerbate the existing PHT (MacLean et al., 1993). 
Therefore, we can see that the pulmonary circulation merits separate consideration 
from the systemic circulation and by understanding the differences between the two 
systems, it may be possible to develop therapies which alleviate PHT without causing 
undesirable systemic hypotension. 
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1.6. The normal pulmonary circulation: 
The normal healthy pulmonary circulation is very efficient at ventilation-perfusion 
matching. The normal circulation is mainly regulated by the concentration of oxygen 
O2 and CO2 found in the blood. Neurotransmitters and locally produced mediators 
also have an effect on the pulmonary circulation, but, the principal influences are the 
respiratory gases. 
When a healthy adult is at rest, the oxygen requirement of the peripheral tissues 
(metabolic rate) is easily matched by cardiac output. During exercise, the metabolic 
requirement for O2 increases causing a corresponding increase in cardiac output. The 
blood entering the tissue via the arteriole contains a much greater concentration of O2 
than the blood leaving the tissue via the venule, thus, increasing the arteriovenous O2 
difference. As the exercise increases the cardiac output, the volume of blood flowing 
through the lung also increases but rarely causes any increase in pulmonary pressure, 
even though the increase in blood volume occurs at the expense of gaseous exchange, 
as the pulmonary circulation recruits reserve vessels found near the apex of the lung 
and other vessels that are already open dilate slightly. However, a person with heart 
failure cannot match cardiac output to tissue O2 requirement and finds that slight 
exertion such as walking upstairs can leave them fatigued (Fishman, 1988). 
The pulmonary system is a low resistance system compared to the systemic system, 
resulting in a small driving pressure. This lack of resistance is due to the fact that the 
pulmonary arteries are almost maximally dilated in their natural resting state. The 
resistance that does exist in the system appears to originate in the small muscular 
pulmonary arteries, which have an internal diameter of approximately 100-1 OOOOl-tm 
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and the arterioles with diameters of <IOOl-tm. These arteries appear to be the arteries 
that are the most capable of vasoconstriction, and, for that reason, are known as the 
small pulmonary resistance arteries (PRAs). The arteries used in this study are the 
small PRAs with an internal diameter in the range of approximately 100-250l-tm 
(Fishman, 1988). 
As previously mentioned, the pulmonary circulation is a low pressure system. The 
mean arterial pressure in a healthy adult is 12-15mmHg, about an eighth of the mean 
systemic arterial pressure. As the mean left atrial pressure is 5-10mmHg, there is only 
a very small drop in pressure across the whole pulmonary circulation from pulmonary 
artery to the left atrium. The small pressure drop that exists in the system appears to 
occur in the pulmonary capillaries which surround the alveoli and are the site of 
gaseous exchange. In order to carry out in vitro isolated vessel experiments in near 
physiological conditions, it is essential to set the vessels up with a transmural pressure 
equivalent to that which they experience in vivo. The transmural pressure is 
calculated by measuring the difference between the luminal and pleural pressure 
(Fishman, 1988). In the small muscular PRAs of IOO-250l-tm in diameter used in this 
study, the transmural pressure is 16mmhg (Herget et al., 1978; MacLean & 
MCCulloch, 1998). 
The volume of blood in the healthy pulmonary circulation at any given time is about a 
tenth of the total circulating blood volume. Any increase in the pulmonary blood 
volume would occur at the expense of air volume. Therefore, patients with 
congestive heart failure would eventually also have a decreased vital lung capacity. 
Patients with systemic hypertension are also at risk of having a decreased vital 
13 
capacity as systemic vasoconstriction displaces blood back into the pulmonary 
circulation. The pulmonary blood volume appears to be evenly distributed throughout 
the pulmonary circulation (Fishman, 1988). 
The pulmonary arteries are constricted in response to a decrease in inspired P02• This 
condition is known as hypoxia-induced pulmonary vasoconstriction (HPV), and is an 
important mechanism in ventilation-perfusion matching. This HPV occurs mainly in 
the small muscular PRAs and arterioles. The mechanism by which a low P02 elicits 
pulmonary vasoconstriction has yet to be fully elucidated, but many believe there to 
be a pharmacological mediator released in response to hypoxia which acts as a potent 
vasoconstrictor (Fishman, 1988; and Barnes & Liu, 1995). The theories underlying 
the mechanism of HPV are discussed in more detail later. 
When the PC02 concentration of pulmonary arterial blood increases (hypercapnia) to 
a point which lowers the pH of the blood to less than 7.2 (acidosis), the HPV 
mechanism is stimulated. Hypercapnia that does not cause acidosis can 
synergistically enhance hypoxia-induced pulmonary vasoconstriction (Fishman, 
1988). 
1.7. Regulation of pulmonary vascular tone: 
Regulation of the pulmonary circulation is not only influenced by mechanical stimuli, 
it is also influenced by pharmacological mediators and neurotransmitters. 
In normal healthy adults living at sea level, the small PRAs are almost fully dilated 
and have little endogenous tone. This lack of endogenous tone could be due, in part, 
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to a preferential release of vasodilator mediators such as PGI2 and NO. In this state, 
any additional release of vasodilators would make little difference to the tone. In 
normal healthy people living at high altitude, the small PRAs have a greater degree of 
endogenous tone. This increase in tone could be due in part, to a preferential release 
of vasoconstrictor agents such as endothelin or catecholamines (Fishman, 1988). 
Both the sympathetic and parasympathetic nervous systems influence the systemic 
circulation, but, only the sympathetic nervous system appears to influence the 
pulmonary circulation (Fishman, 1988; and Goerke & Mines, 1988). Sympathetic 
nerve innervation activates both a- and ~-adrenoceptor activation, with a-
adrenoceptor activation causing vasoconstriction and ~-adrenoceptor activation 
causing vasodilatation. As the small PRAs are normally fully dilated, sympathetic 
innervation usually results in vasoconstriction (Fishman, 1988; and Barnes & Liu, 
1995). 
There are also many mediators which can elicit vasodilatation in the pulmonary 
circulation. The vasodilator effects of these mediators, when administered 
exogenously, are very slight in the normal dilated pulmonary arteries, but, in those 
with PHT due to altitude or disease, where there is a significant increased vascular 
tone, the effects of the vasodilators are increased. Isoprenaline causes a vasodilatation 
by activating ~2-adrenoceptors in the pulmonary arteries. Vasopressin causes 
vasodilatation in pre-contracted vessels via VI receptors. ANP vasodilates the 
pulmonary arteries via the ANP A and ANPB receptors. When the tone of the arteries 
is high, adenosine and A TP cause vasodilatation via the A2 and P2y receptors 
respectively. Acetylcholine activates NO production, which stimulates cGMP 
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production resulting in vasodilatation. There are also a few vasodilator 
prostaglandins. PGI2 and PGE! cause vasodilatation via the IP and EP2 receptors 
respectively. Bradykinin generally elicit a vasodilatation in the pulmonary arteries 
mediated mainly by the stimulated release ofPGh and NO, and by direct action ofB! 
and/or B2 receptors (Su & Bevan, 1976; Fishman, 1988; Barnes & Liu, 1995; Rang et 
al., 1995). Endothelin-l can mediated a transient vasodilatation by stimulating the 
production and release of PGh and NO via the ET B receptor (Rubyani & Polokoff, 
1994). Shear stress causes vasodilatation also by stimulating production and release 
of NO (Barnes & Liu, 1995). 
As well as causing PHT by eliciting vasoconstriction, several endogenous mediators 
have a mitogenic effect causing proliferation of the pulmonary vascular smooth 
muscle cells e.g. angiotensin-II, 5-HT and ET-l (Rubyani & Botelho, 1991; Rubyani 
& Polokoff, 1994; Barnes & Liu, 1995). 
1.8. Pulmonary hypertension: 
The mean pulmonary arterial pressure of a normal adult at sea level is 12mmHg-
15mmHg (25/1 OmmHg). When the mean pulmonary arterial pressure increases from 
15 to 25mmHg (35/15mmHg), the person at sea level is classed as having PHT. 
However, adults native to high altitude (above 7000-8000ft) have a mean pulmonary 
arterial pressure of 25mmHg as normal (Fishman, 1988). 
There are five main diagnostic classes, and four functional classes, of pulmonary 
hypertension (PHT). The models of PHT used in this thesis are characterised as 
resulting from left-sided atrial or ventricular heart disease (class 2.1 in World Health 
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Organisation [WHO] classification) and chronic high-altitude exposure (class 3.5 in 
WHO classification) (WHO website, 2002). Primary PHT (class 1.1 in WHO 
classification) is a disease that is usually idiopathic in origin and occurs in isolation 
from other disease (Fauzi, 2000; WHO website, 2002). However, secondary PHT 
arises as a consequence of another, pre-existing disease such as cardiac disease 
(classes 2.1 and 2.2) or other chronic obstructive pulmonary disease (class 3.1) such 
as cystic fibrosis or emphysema (WHO website, 2002). Despite the differences in 
origin of the two classes of PHT, the sustained pulmonary arterial pressure 
experienced by sufferers is caused by an increase in endogenous tone and increase in 
the proliferation of, and changes in the phenotype of, vascular smooth muscle cells of 
the small PRAs. These changes result in pulmonary vascular remodelling causing 
narrowing of the lumen, leading to an increase in vascular resistance and pressure. 
Prolonged PHT will result in cor pulmonale, when the right atrium becomes 
hypertrophied and dilated. As PHT and cor pulmonale progress, the right atrium will 
eventually fail, as a consequence of the increase in pulmonary arterial pressure and 
increased after-load on the right atrium experienced in PHT (Heath et al., 1973; 
Fishman, 1976; Herget, 1978; Fishman, 1988). 
PHT is characterised by a thickening of the muscular tunica media of medium sized 
PRAs (300-1000~ i.d.) and a progressive muscularisation of the previously non-
muscular small PRAs «300ftm i.d.) from lung apex to base. 
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Figure 1.2: Muscularisation of the precapillary arterioles in rat lung in the presence 
ofPHT. A. Normal rat lung with very little smooth muscle. B. Lungs of rat exposed 
to 2 weeks of hypobaric hypoxia resulting in the development of PHT. Illustration 
adapted from MacLean et at., 2000. 
As the phenotype of the vascular smooth muscle cell changes from immature pericyte 
to mature myocyte at a given site in the pulmonary vascular tree, the reactivity of the 
vessel to physical stimuli also alters due to the different K+ channels, receptor 
populations, and contractile proteins in these cell phenotypes (MacLean, 1998). 
PRAs with a tunica media containing mature vascular smooth muscle cells, undergoes 
proliferation resulting in a thickening of the media. PRAs that previously had a media 
comprised of pericytes become muscularised. The stimulus for this vascular 
remodelling has yet to be elucidated. Hypoxia has been shown to elicit pulmonary 
vasoconstriction and vascular remodelling, yet the mechanism producing these effects 
has also eluded explanation so far. We do know that chronic hypoxia is associated 
with PHT. However, there are two theories on the mechanism underlying this 
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phenomenon: the direct effect theory and the indirect effect theory (Fishman, 1976; 
Fishman, 1988). 
It I 
Figure 1.3: Diagrammatic representation of the pulmonary vascular tree. A. In the 
normal lung in which mature SMCs give way to immature SMCs as the vessel size 
decreases before petering out in the precapillary vessels. B. The pulmonary 
hypertensive lung exihibits progressive muscularisation into the normally non-
muscular precapillary vessels as a result of hyperplasia and redistribution of SMC 
phenotypes. Illustration adapted from MacLean et al., 2000. 
1.9. Hypoxic pulmonary vasoconstriction: 
The arteries of the pulmonary circulation have a unique response to low oxygen 
levels. The pulmonary artery smooth muscle myocytes contract in response to low 
oxygen tensions, while smooth muscle myocytes from a systemic artery relaxes in 
these conditions. Therefore, the pulmonary circulation undergoes vasoconstriction 
and the systemic circulation undergoes vasodilatation in low P02 conditions. This 
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vasoconstriction of the pulmonary circulation is known as 'hypoxic pulmonary 
vasoconstriction (HPV) , and is a very important physiological mechanism in this 
system (Sweeney & Yuan, 2000; Coppock et al., 2001; Sylvester, 2001; Waypa et al., 
200 1. The primary site of HPV is the small muscular pulmonary resistance arteries 
(PRAs) as the main and left and right branches of the pulmonary artery either do not 
respond or dilate slightly in response to low O2 levels (Coppock et al., 2001). The 
varied response to hypoxia between the pulmonary and systemic arteries and between 
the large conduit pulmonary arteries and the PRAs may be due to differences in the 
way myocytes from these loci sense O2 or differential expression of 02-sensitive ion 
channels. HPV has two phases, a transient contraction (phase 1) superimposed on a 
sustained contraction (phase 2) (Leach et al.2001). It has been observed that glucose 
is necessary for the production of phase 2 of HPV as the inhibition of glycolysis 
inhibits the phase 2 component of HPV (Leach et aI., 2001). Further evidence to 
support this direct effect theory of HPV comes from the pulmonary vascular response 
to another physiological stimulus, hypercapnia. Acute hypercapnia can induce 
pulmonary vasoconstriction alone if the PC02 is sufficient to cause acidosis, or can 
synergistically augment vasoconstriction during hypoxia (Fishman, 1976; Fishman, 
1988). 
As the role of the lungs is to oxygenate the blood which then feeds the rest of the 
tissues, it is vital to maintain a good ventilation-perfusion matching ratio by diverting 
blood to areas of lung with good alveolar levels of O2 where efficient gaseous 
exchange can occur (Sweeney & Yuan, 2000; Coppock et aI., 2001). The mechanism 
ensures blood reaches only well- ventilated alveoli is HPV. In healthy subjects, HPV 
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is beneficial in diverting blood away from any small areas of the lung where the 
alveoli are under-ventilated (Sweeney & Yuan, 2000; Coppock et at., 2001). HPV 
can protect the physiological mechanism of ventilation-perfusion matching during 
cases of acute hypoxia, as seen in patients experiencing an asthma attack (Sweeney & 
Yuan, 2000; Coppock et at., 2001). In the foetus, HPV is also the mechanism that 
allows blood to be diverted through the ductus arteriosis, bypassing the lungs as 
gaseous exchange is conducted through the placenta (Sweeney & Yuan, 2000). 
However, the nature of HPV becomes pathophysiological rather than protective in 
nature when there is sustained widespread hypoxia of the lungs, for example, in the 
presence of chronic obstructive pulmonary disease or in those living at high altitude 
(Sweeney & Yuan, 2000; Coppock et at., 2001). In these cases, HPV only serves to 
make matters worse by causing a sustained vasoconstriction of the pulmonary 
circulation which leads to PHT and vascular remodelling. If these conditions are 
sustained for long enough, the PHT may progress, leading to right ventricular 
hypertrophy and a poor prognosis (Sweeney & Yuan, 2000; Coppock et at., 2001). 
Therefore, understanding the mechanism of HPV could lead to new treatments for 
PHT. 
Previous studies into the mechanism(s) underlying HPV have been conducted in the 
intact animal, isolated lungs, individual isolated vessels (endothelium-intact and -
denuded), and pulmonary artery smooth muscle cells (PASMCs) and have shown 
contraction in all preparations in response to hypoxia These results revealed that 
everything required for HPV is found intrinsically in the P ASMC and that the 
endothelial layer of the pulmonary arteries are not required for the initiation of HPV 
(Sweeney & Yuan, 2000; Coppock et at., 2001; Leach et at., 2001; Sylvester, 2001; 
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Waypa et at., 2001). However, the endothelium can modulate HPV by releasing 
either vasodilator endothelial factors (nitric oxide or prostacyclin) or vasoconstrictor 
factors (endothelin-l or thromboxane A2)' It has been suggested that the release of 
endothelin-l from the endothelium 'primes' the contractile machinery of the PASMC 
to HPV by increasing the Ca2+ -sensitivity of the cell and by partially depolarising the 
membrane causing an increase in the intracellular Ca2+ concentration by allowing 
Ca2+ to enter the cell via voltage-gated Ca2+ channels (Sweeney & Yuan, 2000; 
Sylvester, 2001). 
Many aspects of HPV are still under debate, such as the identity of the O2 sensor and 
the pathways which mediate the vasoconstriction after low O2 level has been sensed. 
However, it is now widely accepted that an increase in intracellular / cytosolic Ca2+ 
concentration ([Ca2+]D is the main mechanism underlying the contraction of the PRAs 
during HPV (Sweeney & Yuan, 2000; Coppock et at., 2001; Leach et at., 2001; 
Sylvester, 2001). The Ca2+ channel blocker, verapamil, inhibited HPV in isolated 
lung preparations and intact animals (Sweeney & Yuan, 2000). A current hypothesis 
is that hypoxia, sensed by an as yet unknown O2 sensor, mediates the release of Ca2+ 
from the sarcoplasmic reticulum (SR) which causes an influx of Ca2+ into the cytosol 
from Ca2+ stores. This modulates the activity of the ion channels in the vascular 
smooth muscle cell (VSMCs) membrane leading to depolarisation of the membrane 
which causes the opening of voltage-gated C~+ channels (L-type channels). This 
further increases [Ca2+]i leading to activation of the Ca2+-calmodulin complex which 
activates myosin light chain kinase causing contraction of the myocyte (Sweeney & 
Juan, 2000; Coppock et at., 2001; Leach et al., 2001; Sylvester, 2001; Waypa et at., 
22 
2001). The increase in [Ca2+]i may also be the trigger for the increased myocyte 
proliferation observed in chronic hypoxia (Sweeney & Yuan, 2000). In support of 
this theory, hypoxia has been shown to depolarise isolated arteries and P ASMCs, the 
depolarisation of PASMCs by hypoxia was typically 15 - 20mV (Coppock et ai., 
2001). The L-type channel blocker, verapamil, reduced the hypoxic response in 
isolated lung preparations (Sweeney & Yuan, 2000). These studies revealed that 
depolarisation of the P ASMC membrane is a necessary requirement for HPV. 
Some studies have proposed that the step between the release of Ca2+ from 
intracellular stores and the membrane depolarisation which allows the opening of 
L-type Ca2+ channels causing an increase in [Ca2+]i is the inhibition of voltage-gated 
K+ channels (Sweeney & Yuan, 2000; Coppock et ai., 2001; Sylvester et ai., 2001). 
There are three different classes ofK+ channels present in VSMCs: ATP-activated K+ 
channels (KATP)' Ca2+-activated K+ channels (Kca), and voltage-gated K+ channels 
(Kv). All three channel types are thought to be involved in the production of the K+ 
current (h) which regulates the basal membrane potential and, therefore, regulates the 
basal tone of the pulmonary arteries (Evans et ai., 1996; Barman, 1998; Sweeney & 
Yuan, 2000; Coppock et ai., 2001). As the Kv channel blocker 4-aminopyridine 
(4-AP) caused a significant partial inhibition of the total h in the PASMC, the Kv 
channels are the main, but not the only, channels through which the IK flows to 
regulate the low basal tone of pulmonary arteries (Sweeney & Yuan, 2000; Coppock 
et ai., 2001). 
It has been shown that Kv channels are homo or heteromultimeric tetramers that are 
comprised of two different types of subunits, the membrane-spanning a-subunits 
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which form the pore of the channel and the outer p-subunits which regulate the 
activity of the channel (Sweeney & Yuan, 2000; Coppock et al., 2001). 
There are four subfamilies of genes which encode functional Kv channel a-subunits. 
These families are Ky1, Ky2, Ky3, and Ky4. There have been four subfamilies of 
electrically silent Ky channel a-subunits cloned. These families are Ky5, Ky6, Ky8, 
and Ky9. The electrically silent a-subunits must be co-expressed with a functional a-
subunit in order to form a functional channel (Sweeney & Yuan, 2000; Coppock et 
al., 2001). The electrically silent a-subunit modulates the properties of the Ky 
channels that they make up by determining the speed of activation and inactivation, 
voltage-dependence, and expression levels of the Ky channels (Sweeney & Yuan, 
2000). The a-subunits Ky1.2, Kv1.5, Ky2.1, Ky3.1, Ky4.2, and Ky9.3 are proposed 
as the a-subunits which form 02-sensitive K+ channels. A role for Ky channels in the 
O2 sensing mechanism in 02-sensitive cells, such as neuroepithelial cells and cells of 
the aortic and carotid bodies (Sweeney & Yuan, 2000). However, these a-subunits 
are also expressed in VSMCs from systemic arteries yet systemic arteries dilate in 
response to hypoxia (Sweeney & Yuan, 2000; Coppock et aI., 2001). As there have 
been no qualitative differences in the a-subunits from these different circulations, the 
reason for the differential response to hypoxia in the pulmonary and systemic systems 
has yet to be elucidated. 
There are three subfamilies of Ky channel p-subunits identified in mammalian 
VSMCs. These families are Ky1, Ky2, and Ky3. The p-subunits also modulate the 
properties of the Ky p-subunits they are coexpressed with by determining the 
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speed of activation and inactivation, and the protein kinase activation of the functional 
a-subunits (Sweeney et at., 2000; Coppock et at., 2001). A role for Kv~-subunits in 
O2 sensing has been proposed, especially for the Kv~ I-subunit which binds 
specifically to Kv1 a-subunits (Sweeney & Yuan, 2000; Coppock et at., 2001). The 
~-subunits can also act as an open-channel blocker, thus, reducing the h(V) (Sweeney 
& Yuan, 2000). 
The homomeric Kv channels formed by Kyl.2, Kyl.5, Ky2.1, and Ky3.l a-subunits, 
and the heteromultimeric Ky channels formed by Kyl.2IKvl.5 and Ky2.1IKv9.3 a-
subunits have been proposed as the channels inhibited by hypoxia leading to 
membrane depolarisation (Sweeney & Yuan, 2000; Coppock et at., 2001). 
Therefore, it appears that acute hypoxia inhibits Ky channel function which causes 
membrane depolarisation which causes the opening of VDCCs and an increase in 
[Ca2+]i resulting in HPV (Sweeney & Yuan, 2000; Coppock et at., 2001; Leach et at., 
2001; Sylvester et at., 2001; Waypa et at., 2001). The mechanism by which hypoxia 
inhibits the Ky channels has not yet been elucidated but could involve altering the 
function of Ky channels by: increased superoxide production, inhibition of 
cytochrome P450, or inhibition of oxidative phosphorylation (Sweeney & Yuan, 
2000). More than one of these mechanisms is probably involved in the inhibition of 
Ky channels in order to preserve the efficiency and sensitivity of HPV (Sweeney & 
Yuan, 2000). 
A previous study investigating the effect of chronic hypoxia on K+ current revealed 
that hypoxia altered the K+ channels involved in regulating the pulmonary vascular 
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tone of intrapulmonary arteries. The Kv channel blocker, 4-AP, contracted the 
intrapulmonary arteries of chronic hypoxic rats but had little effect on these vessels 
from control rats. Therefore, the resting potential ofVSMCs under normal conditions 
was regulated by a non-inactivating delayed rectifier K+ current (IK(N)) , while the 
resting potential of chronically hypoxic VSMCs were regulated by a voltage-gated K+ 
current (h(v) ) (Osipenko et ai., 1998). In cases of chronic hypoxia, the h(v) is 
decreased causing membrane depolarisation. Therefore, chronic hypoxia inhibits the 
function of Kv channels as did acute hypoxia, with probably the same mechanisms 
being involved in each case (Sweeney & Yuan, 2000; Coppock et ai., 2001).However, 
it has been observed that the HPV response was 'blunted' in chronically hypoxic rats, 
while the response to vasoconstrictor agonists, such as ET -1, was enhanced (Sweeney 
& Yuan, 2000; Sylvester, 2001). Therefore, this evidence suggests that chronic 
hypoxia affects the expression of Kv channels by up or down-regulating 
transcriptional factors (such as c-jun) which control the expression of functional Kv 
channels (Sweeney & Yuan, 2000; Coppock et ai., 2001). The down-regulation of the 
mRNA and protein expression of Kv -subunits causing a decrease in K v channel 
expression may explain the increased basal tone observed in chronic hypoxic rat 
vessels (McCulloch & MacLean, 1998). 
Although there are compelling arguments which point to the involvement of Kv 
channel inhibition as an effector mechanism of HPV, other studies have shown that 
4-AP did not prevent HPV. However, it has been proposed that there is a 4-AP 
insensitive isoform of Kv channel which could be involved in regulating h(v) in the 
PASMCs (Coppock et ai., 2001; Sylvester, 2001). 
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1.10. The identity of the O2 sensor: 
The mitochondria have recently been implicated as the O2 sensor involved in HPV 
(Leach et al., 2001; Sylvester, 2001; Waypa et al. ,2001). The role of mitochondria in 
O2 sensing in the P ASMCs had been previously discounted as the mitochondrial 
electron transport chain (ETC) inhibitor, cyanide, failed to inhibit HPV (Sylvester, 
2001; Waypa et al., 2001). However, newer studies have shown that inhibitors of the 
proximal region of the mitochondrial electron transport chain (ETC) (such as rotenone 
and myxothiazol) attenuated HPV in perfused lung preparations and P ASMCs. These 
proximal inhibitors did not affect agonist-induced vasoconstriction in perfused lung 
preparations and PASMCs (Leach et al., 2001; Waypa et al., 2001). Both proximal 
and distal (cyanide and antimycin A) ETC inhibitors blocked oxidative 
phosphorylation,. These results showed that mitochondrial electron transport was 
necessary for HPV, but mitochondrial ATP was not, and that the complex at which 
the ETC inhibitor acts is an important factor in whether HPV is abolished or not 
(Leach et al., 2001; Sylvester et al., 2001; Waypa et al., 2001). Therefore, 
mitochondria could act as an O2 sensor in P ASMCs. 
It has been postulated that the mitochondria generates reactive oxygen species (ROS) 
at complex III of the ETC, and that this production is increased in response to HPV 
(Leach et al., 2001; Waypa et al., 2001). The mechanism involved in the increase of 
ROS production has yet to be elucidated. Once the superoxide has been generated, it 
enters the cytosol through anion channels where it is dismuted to hydrogen peroxide 
(H20 2) by Cu, Zn superoxide dismutase (Cu, Zn SOD) (Sylvester, 2001; Waypa et al., 
2001). It is proposed that H20 2 acts as a second messenger that triggers other 
mechanisms involved in HPV. It was shown that HPV was inhibited by antioxidants 
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and antagonists of Cu, Zn SOD, revealing that conversion of superoxide to H20 2 is a 
necessary step in the mechanism ofHPV (Sylvester, 2001; Waypa et ai., 2001). As a 
second messenger, H20 2 could reduce proteins of the Kv -subunits. This would 
inhibit the Kv channels causing membrane depolarisation and increased [Ca2 +]i 
resulting in contraction of the P ASMCs. Therefore, only proximal mitochondrial 
ETC inhibitors which act at complex III and above inhibit the generation of ROS by 
fully oxidising the complex resulting in a lack of electrons and a decrease in 
superoxide generation and, subsequently, HPV (Leach et al., 2001; Sylvester, 2001; 
Waypa et al., 2001). The inhibition of the ETC by a distal inhibitor such as cyanide 
allows the complex to become fully reduced supplying a lot of electrons for the 
generation of superoxide and, thus, do not inhibit ROS generation or HPV (Waypa, et 
al., 2001). 
An increase in the generation of ROS in response to hypoxia is seen in endothelial 
cells, cardiac myocytes and macrophages as well as P ASMCs. This suggests that 
there are differential responses to hypoxia in different cell types which is made 
possible by differentiation in the downstream signal transduction pathways, not by 
differences in O2 sensing. This allows P ASMCs to contract, systemic VSMCs to 
dilate, and cardiac myocytes to undergo ischaemic conditioning in response to 
hypoxia. 
It had also been proposed that NADPH oxidase could act as an electron donor for the 
generation of superoxide and could also be involved in O2 sensing in the P ASMCs. 
However, mice with the gp91 phox subunit of the NADPH oxidase complex knocked 
out were shown to exhibit vasoconstriction in response to hypoxia. Therefore, 
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NADPH oxidase is not involved in HPV (Coppock et at., 2001; Leach et at., 2001; 
Waypa et at., 2001). 
As these studies show, there is still no consensus on the mechanism underlying 02 
sensing and HPV. However, the elucidation of these mechanisms could one day 
herald a new therapeutic approach for the treatment of PHT. 
1.11. The indirect effect theory of HPV: 
Many people believe the indirect effect theory of HPV which states that the effect of 
hypoxia on pulmonary vasoconstriction is indirect, and elicited by the release of a 
chemical mediator or mediators from the lungs in response to hypoxia. As yet, no 
single mediator has appeared to be the effector of the vasoconstriction though many 
have been considered. The search has investigated the catecholamines (noradrenaline 
and adrenaline), histamine, angiotensin-II, prostaglandins (PGF2a and PGE2), 
leukotrienes (LTC4), and 5-HT. None of these has satisfied all of the criteria for 
being the mediator of the response to hypoxia (Fishman, 1976; Fishman, 1988). All 
of these vasoactive substances could play a part in the increased tone of the small 
PRAs observed in PHT. However, the identification and isolation of a potent 
vasoconstrictor substance named endothelin (ET -1) in 1988 renewed the interest in 
the involvement of a chemical mediator in HPV (Yanagisawa et at., 1988). Indeed, it 
has been demonstrated that there is an increase in the level of ET -1 in patients with 
PHT (Stewart et at., 1991). It has also been shown that there is an increase in the 
response to ET -1 in the small PRAs of the chronic hypoxic rats (MCCulloch et at., 
1998), and that this effect is concomitant with the alteration of the phenotype of 
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pulmonary vascular smooth muscle cells in these vessels (MacLean, 1998). The role 
of ET -1 will be discussed in more detail later (chapter 5). 
1.12. Genetic basis for primary PHT: 
Primary PHT is usually idiopathic in origin, but an increase in its incidence has been 
linked with the ingestion of a certain brand of appetite suppressant in 1965, aminorex 
(Fishman, 1988). A more recent increase in primary PHT cases in the 1990's was 
attributed to another appetite suppressant, Fenfluramine (see MacLean, 1999 for 
review). The mechanism by which aminorex caused primary PHT is unclear, but its 
ability to stimulate the release of endogenous catecholamine stores could account for 
the increase in tone observed in PHT vessels (Fishman, 1988). A novel feature of 
these lungs was their hyperreactivity to the administration of 5-HT, as pulmonary 
arteries exhibited an increase in 5-HT-induced maximum contractile response and 
mitogenesis (MacLean, 1999; Eddahibi et al., 2001). As with idiopathic primary 
PHT, aminorex-induced PHT lungs showed plexiform lesions which appear as a 
dilated branch of muscular artery, as well as the characteristic progressive 
muscularization of PRAs. The plexiform lesion branches are not lined by vascular 
endothelium as normal arteries are, rather they are lined by fibrillary or 
myofibroblasts cells (Heath & Edwards, 1958; Heath et al., 1987; Fishman, 1988). 
However, as not all of the people who ingested aminorex developed PHT, a genetic 
predisposition to the development of the disease has been suggested. Indeed, some 
patients in the early stages of aminorex-induced PHT found that their symptoms 
regressed without treatment (Fishman, 1988). There have been two main types of 
genetic differences found between patients with primary PHT and normal controls 
which suggest that there is a genetic predisposition for primary PHT. The first type of 
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variation involves the 5-HT transporter (5-HTT) which is expressed in various cell 
types including neurones, platelets, and both pulmonary arterial endothelial and 
smooth muscle cells (Eddahibi et at., 2001). Polymorphism of the 5-HTT gene 
promoter has been found, resulting in the expression of either a long (L) or short (S) 
form of the gene promoter. The L-allelic form has been shown to promote an 
increased expression and activity of 5-HTT (Eddahibi et at., 2001). This has 
important ramifications for the pulmonary vasculature as an increase in the expression 
of 5-HTT increases the intemalisation of indole amine which is necessary for the 
mitogenic and co-mitogenic actions of 5-HT. Therefore, the increase in expression of 
the 5-HTT resulted in an increase in pulmonary artery SMC growth. Indeed, hypoxia 
caused an increase in the expression of 5-HTT and mitogenic effect of 5-HT and an 
increase in 5-HTT expression was also observed in remodelled pulmonary arteries 
from animals with hypoxia-induced PHT (Eddahibi et at., 2001). It was revealed that 
65% of primary PHT patients had the L-allelic variant compared to only 27% of 
controls. Therefore, having the L-allelic variant of the 5-HTT gene promoter may 
confer an increased susceptibility for the development of primary PHT. There is also 
evidence of increased 5-HTT expression in the platelets of patients with chronic 
obstructive pulmonary disease. This suggests the involvement of a genetic 
predisposition in the form of polymorphism of the 5-HTT gene promoter in PHT of 
different aetiologies (Eddahibi et at., 2001). The second genetic variation to be 
associated with primary PHT is a mutation of the bone morphogenetic protein type II 
receptor (BMPR-II) resulting from 10 different missense mutations causing deletions 
in the BMPR2 gene sequence (Machado et at., 2001). These mutations of the BMPR2 
gene alter highly conserved regions of the BMPR-II receptor resulting in structural 
alterations of the ligand-binding domain of the receptor and a loss of receptor function 
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(Machado et at., 2001). The BMPR-II gene codes for the transforming growth factor-
(TGF-) receptor. It is unclear how altering the TGF- pathway promotes 
primary PHT. However, as TGF- is involved in the response to injury of the 
pulmonary vasculature, the mutation of a gene encoding a receptor which mediates 
the effect of TGF- may result in a loss of this pathway allowing the survival of 
damaged cells which form plexiform lesions and hyperplasia of VSMCs. This study 
revealed that 72% of patients with familial primary PHT and 3 patients with sporadic 
primary PHT were identified as having a BMP R2 mutation or show evidence of 
linkage to the BMPR2 locus (Machado et at., 2001). Therefore, mutation of the 
BMPR2 gene may confer an increased susceptibility for the development ofPHT. 
It has been demonstrated that experimentally-induced PHT from chronic hypoxia can 
be reversed when the animals were subsequently returned to normoxic conditions for 
a number of weeks (Heath et at., 1973; Herget et at., 1978). When the mechanisms 
underlying pulmonary vascular remodelling are understood, steps to inhibit its 
progression can be undertaken. Secondary PHT can result from pre-existing 
pulmonary or cardiac disease. The pulmonary vascular vasoconstriction and vascular 
remodelling seen in primary PHT are also seen in secondary PHT but the 
vasoconstriction is enhanced by the hypoxia also caused by the pre-existing condition. 
This thesis describes a study involving patients with secondary PHT as a consequence 
of left ventricular dysfunction (LVD). LVD causes an increase in pulmonary venous 
pressure leading to an increase in capillary bed hydrostatic and filtration pressure 
which results in pulmonary oedema. Pulmonary oedema causes an increase in the 
respiration rate leading to high frequency, but shallow breathing. The increase in 
pulmonary arterial pressure is not proportional to the increase in left ventricular end-
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diastolic pressure (L VEDP), suggesting that reflex mechanisms are involved in the 
pulmonary propagation of hypertension. The development of pulmonary oedema has 
three stages: congestion; interstitial oedema; and finally alveolar oedema. Alveolar 
oedema heralds a marked reduction in ventilation-perfusion matching and a decrease 
in pulmonary compliance. If pulmonary oedema persists, vascular resistance is 
increased, PHT is sustained and right atrium failure will also occur. As the 
compliance of the lungs is attenuated, breathing becomes more difficult and dyspnoea 
at rest becomes apparent. The pulmonary blood volume is redistributed away from 
the base of the lungs towards the apices. The pressure throughout the pulmonary 
circulatory system increases as a consequence of increased LVEDP, the result of 
LVD. However, the pressure increase was more marked in the pulmonary arteries 
than veins which implies that an increased pulmonary vasoconstriciton of the arteries 
in response to hypoxia over and above that produced by the vascular remodelling that 
occurs in PHT (Fishman, 1988). 
1.13. Investigations undertaken in this thesis: 
The studies described in this thesis are conducted on both rat and human small 
muscular PRAs and human systemic resistance arteries (SRAs). Chapter 3 
investigates the mediators involved in the ACh-induced vasodilatation of control and 
chronically hypoxic rat PRAs. This study investigates whether the presence of PHT 
has any effect on the mediator profile of the ACh-induced relaxation. Chapter 4 looks 
at the effect of human urotensin-II (hU-II) on human PRAs from patients undergoing 
bronchial carcinoma resection and on human SRAs from patients undergoing hernia 
repair. The mediators involved in the hU-II-induced vasodilatation of human PRAs is 
also investigated. Chapter 5 investigates the ET -1 response in the human PRAs from 
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patients undergoing bronchial carcinoma resection and patients with differing degrees 
of left ventricular dysfunction (L VD) to see whether the propogation of PHT 
secondary to L VD alters the ET -1 response. This study also looks at the effect that 
three novel mixed ETAIETB antagonists, SB 247083, SB 234551, and SB 217242, 
have on the ET -1 response in these different patient groups. Chapter 6 looks at the 
effects of ET -Ion rat PRAs in the presence and absence of PHT induced by chronic 
hypoxia. The effect of the three novel mixed ETA/ETB antagonists is also investigated 
in the PRAs of control and chronic hypoxic rats. 
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2.1. Background of myography: 
The most important vessels, with respect to hypertension, are the resistance arteries. 
The resistance arteries are the vessels responsible for the generation of 50-70% of the 
peripheral resistance in each organ, and therefore, the body as a whole (Mulvaney & 
Halpern, 1976; Mulvaney & Halpern, 1977; Bohlen, 1986; and Mulvaney & Aalkjaer, 
1990). The classification of resistance vessels are the small muscular arteries with 
diameters of <500f,Lm and the arterioles with diameters of <100[tffi in both the 
pulmonary and systemic circulations (Mulvaney & Halpern, 1976; Mulvaney & 
Halpern, 1977; Duling et at., 1981; Mulvaney & Aalkjaer, 1990; and MacLean, 
1998). This evidence suggests that the properties of resistance arteries should be 
studied in order to understand the mechanisms underlying hypertension. However, 
the very size of these vessels means that the traditional organ bath technique used in 
the study of isolated larger vessels cannot be employed here (Leach et at., 1992). 
Therefore, there was a need to develop a technique that allowed the study of the small 
resistance vessels. 
2.2. Myography application: 
Mulvaney & Halpern (1977) developed a technique that allowed the study of the 
intrinsic mechanical and contractile properties of the microvasculature, vessels with 
diameters of <300f,Lm. This technique was called wire myography. Mulvaney and 
Halpern were able to accurately determine the internal circumference of the resistance 
vessel being used. This information was used to calculate the transmural pressure 
which is required to hold the vessel at this internal circumference and wall tension 
whether the vessel is relaxed or contracted using an equation derived from the 
Laplace relationship (see page 50). The plotting of the wall tension against the 
36 
internal circumference of a vessel displays an exponential curve. The curve produced 
by the resting: internal circumference relationship can be used to determine the 
internal circumference of a vessel under a given transmural pressure in a relaxed state. 
The new technique of myography showed that the resting wall tension: internal 
circumference relationship of systemic resistance arteries of normotensive (WKY) 
and spontaneously hypertensive (SHR) rats were not significantly different. 
However, the wall tension: internal circumference relationship for vessels that are 
contracted by extracellular Ca2+ was significantly different in the WKY and SHR rat 
vessels with SHR rat resistance arteries having a greater wall tension for a given 
internal circumference than WKY rats. This technique showed the differences in the 
contractile properties of the systemic resistance arteries from SHR and WKY rats for 
the first time. 
2.3. Myography equipment: 
The myography apparatus consists of a stainless steel 5ml organ bath chamber 
containing two mounting jaws. One of the mounting jaws is fixed in place and is 
attached to an isometric force transducer while the other mounting jaw is attached to a 
sliding arm and micrometer which allows the distance between the jaws to be altered. 
The micrometer allows this distance to be calculated so that the internal diameter of 
the vessels can be measured. This measurement is then used to calculate the 
displacement of the jaws needed to set the vessels at a precise transmural pressure 
using the Laplace relationship. The myograph models used in these experiments were 
the 500A, 600M and the 610M. The myograph model 500A allows the insertion of 
two vessel preparations at a time. These myograph blocks were not moveable, so the 
vessels were inserted at the site with the aid of a microscope. The myograph models, 
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600 and 610M, has 4 individual myograph blocks which can be removed from the 
myograph interface to allow the vessels to be mounted in the chambers with the aid of 
a microscope. The microscope used was a Stemi 2000 (Zeiss) at a magnification of 
x2.5. 
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Figure 2.1: Schematic diagram (not to scale) of 500A model of Mulaney / Halpern 
wire myograph. All models allow in vitro measurement of isometric force changes. 
The vessels are mounted in the baths by the insertion of two wires (40 m i.d.) 
secured to the vessel support heads. 
The tension, and therefore, the transmural pressure changes are recorded by a flatbed 
4 channel L6514 Linseis chart recorder connected to myography models 500A, 600M 
and 610M. The pressure changes can be measured from the pen trace. Another of the 
610M myograph interfaces is connected to a PC which records the pressure changes 
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using the Myodaq 2.01 progranune and these are analysed using the same programme. 
The vessels are bathed in Krebs solution, the temperature of which is kept at 3rC ± 
0.1 by internal heating pads. A Douglas bag is filled with a mixture of 16% O2/ 5% 
CO2/balance N2. The Douglas bag is connected to a vacuum pump which is then 
connected to the myograph interface where the aerator pipe is split up so that each of 
the aerators terminates in each individual chamber to bubble the Krebs solution. 
2.4. Dissection of resistance arteries: 
2.4.1. Rat pulmonary resistance arteries 
The left lobe of the rat lung is cut from the left branch of the main pulmonary artery at 
the hilus. The lobe is placed on a dissecting dish with the costal surface lying down 
and the mediastinal surface exposed. The lobe is carefully pinned out and covered 
with ice cold Krebs solution. In this position, the interlobar vessels of the lung lie 
with the vein superior, and the artery inferior, to the bronchus. The point of a pair of 
spring scissors was inserted into the lumen of the bronchus and a cut extending to the 
apex of the lobe was made. This cut reveals the arteries which can be visualised 
beneath a layer of the bronchus wall. The bronchus wall is dissected from the top of 
the interlobar artery, taking care not to puncture the artery below. The bronchus wall 
still covers the branches of the interlobar artery and this is dissected away to allow the 
branches to be visualised more readily. 
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Interlobar arteries Left lobe 
Pulmonary resistance arteries 
Figure 2.2: Diagram of the left lobe of the rat lung. The arteries used in the rat 
studies were the pulmonary resistance arteries. 
After selecting a branch of the interlobar artery, the bronchus wall is dissected away 
and the surrounding parenchyma is carefully cut away so that the resistance artery can 
be cut from the interlobar artery and cleanly lifted free. The dissection preparation is 
washed with ice cold Krebs solution at regular intervals to prevent it from drying out 
caused by the microscope light. The dissected resistance artery is placed in another 
dissection dish full of Krebs solution so that any remaining parenchyma attached to 
the artery can be removed. The vessel is now ready for mounting or can be placed in 
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a glass vial of ice cold Krebs solution and kept in the fridge overnight for use the next 
day. All the vessels were either used on the day of sacrifice or the day after. 
2.4.2. Human pulmonary resistance arteries 
The biopsy tissue used in the human pulmonary artery experiments came from two 
sources. The control biopsies came from patients undergoing thoracotomies to 
remove cancerous lung tissue. These lung resections resulted in various sizes of lung 
being removed, however, the biopsy of macroscopically normal 'safety margin' tissue 
was usually in the region of 5x4xO.5cm. The chronic heart failure biopsies came from 
patients who were to undergo coronary artery bypass grafts and had consented to take 
part in a study which investigated whether the effect of various vasoactive substances 
was altered by the presence and degree of left ventricular dysfunction (L VD). This is 
discussed in more detail in chapter 5. Briefly, patients were assessed for degree of 
L VD using echocardiographic measurement of their ejection fraction. The patients 
were classified according to their ejection fractions. Patients with an ejection fraction 
of ~40% were classed as having good left ventricular function (good L VF), patients 
with an ejection fraction of 30-40% were classed as having moderate left ventricular 
function (moderate LVF), and patients with an ejection fraction of <30% were classed 
as having poor left ventricular function (poor L VF). Before the bypass graft took 
place, in vivo experiments were conducted by infusing vasoactive substances into the 
forearm and recording the resulting changes in blood pressure (Singh et ai., 2002). 
Consent was also given to take a small (2x1.5xO.5cm) biopsy from the anterior costal 
surface of the superior lobe of the left lung to conduct in vitro wire myography 
experiments. However, the resistance arteries from the tissues of both sources were 
dissected in the same manner. The biopsy was placed on a dissecting dish and 
41 
covered in ice cold Krebs solution. The biopsy was carefully pinned out with any 
surface showing arteries uppermost. The resistance arteries are identified by their 
appearance and structure as they have thick walls with respect to their lumen and are 
often found to contain coagulated blood. The bronchi are identified by the fact that 
their walls are thinner than those of the arteries and are often found to contain 
mucous. The veins collapse and are generally not seen during dissection. When an 
artery is identified, the parenchyma is dissected from above the artery and it is 
followed until vessels in the correct size range were reached. The arteries branch 
frequently so that a biopsy of the aforementioned dimensions can yield a number of 
suitable vessels. Once a vessel of the correct size is found, parenchyma surrounding 
the artery is dissected away so that the resistance artery can be lifted out easily. The 
resistance artery is transplanted to another dish full of Krebs solution so that any 
remaining parenchyma attached to the artery can be removed. The vessel is now 
ready for mounting or can be placed in a glass vial of Krebs solution and kept in the 
fridge overnight. 
2.4.3. Human abdominal systemic resistance arteries 
The biopsies used in the human abdominal artery experiments came from patients 
undergoing a hernia repair operation. Consent was given to take an abdominal skin 
biopsy (4xO.5cm) with a section of subcutaneous fat (3x3xO.5cm) attached. The 
biopsy was pinned out carefully with any surface showing arteries uppermost. The 
resistance arteries in this biopsy can be found, the surrounding fat is dissected away 
and the resistance artery lifted clear. The resistance artery is placed in another dish 
full of Krebs solution so that any remaining fat attached to the artery can be removed. 
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The vessel is now ready for mounting or can be placed in a glass vial of Krebs 
solution and kept in the fridge overnight. 
2.5. Mounting procedure: 
Figure 2.3 shows the steps involved in mounting an artery on the Mulvaney / Halpern 
wire myograph. The resistance arteries are placed in a dissecting dish containing ice 
cold Krebs solution. The vessel is threaded with a 6cm length of tungsten wire with a 
diameter of 40""m under a Stemi 2000 (Zeiss) microscope on a magnification ofx2.5. 
The proximal artery wall is held gently between the points of a pair of forceps in one 
hand. With the other hand, lift the mounting wire between the points of a pair of 
forceps. The tip of the mounting wire is gently placed into the proximal lumen of the 
resistance artery. This step can be hindered by the properties of the vessel as human 
resistance arteries generally have 'sticky ends' which can make the entry of the wire 
into the vessel difficult. Once the wire tip is in the artery lumen, the wire is gradually 
eased further into the lumen. The wire should remain in the centre of the lumen to 
prevent damaging the endothelial layer. Extra care should be taken if the artery is 
curled as the wire is more likely to scrape the wall during its advancement. Once the 
wire protrudes from the distal lumen of the artery, the wire is pushed further through 
the artery very slowly so that there is at least a 2cm length of wire on either side of the 
vessel. An individual myograph block is placed under the microscope with the 
micrometer on the right hand side and 5mls of Krebs solution was added to the organ 
chamber. Step 1: The wire skewering the vessel is then picked up by forceps and 
placed between the mounting jaws. The jaws are closed with the vessel situated in the 
2cm gap between the prongs of the jaws. Step 2: The distal end of the wire is pulled 
across to the distal mounting screw on the left hand fixed jaw that is attached to the 
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transducer. The wire is wrapped around the mounting screw in a clock-wise direction 
before the screw is tightened. The proximal end of the wire is pulled across to the 
proximal mounting screw on the fixed transducer jaw. The wire is wound around the 
mounting screw in a clock-wise direction and the screw tightened. The first wire and, 
therefore, the artery are now secured to the mounting jaw of the fixed transducer arm. 
Step 3: Any surplus wire around the screw is carefully removed to prevent pulling on 
the vessel during drug additions. The jaws are opened slightly to allow the insertion 
of the second 6cm long wire. Step 4: The wire is gently placed into the proximal 
lumen of the artery and is gradually advanced through the lumen until a length of 
approximately 2cm protrudes from the distal end of the lumen. When inserting the 
second wire, care must be taken to ensure that the wires run parallel and are not 
crossed before the ends are secured. Step 5: The distal end of the wire is pulled 
across to the distal mounting screw on the right hand moveable micrometer jaw. The 
wire is wrapped around the distal mounting screw in a clock-wise direction and the 
screw tightened. The proximal end of the wire is pulled across to the proximal 
mounting screw on the right hand jaw. The wire is wrapped around the mounting 
screw in a clock-wise direction and the screw tightened. Step 6: The jaws are moved 
apart so that a small but distinct gap between the two intraluminal wires can be seen. 
The myograph block is then plugged into the myo-interface. This procedure is 
repeated until all four chambers have been set up. The vessels are left to equilibrate 
for 45mins or until spontaneous tension generation has levelled off. 
The vessel is then placed under a tension that is equal to the transmural pressure 
experienced by the vessels in vivo. As the pulmonary circulation is a low pressure 
system with respect to the systemic circulation, the transmural pressure of small 
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muscular pulmonary resistance arteries is 16mmHg (MCCulloch & MacLean, 1996). 
The myography models 600M and one of the 610M and 500A are attached to a 4 
channel flat bed L6514 Linseis pen recorder. The pens are manually placed at the top 
of the chart (left hand side) so that a full-scale deflection can be observed when the 
jaws are slowly closed together by turning the micrometer in a clock-wise direction. 
When the pen was deflected to the bottom of the chart (right hand side) the reading on 
the micrometer is written and denoted as 'Xo'. This is the point when the intraluminal 
wires are touching together. Further closure of the jaws may result in damage to the 
transducer and should be avoided. The jaws are then opened again by turning the 
micrometer in an anti-clock-wise direction. When the pen is back at the top of the 
chart, the intraluminal wires are the same distance apart as they were during the 
equilibration period. This full-scale deflection procedure was repeated for all four 
arteries. The pens were then manually moved to the bottom of the chart (right hand 
side) where they were spaced apart so that each individual trace can be distinguished 
easily seen. The transmural pressure was increased in the vessel by widening the gap 
between the jaws by turning the micrometer in an anti-clock-wise direction. The 
micrometer is turned until the pen has displaced by ten small boxes on the chart paper. 
Due to the calibration of the recorder, each small box represents O.123mN so that the 
initial tension placed on the vessel is 1.23mN. The tension can slip off and have to be 
reapplied. When the trace has levelled off, the micrometer reading is recorded and 
denoted as 'Xl'. The difference in the micrometer readings (XI-Xo) is then put into 
the equation to calculate the internal circumference of the artery. The internal 
circumference (lC) is used in the equation derived from the Laplace relationship to 
determine the exact number of small boxes of tension needed to create a transmural 
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pressure of - 16mmHg with a final resting tension of between 0.S4 - 0.9SmN (100 -
2S0 m i.d.) (see below). 
When the trace has stabilised at a tension equal to 16mmHg, manually place the pens 
at a graduated baseline. The vessel is now ready to have its viability assessed. The 
physiological viability is demonstrated by a rapid vasoconstriction of the resistance 
artery in response to the addition of 2M KCl. Once the constriction has levelled off 
and the pressure change recorded, the chamber is flushed out and refilled with a Sml 
of Kreb's solution. This washout procedure is repeated 4 times. When the trace has 
returned to its original baseline, the addition of 2M KCI is repeated and is washed out 
of the preparations after the vasoconstriction had stabilised. One of the myography 
models, 610M, is attached to a PC running the Myodaq 2.01 programme. A file is 
opened up for each experiment in the myodata folder. The channels are zeroed and 
the jaws are closed by turning the micrometer in a clock-wise direction until the 
myograph display on the myo-interface reads --ISmN. This is the point where the 
two intraluminal wires are touching together. The reading on the micrometer is 
recorded as 'Xo'. The jaws are moved apart by turning the micrometer in an anti-
clock-wise direction until the myo-interface display reads OmN again. Tension is 
placed on the vessel by increasing the gap between the jaws. The micrometer is 
moved in an anti-clock-wise direction until the display on the myo-interface and the 
force on the scale of the computer screen reads 1.23mN, which is equivalent to then 
small boxes on the linseis paper. Once the computer trace has levelled off, the second 
micrometer reading is taken as 'Xl'. The internal circumference is calculated and 
used to work out the tension needed to place the artery under a transmural pressure of 
-16mmHg. The equation calculates the number of displacement boxes needed and 
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multiply that by O.123mN to determine the force in mN equal to 16mmHg. When the 
trace has stabilised at the desired tension the myograph channels are zeroed. The 
physiological viability is assessed with two additions of 2M KCI with a wash in 
between the additions and after. 
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Figure 2.3: diagram of mounting procedure for pulmonary and systemic resistance 
arteries. 
2.6. Calibration of a myograph: 
The first step in calibrating a myograph is to attach a mounting wire to the support 
jaw attached to the transducer arm in each of the 4 chambers. The wire is secured 
with the mounting screws. The chamber is then filled with 5mls of Krebs solution 
and the chambers are left to settle to allow the Krebs solution to warm up to 37°C for 
30mins. A pan-handle balance is placed over the chamber of the first myograph 
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block. The base of the balance is placed at right angles to the direction of movement 
of the jaws so that the transducer arm of the balance is inserted into the chamber 
between the mounting wire and the transducer jaw it is attached to. The transducer 
arm should be free-swinging so that it is touching neither wire nor jaw. The balance 
is left in this position for 30mins. A 2g weight is added to the pan arm of the balance 
choosing the side which causes the transducer arm of the balance to be tipped towards 
the mounting wire. In order to calibrate the myograph and recorder, the force applied 
to the transducer must be calculated. This is done using the equation: 
Ftransducer = W x g x (arm ratio) 
When arm ratio = (pan arm) / ( transducer arm) and 'g' is the gravitational 
acceleration (9.S1mN/gram) 
In the balances used to calibrate the myographs used in these experiments, the pan 
arm / transducer arm ratio is 0.5. 
Thus, for a 2g load, the load on the transducer is 2 x 9.S1 x 0.5 = 9.S1mN. 
When calibrating the myograph models 500A, 600M and 610M which were attached 
to Linseis chart recorders, the channel corresponding to the myograph block being 
calibrated is switched to calibrate before the 2g weight is placed on the balance. 
When the weight is placed on the balance, the transducer arm touches the wire and the 
pen is deflected across the chart paper. The recorder has been calibrated so that each 
small box represents 0.123mN. Therefore, a 2g load producing 9.S1mN of force 
should cause a deflection of SO small boxes. If the deflection is too short, the variance 
is adjusted by turning the variance screw anti-clock-wise and if the deflection is too 
long, the variance screw is turned in a clock-wise direction until the pen is SO small 
boxes from its baseline. Once that pen is calibrated, the switch is turned back to the 
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variance scale. The balance is removed from the first chamber and placed in the next. 
The balance is left in this position for 30mins before adding the 2g load. This process 
is repeated for each of the 4 myograph blocks. The myograph model 610M also 
shows the force generated by the 2g load in mN on its display. 
When calibrating myograph model 610M attached to a PC running the Myodaq 2.01 
programme, the procedure is identical to that conducted on the myograph models 
attached to pen recorders until the 2g weight is applied. The calibration menu is 
selected and the chamber containing the balance is highlighted. The 2g weight is 
placed on the balance adding 9.81mN of force to the wire. When the display has 
settled on a figure, press select to calibrate that channel. The force on the transducer 
is shown as a deflection on the screen of the PC and on the display of the myo-
interface in mN. This is repeated for each of the 4 chambers. The Myodaq 2.01 
programme automatically adjusts itself so that the addition of the 2g weight always 
causes a deflection of the correct size to be shown on the screen. 
2.7. Setting of transmural pressure: 
The myography experiments are conducted at a transmural pressure that is 
experienced by the vessel in vivo. Laplace's Law of pressure within a sphere is the 
basis of the equation used to determine the pressure of a blood vessel. Laplace's Law 
states that the pressure (P) within a sphere is indirectly proportional to the internal 
radius (r): 
P=2T 
r 
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Tension (T) is defined as stress (S) multiplied by the wall thickness (w). Stress is the 
force per unit cross sectional area of wall. Therefore, Laplace's Law can be written 
as: 
P=2Sw 
r 
This law states that as the radius of the sphere increases, the magnitude of the inward 
component of the wall stress decreases which causes less pressure to be generated 
inside the sphere. This law has been expanded upon to devise an equation which 
allows the stretch of a vessel needed to produce a certain effective pressure (PD to be 
determined. 
The Laplace relationship can be used to determine the effective pressure in KPa, 
which is an estimate of the pressure necessary to extend the vessel to the measured 
internal circumference (lC). 
Pi = wall tension / IC / (2xn) 
The IC can be measured as follows: 
Xo is the point where the wires are touching each other: 
As the wires are 40[.tm in diameter, this point is calculated as: 
2 + n x 40, so at Xo, the ICO is 20S.6[.tffi 
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Xl is the point where the wires are apart and some initial tension has been applied to 
the vessel: 
Therefore, Ie = (micrometer reading after tension applied [Xd- micrometer reading 
at Xo) x 2 + Ie at Xo 
The Ie is converted to mm before being put into the equation i.e. 205.6!-Ull is now 
0.2056mm. The wall length is measured then doubled since there is an upper and 
lower wall. 
Wall tension is the measured force divided by the wall length so: 
Wall tension = force (F) 
(length x 2) 
Pi = wall tension / Ie /2 x n 
Pi = (2 x n) x wall tension 
Ie 
Pi = (2 x n) x F 
2 x length x Ie 
Pi = 2 x n a # 
2x Ix Ie 
where a is calibration factor O.123mN and # is the number of boxes needed to 
increase the pressure in the vessel to a given pressure. 
51 
The pressure calculated by this equation is in KPa. The pressure exerted by a hnm 
tall column of mercury (lmmHg) is 133Pa. Therefore, the effective pressure is 
divided by 0.1333 to calculate the pressure in mmHg. If the tension is too low, more 
tension is applied (by moving the wires further apart) before redoing the calculation. 
The effective transmural pressure of human and rat pulmonary resistance arteries is 
16mmHg as seen in vivo. The transmural pressure of chronic hypoxic rat pulmonary 
resistance arteries is 32mmHg. The transmural pressure of systemic resistance 
arteries from abdominal adipose tissue is 90mmHg. 
2.8. Small animal hypobaric hypoxic chamber design: 
The two chambers used by our lab (see Figure 2.4) were designed and manufactured 
by The Royal Hallamshire Hospital, Sheffield. The chambers are made from clear 
plexiglass with a removable panel which acts as a door to allow the insertion of the 
animal cages. The chambers can accommodate two animal cages, both housing up to 
four rats at a time. The cages are placed in the chamber with the food and water 
dispensers at the back of the chamber to allow a clear view of both the rats and the 
water and food supplies. The chamber is continuously ventilated by an air flow of 45 
Llmin and the air is also removed continuously via a tube connected to a pump which 
creates a vacuum that controls the pressure inside the chamber by operating the inlet 
valve located on the front door of the chamber. A pressure gauge at the rear of the 
chamber displays the pressure within and a safety switch which stops the pump if the 
pressure falls below 460mbar. The temperature (~21 °C) in the chamber is monitored 
by the insertion of a mercury thermometer. 
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Figure 2.4: Diagrammatic representation of hypobaric chamber (not to scale). At the 
rear of the chamber, the vacuum hose tube leaves the chamber and is connected with 
the pump. The inlet valve located on the door of the chamber is rotated to control the 
pressure inside the chamber (anticlockwise-decrease pressure and clockwise-increase 
pressure). The safety vacuum switch located on the back of the chamber cuts the 
pump if the pressure inside the chamber falls dangerously low. The pressure gauge is 
also located at the rear of the chamber. 
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2.9. Maintenance of animals: 
The chambers are located in a specially designed, sealed room in which the 
environment is strictly controlled with filtered air so that the temperature is ~21 °C and 
there is 55% humidity. Any change in the environmental conditions activated an 
alarm in the lab and the university gate house so that any problems during out of 
hours periods would be noticed and dealt with. All rats used in these studies were 
male Wi star Kyoto rats. Animals destined for the chamber were ordered so that they 
were 30 days old on the day they entered the chamber. Age-matched controls were 
ordered and delivered at the same time. The rats arrived 5 days before the start of the 
14 day experimental period, using this time to acclimatise. On the first day of the 
experiment, the rats were divided into chamber and age-matched control groups. The 
experimental rats were placed in the chamber and the door put in position before 
switching on the pump. Once the pump is running, the door is held in place while a 
seal is made. Once the chamber is properly sealed, the inlet valve is gradually closed 
to reduce the pressure by 50mbar every 30-45mins until the pressure inside the 
chamber was 750mbar. On the second day of the experimental 14 day period, the 
pressure in the chamber was reduced in the same manner until it reached the 
experimental set point of 550mbar. The pressure was checked every 15 mins for an 
hour after manipulation of the pressure was completed for the day to ensure that the 
pressure remained stable. The chambers were gradually returned to nOlmal 
atmospheric pressure every 3-4 days in order to clean out the cages and replenish 
water and food supplies. The chambers were off for 30mins during this cleaning 
period before being gradually returned to the experimental pressure. The time course 
for the pressure manipulations before and after cleaning were ~ 2 hrs, faster than the 
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initial decreasing of pressure at the start of the experimental period. The chambers 
were checked by staff from the Glasgow University animal facility at the weekend. 
At the end of the experimental period, the chamber was returned to atmospheric 
pressure and the rats removed. The rats were killed by overdose of sodium 
pentobarbitone immediately on removal from the chamber. The heart and lungs were 
removed for studying that day or to be placed in a vial of ice cold Krebs for studying 
the next day. The age-matched controls were killed and used in the same way. 
2.10. Validation of hypobaric hypoxic rat model: 
The hypobaric hypoxic rat model has been used for several years by this group and all 
of the validation of our model of PHT was done by Dr. KM. McCulloch, the first 
PhD student in this lab, as part of her doctoral thesis (McCulloch, 1996). The 
validation of this model was achieved through the in vivo and in vitro assessment of 
three characteristic features which demonstrate the development of PHT: pulmonary 
artery pressure (PAP), ventricular ratio, and percentage of thick walled pulmonary 
vessels (TWPVs). As well as demonstrating that chronic exposure to the hypobaric 
hypoxic conditions in the chamber results in the development ofPHT, Dr. McCulloch 
also determined the correct transmural pressure to which the control and chronic 
hypoxic PRAs should be set. These studies revealed that the PRAs from control rats 
should be set up under low tension (~ 16mmHg) while chronic hypoxic rat PRAs 
should be set up under high tension (~ 36mmHg) (McCulloch, PhD thesis, 1996; 
MacLean & McCulloch, 1998). These are the transmural pressures experienced in 
vivo by PRAs from control and pulmonary hypertensive rats (Herget et ai' J 1978). 
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Previous studies have shown the PAP to be significantly increased in rats exposed to 
14 days of hypobaric hypoxia than controls, including the validation studies of this 
lab's model (Chen et aI., 1995; Eddahibi et al., 1991; McCulloch, 1996). A recent 
study by this group revealed an increased right ventricular pressure in this rat model, 
confirmation that this rat model exhibits pulmonary hypertension (Keegan et al., 
2001). An earlier study also showed that hypoxia did not result in an increase in 
mean arterial pressure of the systemic circulation (Rabinovitch et al., 1979). 
Therefore, this model results in an increase in pulmonary vascular resistance leading 
to an increase in PAP and right ventricular pressure. 
The previous validation of this lab's hypobaric chronically hypoxic rat model 
demonstrated a significant increase in the percentage of TWPV s (see Figure 1.2 and 
1.3) with a thickening of both the tunica media and the tunica adventitia in the 
pulmonary resistance arteries (PRAs) of chronic hypoxic rats compared to the 
controls (McCulloch, 1996). Earlier studies have shown significant hypertrophy of 
the vascular smooth muscle cells (VSMCs) and an increase in the amount of collagen 
in the medial layer of large calibre and resistance arteries (100-300Ilm) of the 
pulmonary circulation after chronic hypoxic exposure (Hunter et al., 1974; 
McCulloch, 1996; Meyrick & Reid, 1978; Rabinovitch et al., 1981). Therefore, this 
model of hypobaric hypoxic rat model exhibits the characteristic vascular remodelling 
associated with secondary PHT. 
A reliable indicator of the development of PHT is the assessment of right ventricular 
hypertrophy as measured by calculating the ventricular ratio: 
RV. / L.V. + S 
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Where: RV. = right ventricle, L.V. = left ventricle, and S = septum . 
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Figure 2.5: Diagram of the heart (not to scale). To prepare the heart for 
measurement of RV. / L.V. + S ratio to determine the presence of PHT, the arteries, 
veins and atria are carefully dissected away from the ventricles. 
The ventricular ratio is a reliable index of right ventricular hypertrophy which results 
from the increased pulmonary vascular resistance which occurs in response to 
hypoxia (Hunter et ai., 1974; Leach et ai., 1977; McCulloch, 1996; Rabinovitch et ai., 
1981). The increase in the ventricular ratio reveals the development and severity of 
57 
PHT. A recent study demonstrated the development of right ventricular hypertrophy 
in this rat model (Keegan, et ai., 2001). 
In order to minimise the use of animals, the ventricular ratio is the only method used 
in this current thesis to demonstrate the presence of right ventricular hypertrophy and 
PHT in the hypobaric chronically hypoxic rat. Once the rats had been sacrificed, the 
thoracic cavity was opened and the heart and lungs were dissected free. The heart 
was pinned down before the aorta and pulmonary vessels were removed to leave only 
the ventricular mass. The ventricular mass was delicately dissected along the free 
wall of the right ventricle so that the right ventricle was now separate from the left 
ventricle plus septum (Fulton et ai., 1952). After being rinsed in Krebs solution, the 
ventricles were carefully blotted on a tissue before being weighed. The R.V. / L.V. + 
S ratio was calculated for each control and chronic hypoxic rat used (expressed as 
mean ± SEM). These values can be seen in the appropriate results chapters. 
2.11. Data analysis: 
All experimental data was analysed using the same analysis methods. The vasoactive 
response to the various vasoconstrictor and vasodilator substances used in this thesis, 
in the presence and absence of various antagonists of receptors or downstream 
mediators, were calculated as changes in wall tension and expressed in ruN. The data 
was plotted in graphical form as a percentage of the maximum vasoconstriction of 
50mM KCI in the case of the vasoconstrictor peptide, (endothelin-l) ET-l, and as a 
percentage of the preconstriction elicited by either 10 or 30/-tM of 5-HT or 0.3/-tM of 
ET-l in the case of the vasodilator peptide human urotensin-II (hU-II) or 
acetylcholine, respectively. All the data from the resulting cumulative concentration 
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response curves (CCRCs) were fitted to an equation describing a one-site sigmoidal 
dose response curve of variable slope using GraphPad Prism 3.01 (San Diego, 
California, USA). The equation used for analysis in GraphPad Prism allows the 
calculation of the maximum response, ECso and the Hill slope of the curve. The ECso 
is the molar concentration of an agonist that produces 50% of the maximum effect of 
that agonist (Jenkinson et ai., 1995). The equation used is: 
E = a' [A]nh 
[A]sonh + [A]nh 
where E = response, a = maximum response, [A] = concentration of agonist, [AJso = 
concentration of agonist which produces 50% of the maximum response (a), and nh = 
Hill coefficient (Alexander et ai., 1999). 
This equation was used to determine the ECso of all agonists, in the presence and 
absence of antagonists, used in this thesis. The ECso was calculated for each 
individual CCRC then converted into a pECso value which is the negative logarithm 
to the base 10 of the ECso of an agonist (pECso; Jenkinson et ai., 1995). All agonist 
response data and pECso values were calculated for individual CCRCs before an 
average was taken of the data and expressed as the mean ± SEM. 
Studies involving the reversible competitive mixed ET NET B antagonists were 
analysed using the method described above. The potency of an antagonist can be 
quantified by calculating the dissociation equilibrium constant (Kg) for the 
combination of a reversible competitive antagonist (B) with the receptor, the molar 
59 
concentration of ligand required to occupy 50% of the receptor population (Jenkinson 
et ai., 1995). The potency ofthe antagonist is expressed in this thesis as a pKB value, 
the negative logarithm to the base 10 of the molar concentration of the dissociation 
equilibrium constant. The pKB values could not be calculated for the mixed ET AIET B 
antagonists in the human study of left ventricular dysfunction (chapter 5) as the 
maximum response to ET -1 in the presence of one concentration of each of these 
antagonists did not reach the vasoconstrictor response observed in vessels without 
antagonist (Kenakin, 1982). A pA2 value, the negative logarithm to the base 10 of the 
molar concentration of antagonist that makes it necessary to double the concentration 
of agonist needed to elicit the original submaximal response, could not be calculated 
for the mixed ETAIET B antagonists in the rat study of hypobaric hypoxia (chapter 6) 
as there was no clear parallel shift of the ET -1 CCRC between the three 
concentrations tested in the chronic hypoxic rat vessels (Schild, 1947; Arunlakshana 
& Schild, 1959; Jenkinson et aI., 1995). Therefore, an estimated pKB was calculated 
for 1/-tM of these antagonists using the following equations: 
r =.IAJ 
[A] 
where: r = concentration ratio, [A'] = EC50 in the presence of antagonist, [A] = EC50 
in the absence of antagonist. Then: 
KB = [Antagonist] 
r-1 
pKB = -log KB 
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An estimated pKB value was calculated for each individual CCRC then averaged and 
expressed as mean ± SEM. 
2.12. Statistical analysis: 
Comparisons were made between two groups using Students' t-test for unpaired data. 
A P value of < 0.05* was considered to be statistically significant. Comparisons were 
made between four or more groups using a one-way ANOVA with a Dunnetts' post-
test. A P value of < 0.05* was considered to be statistically significant. The statistics 
package used for both of these analyses was GraphPad Prism 3.01. 
2.13. Drugs and solutions: 
The composition of the Krebs-bicarbonate buffer was (in mM): NaCII18.4, NaHC03 
25, KCI 4.7, CaCh 2.5, KH2P04 1.2, MgS04 1.2, and glucose 11. This buffer has a 
pH of 7.4. 
The following drugs were used: endothelin-l and substance P (Calbiochem, Beeston, 
Nottingham, U.K.). Human Big Endothelin38, acetylcholine chloride, 
adrenomedullins2, sodium nitroprusside, isoprenaline, 5-hydroxytryptamine, apamin, 
indomethacin and NW-nitro-L-arginine methylester (Sigma, Poole, Dorset, U.K.). 
Ketanserin tartrate and GR 55562 dihydrochloride (Tocris, A vonmouth, Bristol, 
u.K.). SB 247083, SB 234551, SB 217242, SB 224289, BRL 15572, human 
urotensin-II, porcine urotensin-II and rat urotensin-II (gifted by SmithKline Beecham, 
King of Prussia, Pennsylvania, U.S.A.). Charbydotoxin (gifted by M. Randall, 
Nottingham University, u.K.). 
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Endothelin-1, human Big endothelin38, substance P, acetylcholine chloride, 
adrenomedullins2, sodium nitroprusside, isoprenaline, 5-hydroxytryptamine, apamin, 
ketanserin tartrate, GR 55562 dihydrochloride, Nw-nitro-L-arginine methylester, SB 
234551, SB 217242, human urotensin-II, porcine urotensin-II and rat urotensin were 
all dissolved in distilled water. SB 24708 was dissolved in DMSO. Indomethacin 
was dissolved in a 0.5M NaHC03 solution. 
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Chapter 3 
The mediators involved in the 
ACh-induced vasodilator 
response: 
the effect of chronic hypoxia 
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3.1.1. Vasodilator response to ACh in control and chronic hypoxic rats: 
Previous studies have shown that chronic hypoxia influences the vasodilator response 
induced by acetylcholine (ACh). The small pulmonary resistance arteries (PRAs) of 
chronic hypoxic rats were found to have an increase in their endogenous tone, which 
is uncovered by the addition of the nitric oxide synthase (NOS) inhibitor, L-NAME. 
The rat PRAs exhibit an increased release of basal NO to antagonise the increase in 
the inherent tone of the vessels seen in PHT (MacLean & McCulloch et at., 1998). 
These vessels were also shown to exhibit an increased vasodilator response to ACh 
than vessels from age-matched control rats. The pIC50 of ACh-induced relaxation 
was significantly decreased from 5.77 ± 0.15 in control rats to 7.12 ± 0.19 in the 
hypoxic rats and the maximum vasodilator response to ACh was significantly 
increased from 28.2 ± 2% (of 5-HT-induced tone) in control rats to 72.1 ± 0.2% in 
chronic hypoxic rats (MacLean & McCulloch, 1998). A recent study has shown that 
there is a progressive up-regulation of the eNOS isoform in the large and small 
pulmonary arteries of chronic hypoxic rats during hypoxia of 2, 7 and 14 days 
(Demiryurek et at., 2000). The level of nitrotyrosine is increased in a similar time-
dependent manner to endothelial NOS (eNOS) revealing an increase in the formation 
of the oxidant peroxynitrite in response to hypoxia (Demiryurek et at., 2000). 
Therefore, the compensatory mechanism of an increase of eNOS in response to PHT 
may exacerbate lung damage by leading to an increase in peroxynitrite formation. 
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3.1.2. Endogenous vasodilator mediators of pulmonary arteries: 
These findings required further investigation to determine whether the increase in the 
maximum response and decreased pICso of ACh-induced vasodilatation in chronic 
hypoxic rat PRAs was mainly mediated by an increased release of NO as the results 
of the up-regulated eNOS would suggest or whether the release of other vasodilator 
mediators was also increased. An early study showed that ACh- and histamine-
induced vasodilatation was mediated by two different endothelium-dependent 
vasodilator mediators. ACh-induced vasodilatation was inhibited by the NOS 
inhibitor, L-NMMA. L-NMMA also potentiated the contractile response to hypoxia in 
perfused rat lungs but did not inhibit histamine-induced vasodilatation, this relaxation 
was inhibited by the non-selective K+ channel blocker, tetraethylammonium (TEA) 
(Hasunuma et at., 1991). These findings suggested NO mediated ACh-induced 
vasodilatation and modulated the hypoxic pressor response. The histamine-induced 
vasodilatation may be mediated by an endothelium-derived factor which causes 
relaxation by hyperpolarising VSMCs beyond their resting potential termed an 
'endothelium-derived hyperpolarising factor' (EDHF) (Hasunuma et aI, 1991). A 
study on the effect of pulmonary hypertension on the relaxation induced by the 
calcium ionophore, ionomycin, showed that the NOS inhibitor L-NOARG attenuated 
the relaxation response in the main and first order branches of the pulmonary artery of 
control sheep but did not inhibit this response in chronic hypoxic sheep vessels 
(Kemp et at., 1995). In chronic hypoxic sheep arteries bathed in Krebs with a high K+ 
concentration, L-NOARG was able to completely abolish the ionomycin-induced 
vasodilatation. These findings revealed the presence of a compensatory K+ channel-
mediated vasodilatation mechanism mediated by EDHF which takes over the 
vasodilator response in the absence of NO during PHT in sheep large pulmonary 
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arteries (Kemp et aI., 1995). Other studies have also shown that NO modulates the 
release of EDHF during physiological conditions but, during pathophysiological 
conditions, the loss of NO-induced vasodilation causes the up-regulation of EDHF 
and allows the EDHF to maintain vasodilator responses (Bauersachs et at., 1996; 
McCulloch et at., 1997). However, another study showed that ACh-induced 
relaxations in rat hepatic arteries were mediated by NO, EDHF and another 
endothelium-derived hyperpolarising factor generated by the cyclooxygenase 
pathway, probably PGI2. This study also found that neither the cyclooxygenase 
product nor NO regulated EDHF release, therefore, showing that EDHF-mediated 
relaxation is not just a compensatory mechanism but is involved in the vasodilator 
response in normal physiological conditions in this vessel (Zygmunt et at., 1998). A 
recent study showed that in, the guinea pig coronary and mammary arteries, ACh-
induced relaxation was dependent on EDHF, NO and PG 12 (Tare et at., 2000). 
Hyperpolarisation was required for the mediation of relaxation to EDHF and PGIz but 
not for NO-mediated relaxation as its effect was not dependent on membrane potential 
(Tare et at., 2000). These findings suggest that these arteries exhibit relaxation which 
is both dependent and independent of membrane potential and that these different 
mechanisms are important in preserving the relaxation in pathophysiological 
conditions (Tare et at., 2000). 
The endothelium-derived relaxing factor mediating ACh-induced relaxation of arterial 
smooth muscle was identified as being nitric oxide (NO) (Furchgott & Zawadzki, 
1980). NO is synthesised in endothelial cells from L-arginine by NOS which is 
activated in response to the rise in [Ca2+]i in response to an agonist stimulating a 
receptor. NO diffuses to the vascular smooth muscle cell (VSMC) where it activates 
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soluble guanylate cyclase to convert guanosine triphosphate (GTP) to cyclic 
guanosine 3' 5' -monophosphate (cGMP). The rise in cGMP activates protein 
kinase G (PKG) which phosphorylates and subsequently inhibits targets in the VSMC. 
These targets include inhibiting the production of inositol triphosphate (IP3) and 
diacyl glycerol (DAG) from phosphatidylinositol diphosphate (PIP2) which inhibits 
the release of Ca2+ from intracellular stores. PKG also phosphorylates and inhibits 
voltage-operated Ca2+ channels resulting in the inhibition of the influx of Ca2+ from 
the extracellular space. This results in a decrease [Ca2+]i which leads to a decrease in 
the Ca2+ -calmodulin complex and a decrease in myosin light chain kinase (MLCK). 
This results in the inactivation of the contractile proteins and a subsequent relaxation 
of the vascular smooth muscle. There is also evidence that NO can activate K+ 
channels either directly or indirectly via PKG (Barnes & Belvisi, 1993; Hasunuma et 
al., 1991; Bolotina et al., 1994; Zygmunt et al., 1998; Jiang et al., 2000; and Tare et 
al., 2000). Therefore, NO may playa role in mediating the vasodilatation to ACh in 
the control and chronic hypoxic rat small muscular PRAs. 
Prostacyclin (PGI2) is an arachidonic acid metabolite synthesised by cyclo-oygenase 
(COX) in endothelial cells which is activated by a rise in [Ca2+]i in response to an 
agonist stimulating a surface-bound receptor. There are 2 isozymes of COX, COX-l 
and COX-2, which are differentially expressed in different cells. COX-l is a 
constitutive enzyme found in most cells. COX-2 is an inducible enzyme found in 
inflammatory cells which is stimulated by the release of cytokines (Meade et al., 
1993; Mitchell et al., 1993). Therefore, the isozyme producing PGI2 in the 
endothelial cells is COX-I. 
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PGIz diffuses into the VSMC where it activates the IP receptor which is coupled to a 
Gs protein which activates soluble adenyl ate cyclase (AC) to convert adenosine 
triphosphate (ATP) to cyclic adenosine 3'5'-monophosphate (cAMP). The rise in 
cAMP activates protein kinase A (PKA) which phosphorylates and subsequently 
inhibits targets in the VSMC. These targets include inhibiting the production of 
inositol triphosphate (IP3) and diacyl glycerol (DAG) from phosphatidylinositol 
diphosphate (PIPz) which inhibits the release of Caz+ from intracellular stores. PKA 
also phosphorylates and inhibits voltage-operated Caz+ channels which inhibits the 
influx of Caz+ from the extracellular space. This results in a decrease [Caz+]i which 
leads to a decrease in the Caz+ -calmodulin complex and a decrease in myosin light 
chain kinase (MLCK). PKA decreases the sensitivity of MLCK to Caz+ as well as 
decreasing its activation by Caz+ -calmodulin complex. This results in the inactivation 
of the contractile proteins and a subsequent relaxation of the vascular smooth muscle. 
There is also evidence that PGIz can activate K+ channels either directly or indirectly 
via PKA (Voelkel et at., 1991; Zygmunt et at., 1998; Gambone et at., 1997; Jiang et 
at., 2000; Tare et at., 2000). Therefore, PGIz may be involved in mediating the ACh-
induced relaxation of control and chronic hypoxic rat small muscular PRAs. 
It has been suggested that EDHF may mediate vasodilatation via K+ channel-mediated 
hyperpolarization which reduces Caz+ influx into VSMC's via voltage-dependent Caz+ 
channels. This could have an important action in small PRAs as the VSMC 
phenotype found in vessels of this size are more dependent on Caz+ influx to mediate 
contraction compared to the VSMC phenotype found in the large arteries (Garland et 
at., 1995). The identity of EDHF has not yet been elucidated but it has been 
postulated that EDHF could be one of a number of arachidonic acid, 
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epoxyeicosatrienoic acid or eicosapenatanoic acid metabolites produced by 
cytochrome P-450 epoxygenase, or even K+ itself (Bauersachs et ai., 1996; 
McCulloch et at., 1997; Edwards et at., 1998; Quilley & McGiff, 2000; Dora & 
Garland, 2001; Zhang et at., 2001). Previous studies have shown that EDHF can 
mediate relaxation and hyperpolarization of vascular smooth muscle by activating the 
N a + -K+ ATPase pump or different types of K+ channels depending on the artery being 
studied and the agonist used to induce vasodilatation (Garland et at., 1995; Chen & 
Cheung, 1997; Gambone et at., 1997; Zygmunt et at., 1998; Jiang et at., 2000). 
Previous studies have shown that the presence of EDHF-mediated relaxation and 
hyperpolarization gains a greater significance as the size of the vessel being studied 
decreases (Shimokawa et ai., 1996). Therefore, it might be expected that EDHF has a 
role in mediating the ACh-induced vasodilatation of small muscular pulmonary 
arteries of the control and chronic hypoxic rat. 
These studies led to the investigation of the roles of NO, PGh and EDHF in the 
mediation of ACh-induced vasodilatation and whether the relative importance of these 
individual mediators changes with respect to chronic hypoxia in the small muscular 
PRAs of the rat. 
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3.2. Methods 
Wistar rats were placed in a hypobaric chamber at 30 days old. The chamber was 
depressurized to 550mbars over a period of 48 hours. When the chamber was at 
550mbars, the oxygen concentration was at 10%. The temperature of the chamber 
was maintained at ~ 21°C with a ventilation rate of 45 Llmin. The rats remained in 
these hypoxic conditions for 14 days and sacrificed upon removal from the chamber. 
Age-matched controls were kept in room air for the same time period (MacLean et ai., 
1995; and MacLean & McCulloch, 1998). The right ventricle was dissected free from 
the left ventricle and septum, blotted carefully with a tissue and then weighed. The 
ratio of right ventricular (R.V.) weight / left ventricular + septum (L.V. + S) weight is 
calculated to assess the presence of PHT (Hunter et ai., 1974; Leach et ai., 1977; 
MacLean & McCulloch, 1998). This has recently been confirmed by direct 
measurement of right ventricular pressure (Keegan et ai., 2001). 
The rats were killed by an overdose of sodium pentobarbitone by intra-peritoneal 
injection. The thorax was opened and the heart and lungs were dissected free then 
placed in ice cold Krebs. Second order intralobal small muscular resistance arteries 
« 250/lm) were dissected out of the lung tissue and carefully cleaned of surrounding 
parenchyma with the aide of a microscope. The vessels from both groups of rat were 
taken from the same region of the left lobe of the lung. The vessels were trimmed to a 
length of 2mm before passing two wires (40/lm in diameter) through the lumen of the 
vessel and mounting it on a wire myograph (Mulvaney & Halpern, 1977). The 
myography bath contained Krebs solution at 37°C and bubbled with 16% O2 /5% 
CO2 / balance N2 from a gas pipe connected to a Douglas bag. Previous studies have 
measured the gas tensions in the baths using these parameters and found the O2 
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tension to be 120 mrnHg and CO2 tension to be 35 mrnHg, which is equivalent to the 
gas tensions seen in the alveolar and pulmonary arteries in vivo (MacLean & 
McCulloch, 1998). 
The vessels were left to equilibrate for an hour after being mounted in the baths. 
Tension was carefully applied to the vessels so that the control rat vessels were set at 
~ 16 mmHg and the hypoxic rat vessels were set at ~ 36 mmHg , tensions which are 
equivalent to those experienced by the vessels in vivo (Herget et aI, 1978; MacLean & 
McCulloch, 1998). After the tension was stabilised at appropriate level, the vessels 
were left to equilibrate for a further 45 minutes. The viability of the vessels was then 
assessed by the addition of 50mM KCI to the baths. Once the vasoconstriction had 
levelled off, the baths were washed out several times until the tension had returned to 
the baseline. The KCI addition was repeated until two reproducible vasoconstrictions 
were obtained. The viability of the endothelium was then assessed by 
vasoconstriction of the vessels with 30~M 5-HT and subsequent vasodilatation by 
l~M ACh. However, the vessels displayed desensitization to 5-HT when it was used 
to pre-constrict the vessels for the main experiment. ET -1 could not be used to 
vasoconstrict the vessels to determine endothelial integrity as ET -1 is resistant to 
wash out and would interfere with the main experiment (Maguire et al., 2000). 
Therefore, it was assumed that the vessels all had an intact endothelium. This 
assumption was proved during the experiment by the ACh-induced vasodilatation. 
The submaximal doses of 30~M 5-HT and lO~M 5-HT, in the control and hypoxic 
Wistar rats respectively, were used to pre-constrict the vessels before a cumulative 
concentration response curve (CCRC) to ACh was conducted. A lower dose of 5-HT 
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was used in the chronic hypoxic rats as it has been shown that the presence of hypoxia 
-induced PHT increases the 5-HT response (MacLean & Morecroft, 2001). Some 
subsets of vessels were incubated with an inhibitor of various vasodilator mediators to 
assess the mechanisms behind ACh-induced vasodilatation in the small muscular 
pulmonary arteries. A subset of the vessels was pre-constricted to 5-HT and left as 
time controls. Some vessels were pre-constricted to 5-HT before the CCRC to ACh 
was conducted. Some were incubated for an hour with 0.1mM of the nitric oxide 
synthase (NOS) inhibitor, L-NAME, before the 5-HT pre-constriction and ACh 
CCRC to determine the role of NO in the ACh-induced vasodilatation. A subset of 
vessels was incubated for an hour with 1flM of the cyc100xygenase (COX) inhibitor, 
indomethacin, before the 5-HT pre-constriction and ACh CCRC. As well as having a 
differential distribution, the two COX isozymes are differentially sensitive to various 
nonsteroidal anti-inflammatory drugs (NSAIDs) and are pharmacologically distinct. 
Indomethacin preferentially inhibits COX -1, the isozyme responsible for the 
production of PGlz, thromboxane Az (TXAz), PGFz , PGDz, and PGEz in the 
endothelial cells. Therefore, indomethacin was used to inhibit PGlz synthesis in this 
study. This was to determine the role ofPGIz in the ACh-induced vasodilatation. 
Another group of vessels was incubated for an hour with O.lflM of two K+ channel 
inhibitors. One of the K+ channel inhibitors used is an inhibitor of the large and 
intermediate conductance Caz+-activated K+ channels (BKca and IKca) inhibitor, 
charybdotoxin (ChTX), and the other inhibitor used is an inhibitor of the small 
conductance Caz+ -activated K+ channels (SKca), apamin. These K+ channel inhibitors 
were used to investigate the role of endothelium-derived hyperpolarizing factor 
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(EDHF) in the vasodilator effects of ACh. Two subsets of vessels were pre-
constricted with 50rnM KCI instead of 5-HT, with one set being left as a KCI time 
control and the other set undergoing a CCRC to ACh to investigate further the 
possible role of EDHF as mediator of ACh-induced vasodilatation, as high 
concentrations ofKCI has been shown to inhibit EDHF release. 
3.3. Results 
3.3.1. Presence of pulmonary hypertension: 
The right ventricular to left ventricular + septum ratio is a reliable index for the 
presence of PHT (Hunter et at., 1974; Leach et at., 1977). Previous studies have 
shown that 14 days of hypobaric treatment was sufficient to cause PHT in rats as the 
ratio was significantly greater in the hypoxic rats when compared with control rats 
(MacLean et at., 1995; and MacLean & McCulloch, 1998). The results from this 
present study show that the ratio is significantly greater in the hypoxic rats 
(P < 0.001) when compared with control rats (Table 3.1). This demonstrates that the 
hypoxic rats in this study had developed significant PHT. Tables 3.4 and 3.5 
demonstrate an equivalent contractile response to 50rnM KCI and 30~M 5-HT in the 
different protocol groups of control rat PRAs. 
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Experimental Control Hypoxic 
Group Wistar Rat Wi star Rat 
R.V. I L.V. + S 0.22 ± 0.01 0.31 + 0.01 *** Ratio 
n= number n= 12 n= 11 
Table 3.1: Measurement of the right ventricle (R.V.) Ileft ventricle + septum 
(L.V. + S) ratio in the control and hypoxic Wi star rat groups. Data expressed as mean 
± SEM. n = number of individual heart preparations. Statistical comparison was 
made using Students' unpaired t-test. P < 0.001 *** vs. control rat ratio. 
3.3.2. Differences between the ACh-induced vasodilatation in control and 
hypoxic rats: 
Previous studies have shown that the 5-HT-induced vasoconstrictor response is 
enhanced in PRAs from chronic hypoxic rats (MacLean et al., 1996; MacLean & 
Morecroft,2001). Therefore, these studies were used to determine the concentration 
of 5-HT that should be used to pre-constrict PRAs from the control (30IlM) and 
chronic hypoxic (lOIlM) rats. However, despite the use of different concentrations of 
5-HT to induce pre-constriction in the control and chronic hypoxic rat PRAs, the final 
tone achieved was higher in the hypoxic rat PRAs (see Table 3.5 and Table 3.9). 
There was a significant augmentation in the 5-HT pre-constriction achieved in the 
5-HT time control (P < 0.05) and apamin & charybdotoxin (P < 0.01) protocol groups 
from hypoxic rats when compared to the pre-constriction achieved by 5-HT in the 
control protocol groups. 
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There was no significant difference between the potency of ACh in the control and 
hypoxic Wi star rats. These results are shown in Table 3.2. However, there was a 
significant difference between the maximum vasodilator response to ACh in the 
control and hypoxic Wi star rat PRAs as the maximum relaxation response is greatly 
augmented in the hypoxic rat (P < 0.01). These results are displayed in Table 3.3. 
The ACh-induced relaxation response in control and chronic hypoxic rat PRAs is 
shown in Figure 3.1. 
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Figure 3.1: Vasodilator response to ACh in the control and chronic hypoxic Wistar 
rat PRAs. Control 5-HT time control (TC) (n=6); control ACh (n=6); hypoxic 5-HT 
time control (TC) (n=8); hypoxic ACh (n=8). Data expressed as percentage of 30llM 
and 10IlM 5-HT-induced tone respectively. Each point represents the mean ± SEM. 
n number of individual PRAs from the same number of individual lung 
preparations. 
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Protocol pECsovalue n number Group 
Control ACh 6.38 ± 0.63 n=6 
. 
Hypoxic ACh 7.71 ± 0.30ns n=8 
Table 3.2: pEC50 values for ACh in control and hypoxic Wi star rat PRAs. Data are 
expressed as mean ± SEM. n = number of individual PRAs from the same number of 
lung preparations. Statistical comparison was made using Students' t-test. ns = not 
significant vs. control rat ACh pEC50• 
Protocol Max. 
n number Group relaxation 
Control ACh 40±7 n=6 
Hypoxic ACh 76 ± 6** n=8 
Table 3.3: Maximum ACh-induced relaxation response values in control and 
hypoxic Wistar rat PRAs as % of 30 and 10/-LM 5-HT -induced tone respectively. Data 
expressed as mean ± SEM. n = number of individual PRAs from the same number of 
individual lung preparations. Statistical comparison was made using Students' t-test. 
P < 0.01 ** vs. control rat ACh-induced maximum vasodilator response. 
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j-; 
3.3.3. Control Wistar rat PRAs: 
ACh induced vasodilatation in control Wistar rat PRAs with a pECso of 6.38 ± 0.63 
(n = 6) and a maximum relaxation response of 40 ± 7% (as % of 5-HT-induced tone). 
A summary of pECso values are shown in Table 3.6. The ACh-induced 
vasodilatation was significantly different from the time control fall off of tone (P < 
0.01). The vasodilator responses to ACh are displayed in Figure 3.2. 
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Figure 3.2: Vasodilator response to ACh in the control Wistar rat PRAs in the 
presence and absence of various vasodilator inhibitors. 5-HT Time control (n=6); 
ACh alone (n=6); L-NAME (n=6); indomethacin (n=6); and apamin (Ap) & 
charybdotoxin (ChTX) (n=6). Data expressed as percentage of 30/lM 5-HT-induced 
tone. Each point represents the mean ± SEM. n = number of individual PRAs from 
the same number of individual lung preparations. 
ACh induced vasodilatation in control Wistar rat PRAs with a pECso of 6.38 ± 0.63 
(n = 6) and a maximum relaxation response of 40 ± 7% (as % of 5-HT-induced tone). 
A summary of pECso values are shown in Table 3.6. The ACh-induced 
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vasodilatation was significantly different from the time control fall off of tone (P < 
0.01). The vasodilator responses to ACh are displayed in Figure 3.2. 
ACh-induced vasodilatation in the presence of 100/lM of the NOS inhibitor L-NAME 
(n=6), was significantly different from the fall off in tone (P < 0.01). There was no 
significant decrease in the potency of ACh in the presence of L-NAME. A summary 
of the pECso values can be seen in Table 3.6. There was no attenuation of the 
relaxation response to ACh in the presence ofL-NAME, nor was there any significant 
difference between the vasodilatation effected at any given concentration of ACh. A 
summary of these results is shown in Table 3.7. The presence of L-NAME did not 
affect the basal tone of the control rat PRAs. 
ACh-induced vasodilatation was significantly different from the fall off of tone in the 
presence of l/lM of the COX inhibitor, indomethacin (n=6) (P < 0.01). There was no 
significant decrease in the potency of ACh in the presence of indomethacin. A 
summary of the pECso values can be seen in Table 3.6. There was no attenuation of 
the relaxation response to ACh in the presence of indomethacin, nor was there any 
significant difference between the vasodilatation effected at any given concentration 
of ACh. A summary of these results is shown in Table 3.7. The presence of 
indomethacin had no effect on the basal tone of the control rat PRAs. 
ACh-induced vasodilatation in the presence of O.I/lM of Kca channel blockers, 
apamin & charybdotoxin (ChTX) (n=6), was not significantly different from the fall 
off in 5-HT-induced tone. As there was no real relaxation response in the vessels 
incubated with these Kca channel blockers, the pECso could not be calculated. A 
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summary of pECso values can be seen in Table 3.6. However, there was a significant 
attenuation of the maximum vasodilator response to ACh in the presence of apamin 
and ChTX (P < 0.05). A summary of these results is shown in Table 3.7. The 
presence of apamin and ChTX did not affect the basal tone of the control rat PRAs. 
Protocol 5-HT ACh L- Indom- Apamin KCI KCII 
Group Time alone NAME ethacin & Time ACh Control ChTX Control 
KCI-induced 2.81 4.03 3.17 3.54 3.93 1.50 1.63 
Constriction ± ± ± ± ± ± ± 
(mN) 0.70 1.23 0.38 0.60 0.67 0.30 0.24 
Vessel 198 192 210 212 173 221 199 
± ± ± ± ± ± ± Size (J.tm) 15 11 16 12 17 16 25 
n=number n=6 n=6 n=6 n=6 n=6 n=4 n=4 
Table 3.4: Dimensions and measurements of 50mM KCl-induced tone achieved in 
the various protocol groups before antagonists added. Data expressed as mean ± 
SEM. n = number of individual PRAs from the same number of individual lung 
preparations. 
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Protocol 5-HT Time AChalone L-NAME / Indomethacin Apamin & Group Control hU-II ChTX 
5-HT-
Induced 0.87 ± 0.09 1.17 ± 0.36 1.30 ± 0.31 1.24 ± 0.21 1.06 ± 0.11 Pre-tone 
(ruN) 
n =number n=6 n=6 n=6 n=6 n=6 
Table 3.5: Measurements of 30llM 5-HT-induced pre-constriction achieved in the 
PRAs of various protocol groups from control Wi star rats. Data expressed as mean ± 
SEM. n = number of individual PRAs from the same number of individual lung 
preparations. 
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Protocol pECsovalue n number Group 
AChalone 6.38 ± 0.63 n=6 
L-NAMEI 6.6S ± 0.S9ns n=6 ACh 
Indomethacin I 6.64 ± 0.S8ns n=6 ACh 
I 
Apamin& Not Calculated n=6 ChTXI ACh 
Table 3.6: pECso values for ACh ± various vasodilator inhibitors in control Wi star rat 
PRAs. Data are expressed as mean ± SEM. n = number of individual PRAs from the 
same number of lung preparations. Statistical comparisons were made using one-way 
ANOVA with a Dunnetts' post-test. ns = not significant vs. ACh control. 
The raising of tone in small resistance arteries with SOmM KCI has been shown to 
inhibit the release of endothelium-derived hyperpolarising factor (EDHF). Therefore, 
experiments were conducted in which the tone of the arteries was raised by the 
addition of SOmM KCI instead of 30/lM S-HT before conducting the ACh CCRC. 
There was no significant difference in the relaxation response induced by ACh in the 
KCII ACh protocol group compared to the fall off of tone in the KCI time control 
group at any given concentration of ACh (both n=4). However, the ACh-induced 
vasodilatation after pre-constriction with KCI is significantly less than the relaxation 
effected by ACh after S-HT pre-constriction (P < 0.01) at the highest concentration 
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of ACh. A summary of these results is shown in Table 3.7. There is no graph of 
these results as the decrease in KC1-induced pre-constriction was so small as to be 
difficult to distinguish from the x axis of the graph. 
AChBath S-HT I S-HT I S-HT I Ap & KCll ACh ConeD L-NAME Indomethacin ChTX 
-9 6 ± 3llS 7 ± 4DS 1 ± IDS O±O 
-8.S 8 ± 3llS 8 ± 3llS 4 ± 2llS O±O 
-8 13 ± 3llS 13 ± 4llS 6 ± 2llS O±O 
-7.S 20 ± 6llS 17 ± SllS 7 ± 2llS o±o 
-7 21 ± SllS 17 ± SllS 7 ± 2llS 1 ± IllS 
-6.S 24 ± 6llS 18 ± SllS 8 ±2* 1 ± 1 * 
-6 26 ± 6llS 28 ± lOllS 12 ± 4* 1 ± 1 * 
-S.S 30 ± SllS 33 ± 9llS 12 ± 3* 1 ± 1 * 
-S 3S ± 6llS 39 ± lOllS 17 ± 4* 1 ± 1 * 
-4.S 39 ± 7llS 43 ± lOllS 19 ± 4* 1 ± 1 * 
-4 42 ± 7llS 4S ± lOllS 19 ± 4* 1 ± 1 * 
-3.S 42 ± 7llS 47 ± lOllS 19 ± 4* 1 ± 1 ** 
Table 3.7: Control rats: The measurement of vasodilatation as % of30!-1M S-HT- or 
SOmM KCl-induced tone effected at each point in the ACh CCRC. L-NAME (n=6); 
indomethacin (n=6); apamin (Ap) & charybdotoxin (ChTX) (n=6); and KCl/ACh 
(n=6). Data expressed as mean ± SEM. Statistical comparisons were made using a 
one-way ANOVA with a Dunnetts' post-test. P < O.S*, P < 0.01 ** vs. ACh control. 
ns = not significant. 
82 
3.3.4. Hypoxic Wistar rat PRAs: 
ACh induced vasodilatation in hypoxic Wi star rat PRAs with a pECso of 7.71 ± 0.30 
(n = 8) and a maximum relaxation response of 76 ± 6% (as % of 5-HT-induced tone). 
The ACh-induced vasodilatation in chronic hypoxic rats is compared with that 
observed in the control rats later in the results section. A summary of pECso values 
are shown in Table 3.10. The ACh-induced vasodilatation was significantly different 
from the time control fall off of tone (P < 0.01). The vasodilator responses to ACh 
are displayed in Figure 3.3. 
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Figure 3.3: Vasodilator response to ACh in the hypoxic Wi star rat PRAs in the 
presence and absence of various vasodilator inhibitors. 5-HT Time control (n=8); 
ACh alone (n=8); L-NAME (n=6); indomethacin (n=8); and apamin & charybdotoxin 
(n=7). Data expressed as percentage of lO/lM 5-HT-induced tone. Each point 
represents the mean ± SEM. n = number of individual PRAs from the same number 
of individual lung preparations. 
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Tables 3.8 and 3.9 demonstrate an equivalent contractile response to 50mM KCl and 
10~M 5-HT in the different protocol groups of chromic hypoxic rat PRAs. However, 
the contraction to 50mM KCl in the indomethacin and KCli ACh protocol groups is 
significantly smaller than that observed in the protocol group treated with ACh alone 
(P < 0.05). 
Protocol 5-HT ACh L- Indom- Apamin KCl KCl/ 
Group Time alone NAME ethacin & Time ACh Control ChTX Control 
KCI-induced 4.25 4.80 5.08 1.63 4.72 1.70 2.04 
Constriction ± ± ± ± ± ± ± 
(mN) 1.31 1.09 0.91 0.31 * 0.94 0.43* 0.33 
Vessel 135 147 160 168 156 176 158 
± ± ± ± ± ± ± Size (f.tm) 11 13 14 14 18 30 26 
n= number n=8 n=8 n=6 n=8 n=7 n=4 n=4 
Table 3.8: Dimensions and measurements of 50mM KCl-induced tone achieved in 
the various protocol groups. Data expressed as mean ± SEM. n number of 
individual PRAs from the same number of individual lung preparations. 
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Protocol 5-HT Time AChalone L-NAME Indomethacin Apamin& Group Control ChTX 
5-HT-
induced 2.55 ± 0.58 2.40 ± 0.69 3.25 ± 1.31 1.16 ± 0.25 3.68 ± 0.58 Pre-tone 
(mN) 
n=number n=8 n=8 n=6 n=8 n=7 
- --- ---
Table 3.9: Measurements of 10J..lM 5-HT-induced pre-constriction achieved in the 
PRAs of various protocol groups from hypoxic Wistar rats. Data expressed as mean ± 
SEM. n = number of individual PRAs from the same number of individual lung 
preparations. 
ACh-induced vasodilatation in the presence ofO.lmM of the NOS inhibitor, 
L-NAME (n=6), was significantly different from the fall off of tone at 0.3mM ACh 
(P < 0.01). The vasodilator response to ACh in the presence of L-NAME is 
displayed in Figure 3.3. There was no significant decrease in the potency of ACh in 
the presence ofL-NAME. A summary ofthe pECso values can be seen in Table 3.10. 
There was no attenuation of the maximum relaxation response to ACh in the presence 
of L-NAME, however, there was a significant difference between the vasodilatation 
effected between 0.3J..lM-3J..lM ACh (P < 0.05). A summary of these results is shown 
in Table 3.11. The presence of L-NAME caused a 5 ± 1% increase in the basal tone 
of the chronic hypoxic rat PRAs. 
ACh-induced vasodilatation in the presence of IJ..lM of the COX inhibitor, 
indomethacin (n=8), was significantly different from the fall off of tone at 0.3mM 
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ACh (P < 0.01). The vasodilator response to ACh in the presence of indomethacin is 
displayed in Figure 3.3. There was no significant decrease in the potency of ACh in 
the presence of indomethacin. A summary of the pEC50 values can be seen in Table 
3.10. There was a significant attenuation of the maximum relaxation response to 
ACh in the presence of indomethacin, and there were significant differences between 
the vasodilatation effected by 30 M and 0.3mM of ACh ( P < 0.05). A summary of 
these results is shown in Table 3.11. The presence of indomethacin did not affect the 
basal tone of the chronic hypoxic rat PRAs. 
ACh-induced vasodilatation in the presence of O.1~M of Kca channel blockers, 
apamin & charybdotoxin (ChTX) (n=7), was significantly different from the fall off 
of 5-HT-induced tone (P < 0.01). The vasodilator response to ACh in the presence of 
apamin & charybdotoxin is displayed in Figure 3.3. There was no significant 
decrease in the potency of ACh in the presence of apamin & ChTX. A summary of 
pEC50 values can be seen in Table 3.10. However, there was a significant attenuation 
of the maximum vasodilator response to ACh in the presence of apamin and ChTX 
and in the relaxation effected between 0.3~M - 0.3mM (P < 0.05). The Kca channel 
blockers significantly inhibited the relaxation response at concentrations of 0.3~M-
0.3mM of ACh. A summary of these results is shown in Table 3.11. The presence of 
apamin and ChTX did not affect the basal tone of the chronic hypoxic rat PRAs. 
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Protocol pECsovalue n number Group 
ACh alone 7.71 ± 0.30 n= 8 
L-NAMEI 7.82 ± 0.39llS n=6 ACh 
Indomethacin I 7.23 ± 0.44llS n=8 ACh 
Apamin& 7.38 ± 0.41 lls n=7 ChTXI ACh 
Table 3.10: pECso values for ACh ± various vasodilator inhibitors in hypoxic Wistar 
rat PRAs. Data are expressed as mean ± SEM. n = number of individual PRAs from 
the same number of lung preparations. Statistical comparisons were made using a 
one-way ANOVA with a Dunnetts' post-test. ns = not significant vs. ACh control. 
The raising of tone in small resistance arteries with KCI has been shown to inhibit the 
release of endothelium-derived hyperpolarising factor (EDHF). Therefore, 
experiments were conducted in which the tone of the arteries was raised by the 
addition of 50mM KCI instead of 10JlM 5-HT before conducting the ACh CCRC. 
There was no significant difference in the relaxation response induced by ACh in the 
KCII ACh protocol group compared to the fall off of tone in the KCI time control 
group at any given concentration of ACh (both n=4). However, the ACh-induced 
vasodilatation after pre-constriction with KCI is significantly less than the relaxation 
effected by ACh after 5-HT pre-constriction (P < 0.01) at the highest concentration of 
ACh. Therefore, the pre-constriction of hypoxic PRAs with 50mM KCI inhibits any 
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subsequent relaxation response to ACh, an effect not seen when the PRA is pre-
constricted with 10 M 5-HT. A summary of these results is shown in Table 3.11. 
AehBath 5-HT I 5-HT I 5-HT I Ap & KCll ACh Conen L-NAME Indomethacin ChTX 
-9 14 ± 4llS 9 ± 4llS 10 ± 5llS O±O 
-8.5 24 ± 7llS 13 ± 5llS 17 ± 6llS O±O 
-8 28 ± 6llS 21 ± 6llS 26 ± 6llS o ±O* 
-7.5 31 ± 7llS 26 ± 7llS 29 ± 6llS o ± 0* 
-7 33 ± 6llS 27 ± 7llS 31 ± 6llS 1 ± 1 ** 
-6.5 35 ± 5* 36 ± 7llS 34± 7* 1 ± 1 ** 
-6 37 ± 5* 35 ± 8llS 38 ± 7* 1 ± 1 ** 
-5.5 40 ±4* 38 ± 9llS 42 ± 6* 1 ± 1 ** 
-5 43 ± 5llS 41 ± 9llS 43 ± 7* 1 ± 1 ** 
-4.5 55 ± l1 lls 46 ± 10* 44± 7* 1 ± 1 ** 
-4 57 ± lOlls 47 ± 11 * 44 ± 10* 1 ± 1 ** 
-3.5 58 ± lOlls 47 ± 9* 44 ± 10* 2 ± 1 ** 
Table 3.11: Chronic hypoxic rat: The measurement of vasodilatation as % of 10 M 
5-HT- or 50mM KCl-induced tone effected at each point in the ACh CCRC in chronic 
hypoxic rat PRAs.. L-NAME (n=6); indomethacin (n=8); apamin (Ap) & 
charybdotoxin (ChTX) (n=7); and KClIACh (n=4). Data expressed as mean ± SEM. 
Statistical comparisons were made using a one-way ANOVA with a Dunnetts' post-
test. P < 0.5*, P < 0.01 ** vs. ACh control. ns = not significant. 
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3.4. Discussion 
3.4.1. Chronic hypoxic rat model of PHT: 
The right ventricular to left ventricular + septum ratios of the rats used in this study 
display the presence of significant right ventricular hypertrophy in the hypoxic Wistar 
rats. Therefore, the treatment of rats for 14 days in a hypobaric chamber produces a 
reliable and useful animal model of primary PHT (MacLean et ai., 1995; MacLean & 
McCulloch, 1998). 
3.4.2. ACh-induced vasodilatation in control and chronic hypoxic rats: 
The 5-HT pre-constriction achieved was higher in the chronic hypoxic rat PRAs than 
in the control rat PRAs, despite using a smaller concentration of 5-HT in the chronic 
hypoxic rat PRAs. However, this augmentation of the 5-HT pre-constriction was only 
significant in the 5-HT time control and apamin & charybdotoxin protocol groups. It 
is not clear if this disparity would have had any influence over the results in the 
chronic hypoxic group. A previous study involving the chronic hypobaric hypoxia rat 
model revealed that the tension at which vessels were set at during wire myography 
experiments changed the potency of and maximum response to ET -1 and sarafotoxin 
(STXs6c) (MacLean & McCulloch, 1998). This study showed that PRAs from control 
rats were more sensitive to ET -1 when set at ~ 16mmHg, while STXs6c showed an 
increased maximum vasoconstrictor response when set at ~35mmHg. STXs6c was 
more potent than ET -1 in the chronic hypoxic PRAs, but the potency of STXs6c was 
increased further in vessels set at ~35mmHg. These results showed that the basal tone 
of the PRAs influenced the effect produced by STXs6c and ET -1. It is unclear if the 
degree of 5-HT -induced tone has effected the ACh-induced relaxation, but, this 
limitation of the study should be remembered while reviewing these results. 
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A previous study regarding the ACh-induced relaxation in control and chronic 
hypoxic rat PRAs found that the potency of, and maximum vasodilator response to, 
ACh was significantly greater in the chronic hypoxic rat vessels (MacLean & 
McCulloch, 1998). This present study also found that the maximum relaxation 
response was significantly augmented in the chronic hypoxic rats, but did not find an 
increase in the potency of ACh in these vessels. Therefore, the vasodilator response to 
ACh is augmented in the presence ofPHT. 
3.4.3. Mediators of ACh-induced vasodilatation in control rat PRAs: 
This study has revealed that the NOS inhibitor, L-NAME, did not inhibit the 
relaxation produced at any given concentration of ACh. L-NAME did not decrease 
the potency of ACh in these vessels. Therefore, NO does not playa role in mediating 
the vasodilator response to ACh in control rat PRAs. However, a previous study 
showed that there is a NO component in the ACh-induced vasodilatation in all the 
branches of the mesenteric arterial bed. These findings reveal a differential mediator 
profile of the ACh-induced relaxation depending on the vascular bed being studied 
(Parsons et ai., 1994). The inhibition of NO with 1 o o 11M of the NOS inhibitor, 
L-NAME, did not affect the basal tone of the control rat arteries. These results are in 
agreement with earlier studies, in both perfused whole lung preparations and isolated 
small muscular arteries, that showed that NO is not involved in the maintenance of the 
low vascular tone seen in the pulmonary circulation in control rats (Hasunuma et ai., 
1991; MacLean & McCulloch, 1998). The findings of the present study, taken with 
the results from the afore mentioned studies showing no NO component in the 
90 
regulation of vascular tone in control animals, suggests that NO has no role in the 
regulation of the low pulmonary vascular tone or ACh-induced vasodilatation in the 
control rat PRAs. 
The presence of indomethacin, a COX inhibitor, did not inhibit the vasodilatation 
effected by any given concentration of ACh. Indomethacin also failed to decrease the 
potency of ACh in these vessels. Therefore, COX products such as PGI2 do not playa 
role in mediating the vasodilator response to ACh in control rat PRAs. There was no 
increase in the basal tension of the control rat PRAs after the addition of 
indomethacin, suggesting that basal release of prostaglandins such as PG 12 are not the 
regulator of the low vascular tone of these vessels under normal physiological 
conditions. 
The addition of the Kca channel blockers charybdotoxin and apamin, inhibitors of the 
large & intermediate (BKca & IKca) and small (SKca) conductance channels 
respectively, significantly attenuated the maximum relaxation response produced by 
ACh in the control rat PRAs. These K+ channel blockers did not decrease the 
potency of ACh. The addition of apamin and ChTX did not affect the basal tone of 
the control rat PRAs, so EDHF acting via Kca channels is not involved in the 
regulation of the low vascular tone observed in these vessels. Raising the tone of the 
vessels with KCI resulted in an extremely significant inhibition of the ACh-induced 
vasodilatation in the control rat PRAs. Previous studies have shown that pre-
constriction with KCI inhibits the activity ofEDHF in the arteries of various vascular 
beds (Plane & Garland, 1993; Garland et at., 1995; Shimokawa et at., 1996; Urakami-
Harasawa et at., 1997; Ohlmann et at., 1997). Therefore, EDHF, acting via 
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intermediate and small Kca channels, is a mediator of the ACh-induced vasodilatation 
in the control rat PRAs. These findings are in accordance with those of previous 
studies which showed that the presence of EDHF-mediated vasodilatation was 
inversely proportional to vessels size. It was shown in the mesenteric arteries of the 
rat that the importance of EDHF-mediated relaxation increased as the size of the 
vessel decreased and that EDHF-induced hyperpolarization is an essential mechanism 
of vasodilatation in the small resistance arteries (Garland et al., 1995; Shimokawa et 
al., 1996; Urakami-Harasawa et al., 1997). These results suggest that EDHF is 
involved in the maintenance of the low pulmonary vascular tone in physiologically 
normal lungs. However, a previous study had suggested that EDHF-mediated 
regulation of vascular tone in the pulmonary artery is produced through the activation 
ofKATP channels (Quayle & Standen, 1994). Therefore, it is unsurprising that EDHF, 
acting via IKca and SKca channels, mediates part of the ACh-induced vasodilatation 
response in the small muscular pulmonary resistance arteries. However, to really 
prove that EDHF is involved would require electrophysiological studies to be 
conducted. 
EDHF has been shown to mediate vasodilatation and hyperpolarization in rat 
mesenteric arteries; guinea pig coronary arteries and submucosal arterioles; and 
human subcutaneous resistance arteries (Chen & Cheung, 1997; Coleman et al., 2001; 
McIntyre et aI., 2001). However, non-NO-, non-prostanoid-dependent relaxation 
mediated by EDHF has been shown to act via mechanisms other than IKca and SKca 
channels in several vascular preparations in various species. Previous studies have 
shown that EDHF-mediates relaxation and hyperpolarization via the Na+-K+ ATPase 
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extrusion pump as ouabain inhibits the EDHF-mediated effects in the small 
mesenteric and renal arteries of the rat (Jiang et al., 2000; Dora & Garland, 2001). 
There has been considerable speculation over the identity of EDHF. It has been 
postulated that EDHF could be one of a number of arachidonic acid, 
epoxyeicosatrienoic acid or eicosapenatanoic acid metabolites produced by 
cytochrome P-4S0 epoxygenase, or even K+ itself (Bauersachs et ai., 1996; 
McCulloch et ai., 1997; Edwards et ai., 1998; Quilley & McGiff, 2000; Dora & 
Garland, 2001; Zhang et ai., 2001). Recent studies have revealed the mechanism by 
which EDHF released from the endothelial cells mediates hyperpolarization of the 
vascular smooth muscle. These studies have showed that EDHF-mediated K+ channel 
activation is almost instantaneous in the endothelial and vascular smooth muscle cells 
suggesting that the two layers of cells act as a single syncytium due to the presence of 
myoendothelial gap junctions which allow . the electrotonic spread of the 
hyperpolarization to affect the VSMC (Dora et ai., 1999; Harris et ai., 2000; 
Coleman et ai., 2001). 
The results from these studies support the theory that EDHF may not be a single 
substance but a family of substances. It has been suggested that there may be 
variations in the type ofEDHF released and the K+ channels and other effector targets 
stimulated by its release depending on the vascular bed and species being studied 
(Jiang et ai., 2000). Therefore, the results from this study could be explained by the 
fact that one type ofEDHF, which acts via the IKca and SKca channels is released 
from the endothelium in response to concentrations of ACh 0.3/lM and above, and 
that another type of EDHF may be released to maintain the low vascular tone seen in 
normoxic PRAs which acts through other K+ channels and / or Na+-K+ ATPase. 
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However, this study did not determine the other mechanisms of EDHF-induced 
relaxation and hyperpolarization involved in the ACh-induced vasodilatation in the 
control rat PRAs. 
3.4.4. Mediators of ACh-induced vasodilatation in chronic hypoxic rat PRAs: 
This study revealed that L-NAME significantly inhibited the ACh-induced 
vasodilatation between the concentrations of O.3)lM - 3)lM. However, L-NAME did 
not decrease the potency of ACh in these vessels. These results are in contrast to the 
finding of a recent study which documented a decrease in the NO release and NO-
mediated vasodilatation in the intrapulmonary arteries of chronic hypoxic rats (Murata 
et al., 2001). Therefore, NO plays a significant role in mediating the ACh-induced 
vasodilatation in the chronic hypoxic rat PRAs. This is consistent with earlier studies 
showing an increased level of eNOS the large and small pulmonary vessels from 
chronic hypoxic rats (Le Cras et al., 1996; Demiryurek et al., 2000). This increased 
expression of eNOS is not accompanied by a subsequent increase in ACh-induced 
vasodilatation in all arteries as ACh-induced relaxation is attenuated in the large 
pulmonary arteries while being augmented in the small PRA in the presence of 
hypoxia (MacLean et al., 1995; MacLean & McCulloch, 1998). These observations 
are confirmed by the levels of cGMP found in these vessels as the levels are 
decreased in the large pulmonary arteries while remaining unchanged in the PRAs 
(MacLean et al., 1996). A recent study has revealed an increase in the activity of 
cGMP-specific phosphodiesterase V, (PDE5), in large pulmonary arteries from 
chronic hypoxic rats through the de novo synthesis of the PDE5A2 protein, resulting 
in decreased levels of cGMP and subsequent attenuation of ACh-induced 
vasodilatation in these vessels (Murray et al., in press). However, PDE5 levels 
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remain unchanged in the presence of hypoxia in the PRAs which accounts for the 
ability of ACh to induce vasodilatation in PRAs, indeed, this vasodilator effect of 
ACh may be augmented due to increased levels of guanylate cyclase in these vessels 
(Li et at. 1999). These findings are consistent with the previous observations that 
sildenafil, a selective PDE5 inhibitor, selectively induces vasodilatation of the large 
pulmonary arteries but does not affect the PRAs (Oka et at., 2001). A recent study 
has also shown that mice treated with sildenafil were protected from the development 
of hypoxia-induced PHT (Zhao et at., 2001). The presence ofL-NAME revealed the 
higher endogenous tone of these vessels suggesting that NO is also involved in the 
inhibitory mechanism which attempts to compensate for the increased pulmonary 
vascular tone in chronic hypoxic PRAs as seen in previous studies (Hasunuma et at., 
1991; MacLean & McCulloch, 1998). These results agree with a previous study 
which found that there was a significant up-regulation of eNOS in the pulmonary 
arteries of chronic hypoxic rats as no involvement of NO in the ACh-induced 
vasodilatation was seen in the control rat PRAs. Therefore, it can be hypothesised 
that although the increase in NO production and release facilitates the ACh-induced 
relaxation of chronic hypoxic rats, there is also an increase in peroxynitrite production 
which may exacerbate damage to these vessels (Demiryurek et at., 1998). NO 
mediates relaxation by activating guanylate cyclase which increases the concentration 
of cGMP in the vascular smooth muscle cells which activates protein kinase G which 
inhibits IP3-stimulated release of intracellular Ca2+ resulting in relaxation. NO can 
mediate relaxation by activating K+ channels via PKG activation and that NO can also 
directly activate Kca channels (Hasunuma et at., 1991; Bolotina et at., 1994; Tare et 
at.,2000). A previous study showed that NO caused hyperpolarization of VSMC's 
of the rabbit aorta independently of guanylate cyclase activation (Bolotina et at., 
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1994). Another study investigating the mediators involved in the ACh-induced 
vasodilatation in the coronary and mammary arteries of the guinea-pig using an 
integrated approach to study the effects of NO on the tension and membrane potential 
of these vessels found that while NO caused hyperpolarisation of the membrane 
potential via KATP channels, the hyperpolarization was not important to the 
vasodilator effect of NO in these vessels (Rand & Garland., 1992; Tare et al., 1998). 
As this present study did not take an integrated approach, the presence of NO-
mediated hyperpolarization in response to ACh, and its relationship with the 
vasodilator effect of NO in the PRAs of the chronic hypoxic rat can only be 
speculated upon. 
The presence of indomethacin, a preferential inhibitor of COX-I, significantly 
attenuated the vasodilatation effected by ACh at concentrations of 30~M and above. 
However, indomethacin failed to decrease the potency of ACh in these vessels. 
Therefore, PGh does playa role in mediating the vasodilator response to ACh in 
chronic hypoxic rat PRAs. The incubation of chronic hypoxic rat PRAs did not result 
in an increase of the basal tone of these vessels. Therefore, PGI2 is not involved in 
the inhibitory mechanism which attempts to compensate for the increased basal 
pulmonary vascular tone observed in these vessels. This result is surprising 
considering that prostacyclin synthase (PG 12-S) expression has been shown to be 
significantly reduced in pulmonary vessels of all sizes in patients with severe primary 
PHT (Tuder et al., 1999). Previous studies have shown that the expression of PGh-S 
can inhibit the development of PHT in various animal models. A study involving 
transgenic mice designed to over-express PG 12-S showed that the transgenic mice had 
a lower right ventricular pressure and decreased pulmonary vascular remodelling than 
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non transgenic mice after chronic hypobaric hypoxia (Geraci et ai., 1999). Another 
study found that rats with monocrotaline-induced PHT showed a reduction in the 
mean pulmonary arterial pressure and total pulmonary vascular resistance when 
transfected with PG lz-S compared to control rats (Nagaya et ai., 2000). There was 
no increase in the basal tension of the chronic hypoxic rat PRAs after the addition of 
indomethacin, suggesting that basal release of PGh is not a regulator of the low 
vascular tone of the pulmonary vasculature of control or chronic hypoxic rats. PGI2 
mediates vasodilatation in the VSMCs by activating adenyl ate cyclase which 
Increases cAMP which stimulates protein kinase A resulting in a reduction of 
intracellular calcium release and decreasing the sensitivity of the contractile apparatus 
to Ca2+ leading to VSMC relaxation (Gambone et ai., 1997; Zygmunt et ai., 1998; 
Tare et ai., 2000). Previous studies have also shown that PGh can mediate 
hyperpolarisation in the coronary and mammary arteries of the guinea-pig, the renal 
artery of the rat and superior mesenteric arteries of the hamster. In rat the PGI2-
mediated hyperpolarization was resistant to inhibition by glibenclamide and / or 
ChTX plus apamin suggesting that the effect on membrane potential in the rat arteries 
were not produced via ATP-sensitive K+ or IKca and SKca channels. (Zygmunt et ai., 
1998). In the guinea-pig arteries, the PGh-mediated hyperpolarisation was inhibited 
by glibenclamide revealing the role of KATP channels in this effect (Tare et ai., 2000). 
The PGh-mediated hyperpolarisation of the hamster superior mesenteric artery has 
also been shown to be caused by the opening of KATP channels (Thapaliya et al., 
2000). The integrated investigation of the guinea-pig arteries showed that, in contrast 
to NO, the PGI2-mediated hyperpolarisation was important to its vasodilator effect 
(Tare et al., 2000). As this present study was not an integrated study, the role of 
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PGIz-induced hyperpolarisation and its relationship with the PGIz-mediated 
vasodilatation in response to ACh was not investigated. 
The addition of the Kca channel blockers charybdotoxin and apamin, inhibitors of the 
large & intermediate (BKca & IKca) and small (SKca) conductance channels 
respectively, significantly attenuated the maximum relaxation response produced by 
O.3I1M and above of ACh in the chronic hypoxic rat PRAs. These K+ channel 
blockers did not decrease the potency of ACh. Raising the tone of the vessels with 
KCI resulted in an extremely significant inhibition of the ACh-induced vasodilatation 
in the chronic hypoxic rat PRAs. However, the concentration of KCI used in this 
thesis (50mM) could have resulted in such a strong depolarization that no vasodilator 
mediator would have elicited a relaxation. This possibility must be considered due to 
the fact that there was no relaxation in CH PRAs pre-constricted with KCI even 
though NO and PGIz are involved in the relaxation in these vessels. Previous studies 
have shown that pre-constriction with KCI inhibits the release ofEDHF in the arteries 
of various vascular beds (Plane & Garland, 1993; Garland et at., 1995; Shimokawa et 
at., 1996; Urakami-Harasawa et at., 1997; Ohlmann et at., 1997). Therefore, EDHF, 
acting via intermediate and small Kca channels, is a mediator of the ACh-induced 
vasodilatation in the chronic hypoxic rat PRAs. There was no increase in the basal 
tension of the chronic hypoxic rat PRAs after the addition of ChTX and apamin, 
suggesting that basal release of EDHF acting via IKca and SKca channels is not a 
regulator of the low vascular tone of the pulmonary vasculature of control rats and is 
not involved in the inhibitory mechanism which attempts to compensate for the 
increased pulmonary vascular tone observed in chronic hypoxic rats. However, 
EDHF acting via other K+ channels or Na+-K+ ATPase may playa role in the 
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maintenance of the low vascular tone in the pulmonary vasculature of control and 
chronic hypoxic rats as previous studies have shown that other types of EDHF 
mediate relaxation and hyperpolarization via these mechanisms (Jiang et at., 2000; 
Dora & Garland, 2001). It is unlikely that another type ofEDHF, whose mechanism 
of action is not inhibited by the Kca channel blockers, was released in these vessels at 
concentrations of ACh below 10~M as L-NAME inhibits the ACh-induced 
vasodilatation between 0.3-3~M. 
3.4.5. Interaction of mediators involved in the ACh-induced vasodilatation: 
Previous studies have displayed interactions between the endogenous vasodilator 
mediators in some vessels and that the role of certain mediators is only revealed when 
the other mediators are inhibited or lost through disease processes. Several earlier 
studies displayed an inhibition of EDHF-mediated effects in the presence of 
functional NO. NO was the mediator of ionomycin (calcium ionophore)-induced 
vasodilatation in large pulmonary arteries of control sheep. However, NO and EDHF 
mediated the relaxation to ionomycin in the large pulmonary arteries of chronic 
hypoxic sheep, and that the effects ofEDHF are only revealed by the inhibition of NO 
production (Kemp et al., 1995). The NOS inhibitor, L-NNA, was found to reveal an 
EDHF component to the ACh-mediated vasodilatation of the rabbit carotid and 
porcine coronary arteries (Bauersachs et at., 1996). In the superior mesenteric artery 
of the rat, NO and EDHF mediate the vasodilatation induced by the muscarinic 
agonist, carbachol. The EDHF component of the relaxation was increased in the 
presence of L-NAME and decreased in the presence of increased levels of cGMP 
(McCulloch et at., 1997). The results of these studies suggest that EDHF-mediated 
vasodilatation is merely a compensatory backup system which could maintain blood 
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flow and tissue perfusion should the effects of NO be lost. There has been evidence 
that NO release is impaired in patients with pulmonary hypertension, systemic 
hypertension, congenital heart disease, asthma, or in those who smoke (Barnes & 
Belvisi, 1993; Kharitonov et at., 1994; Persson et at., 1994; Schilling et at., 1994; 
Berger et at., 2001). EDHF release has also been shown to be down-regulated in the 
large human arteries in patients who were effected by old age, hypertension, or 
diabetes (Urakami-Harasawa et at., 1997; Coleman et at., 2001). However, another 
study found that EDHF was not modulated by the release of NO and was, therefore, 
not merely a compensatory vasodilator mechanism in the rat hepatic artery (Zygmunt 
et at., 1998). A previous study in canine large pulmonary arteries found that NO and 
PG b synergistically mediated the bradykinin-induced vasodilatation of these arteries. 
This synergy was abolished by the KATP channel inhibitor glibenc1amide (Gambone et 
at., 1997). However, this vasodilator mediator profile was not observed in these 
vessels when the agonist inducing vasodilatation was ACh or the calcium ionophore, 
A23187. These results suggest that the vascular bed and species of animal the 
vessels are being studied from shows variation in whether there is antagonism or 
synergy between the vasodilator mediators as well as influencing which mediators are 
released in response to agonist-induced stimulation. This present study did not 
investigate the possibility of vasodilator mediator interaction by combining the 
inhibitors of two or more mediators at the same time. However, the fact that NO, 
PGI2, and EDHF all playa part in the ACh-mediated relaxation of chronic hypoxic rat 
PRAs suggests that there is no inhibition of EDHF-mediated effects in these vessels. 
Therefore, EDHF does not appear to be a compensatory back up system for NO and 
PG 12-mediated relaxation. 
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The involvement of all three endogenous mediators in one vessel would ensure the 
maintenance of blood flow in the event of a loss of one of these vasodilator pathways 
due to disease (Zygmunt et al., 1998; Tare et al., 2000). The fact that the small 
muscular pulmonary arteries of the chronic hypoxic rat exhibit the involvement of all 
three mediators when compared with the same vessels from the control rat may reflect 
the need for a greater vasodilator capacity to counterbalance the raised endogenous 
tone found in the hypoxic lungs and the importance of keeping these arteries open 
ensuring adequate perfusion of the alveoli. 
3.5. Conclusion 
EDHF is the mediator of ACh-induced relaxation in the control rat PRAs. This effect 
is mediated partly by activation of IKca and SKca channels. However, other types of 
EDHF acting through other K+ channels and the Na+-K+ ATPase pump may mediate 
the low vascular tone observed in control rat PRAs. 
NO, PGh, and EDHF all playa role in the ACh-induced vasodilatation of chronic 
hypoxic rat PRAs. EDHF appears to be mainly mediated through the Kca channels in 
these vessels. The involvement of all three mediators in the relaxation response in 
chronic hypoxic but not control rat PRAs may be a protective mechanism to ensure 
the adequate perfusion of the alveoli despite a greater level of endogenous tone in 
these vessels. 
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Chapter 4 
Effect of human urotensin-II on 
human small muscular resistance 
arteries of the pulmonary and 
systemic circulations 
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4.1.1. History of urotensin-II: 
Urotensin-II (U-II) is a cyclic peptide first isolated from the caudal neurosecretory 
system of the goby fish (Gillichthys mirabilis) (Bern & Lederis, 1969). Goby U-II is 
a 12 amino acid residue peptide (see Figure 4.1) (Davenport & Maguire, 2000). As 
well as inducing widespread contraction of smooth muscle in fish, goby U-II has been 
shown to elicit a vasoactive response in the vascular smooth muscle of isolated 
mammalian arteries from species such as the rat (Gibson, 1987; Itoh et ai, 1987). 
Previous studies using rat major arteries, particularly the thoracic aorta showed that 
goby U-II induced a vasoconstrictor and endothelium-dependent vasodilator effect in 
this tissue (Gibson, 1987; Itoh et aI., 1987). These results revealed a possible 
physiological role for U-II in the cardiovascular systems of mammalian species. 
4.2.2. U-II synthesis: 
The 124 amino acid residue precursor of human U-II (hU-II), prepro-urotensin-II was 
cloned from human colon tumour samples (Coulouarn et al., 1998). hU-II is an 11 
amino acid peptide with a hexapeptide sequence at the c-terminal which has been 
conserved from the goby U-II isoform (see Figure 4.1) and a variable sequence at the 
N-terminal. The discovery of the conserved region of the U-II between the human 
and goby isoforms increased the evidence for a physiological role for U-II in 
mammals. The distribution of human prepro-U-II mRNA was found to be at its 
highest level in the spinal cord, particularly in the ventral horn motor neurones, and 
the medulla oblongata (Coulouarn et al., 1998; Ames et al., 1999; Coulouarn et al., 
1999). Both prepro-U-II and hU-II mRNA and immunoreactivity have been found in 
low levels in peripheral tissues in mammals, such as in skeletal muscle, liver and 
103 
kidney, while UT receptor mRNA has been found in the lung and the pancreas 
(Elshourbagy et aI., 2002). 
I (a) Goby 
1 (b) Human -I 
I (c) Porcine 
I (d) Mouse 
Figure 4.1: Amino acid sequences for (a) goby; (b) human; (c) porcine U-II. The 
predicted sequence of (d) mouse (Coulouarn et aI., 1999; Davenport & Maguire, 
2000). Illustration adapted from Davenport & Maguire, 2000. 
104 
These peptides were found to be expressed in tissues of humans and primates such as 
cardiac smooth muscle cells and coronary atherosclerotic plaques; the kidneys and 
adrenal glands (Coulouam et aI., 1998; Ames et al., 1999; Davenport & Maguire, 
2000). 
4.2.3. U-II isoforms: 
The mouse; porcine; and goby U-II isoforms were also isolated and were found to be 
comprised of 14; 12; and 12 amino acid peptides respectively (see Figure 4.1). These 
isoforms also exhibited the conserved hexapeptide sequence at the C-terminal, 
suggesting that the biological activity of U-II is conferred by the C-terminal 
(Coulouam et aI., 1998; Mori et al; 1999; Davenport & Maguire, 2000). This 
conserved hexapatide sequence has an acidic DIE N-terminus and a carboxyl residues 
which are also conserved between species. This conserved octapeptide sequence is 
the minimum required sequence which allows full biological activity of the U-II 
peptide as truncation of the N-terminus of the peptide only affects biological activity 
when the truncation interrupts this conserved octapeptide sequence (Itoh et aI., 1988; 
Elshourbagy et al., 2002). The amino acid sequences of preproU-II reveals 
differentiation between higher and lower vertebrates with 93% homology between 
human and monkey, 48% between human and mouse and 25% between human and 
carp C-terminus of these sequences (Elshourbagy et ai., 2002). There is also a 
differentiation in the amino acid sequence homology of UT receptors between higher 
and lower vertebrates. The importance of U-II was further secured when an 
endogenous receptor was discovered. The rat orphan G-protein coupled receptor 14 
(GPR14) was found to be selectively activated by the isoforms ofU-II which induced 
Ca2+ mobilisation in cells expressing the receptor (Ames et al., 1999; Mori et ai., 
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1999; Davenport & Maguire, 2000; Elshourbagy et al., 2002). GPR14 is now referred 
to as the U-II receptor and is designated as UT-II. The sequence of the monkey UT 
receptor shows 97 and 77% homology with human and rat UT receptors, while mouse 
UT receptors show 76 and 93% homology with human and rat UT receptors 
respectively (Elshourbagy et aI., 2002). Expression ofUT-II mRNA and radioligand 
binding assays revealed the presence of UT -II receptors in human cardiovascular 
tissues including the cardiomyocytes of the left atrium and ventricles; the endothelial 
and smooth muscle cells of the coronary artery and the aorta (Ames et al., 1999; 
Davenport & Maguire, 2000; Maguire et al., 2000; Affolter & Webb, 2001). No 
significant difference can be found in the affinities of each of the U-II isoforms from 
higher and lower vertebrate species for the recombinant UT-II receptor (Ames et al., 
1999; Elshourbagy et al., 2002). The highest density ofUT-II receptors was found in 
skeletal muscle. However, peripheral distribution of UT-II receptors included 
densities in the kidney; spleen; adrenal; and pituitary glands (Maguire et al., 2000; 
Affolter & Webb, 2001; Totsune et al., 2001). hU-II-Iike immunoreactivity has been 
observed in human plasma and a role as a circulating cardiovascular regulating 
hormone after release from peripheral tissues has been proposed (Affolter & Webb, 
2001; Totsune et al., 2001). The expression ofUT-II mRNA in cardiovascular tissues 
has created an interest of the possible pathophysiological role of U-II in the 
development of coronary atherosclerosis; systemic hypertension; and chronic heart 
failure (Ames et al., 1999; Davenport & Maguire, 2000; Affolter & Webb, 2001). 
However, the distribution of U-II and UT receptor mRNAs in the peripheral tissues 
outwith the eNS and the cardiovascular system suggest that U-II may modulate many 
physiological systems throughout the body, including influencing endocrine function 
and release (Elshourbagy et al., 2002). 
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4.1.4. U-II action: 
The systemic administration ofhU-II in the anaesthetised rat causes a minor increase 
in the cardiac output and a small, decrease overall in the total peripheral resistance of 
the rat vasculature while causing cardiovascular collapse as a result of a decreased 
myocardial contractility and an overall increase in total peripheral resistance in 
anaesthetised cynomolgus monkeys (Ames et at., 1999; Davenport & Maguire, 2000). 
The different species-dependent consequences of systemic hU-II administration may 
be explained by the vasoconstrictor profile ofhU-II on the isolated blood vessels from 
various vascular beds. hU-II was found to elicit a potent vasoconstrictor effect (-log 
[ECso] of 9.09 ± 0.19, n = 13) in the rat thoracic aorta, proximal to the aortic arch, yet 
has no vasoconstrictor activity in the more distal, abdominal aorta (Gibson, 1987; 
Ames et at., 1999; Douglas et at., 2000; Maguire et at., 2000). This is an example of 
the anatomical variation of the vasoconstrictor profile of hU-II. hU-II was more 
potent, but produced a lower maximum response, than ET -1 in this and every other 
isolated blood vessel preparation so far studied in various species (Ames et al., 1999; 
Douglas et at., 2000; Maguire et at., 2000; MacLean et at., 2000). In the human 
coronary artery, hU-II was 50 times more potent than, but only elicited a maximum 
response of 25% of that produced by ET -1 (Maguire et al., 2000). The diversity in 
hU-II-induced vasoconstriction between species is also observed in the pulmonary 
circulation. hU-II causes a potent vasoconstriction in the main pulmonary artery of 
the rat, however, no contraction was observed in the pulmonary artery of the dog 
(MacLean et al., 2000; Douglas et at., 2000). This is another example of the species 
variation in the vasoconstrictor profile ofhU-II. hU-II is a vasoconstrictor peptide of 
both the venous and arterial sides of the cardiovascular system (Douglas et at., 2000; 
Maguire et at., 2000). hU-II does not induce vasoconstriction of any arteries so far 
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studied in the mouse (Douglas et al., 2000). hU-II-induced vasoconstriction is 
observed in the thoracic aorta; common carotid; and main pulmonary artery of the rat 
(Douglas et al., 2000; MacLean et al., 2000). The vasoconstrictor effect was limited 
to the left circumflex and anterior descending coronary arteries in dogs (Douglas et 
al., 2000). The marmoset and pig displayed a variable vasoconstrictor profile of hU-
n -induced constriction. In the pig, the thoracic aorta; pulmonary; internal mammary; 
and common carotid arteries showed variable hU-II-induced constriction (Douglas et 
al., 2000). hU-II induced variable vasoconstriction was seen in the thoracic aorta; 
abdominal aorta; common carotid; and mesenteric arteries of the marmoset (Douglas 
et al., 2000). The most widespread vasoconstrictor profile was observed in the 
cynomolgus monkey. hU-II-induced vasoconstriction was seen in the thoracic and 
abdominal aortae; the left circumflex and anterior descending coronary arteries; the 
pulmonary; renal; internal mammary; femoral; basilar; common carotid; and 
mesenteric arteries. Vasoconstriction was also shown in the pulmonary; saphenous; 
and jugular veins (Douglas et al., 2000). So far, hU-II has been shown to 
vasoconstrict the human coronary; mammary; and radial arteries but not the 
endothelium-intact small muscular pulmonary resistance arteries (MacLean et al., 
2000; Maguire et al., 2000; Russell et al., 2001). However, 30% of small muscular 
pulmonary resistance arteries (PRAs) incubated with L-NAME did display a hU-II-
induced vasoconstriction of variable efficacy (MacLean et al., 2000). hU-II was 
shown to have no vasoconstrictor activity in human internal mammary artery or 
saphenous veins with a functional endothelium in patients with chronic heart failure 
and healthy volunteers (Hillier et al., 2001). However, a recent in vitro study in 
humans showed that removal of the endothelium, inhibition of NOS, and presence of 
chronic hypoxia either increased the potency and/or efficacy of hU-II in the rat main 
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pulmonary artery (MacLean et al., 2000). This reveals that the vasoconstrictor effect 
ofhU-II can be seen when one or several endothelium-derived vasoactive substances 
are removed or inhibited. This suggests a pathophysiological role for U-II in the 
cardiovascular system. hU-II also vasoconstricts endothelium denuded human 
saphenous and umbilical veins (Maguire et al., 2000). A recent in vivo study revealed 
a vasoconstrictor effect ofhU-II in humans. This study revealed that infusion of 
hU-II through the brachial artery resulted in a very significant reduction in forearm 
blood flow, demonstrating that hU-II has a potent in vivo vasoconstrictor effect in 
humans (Bohm & Pernow, 2002). hU-II has also been shown to increase the 
contractility of the myocardium of the right human atrium and ventricle (Russell et 
al., 2001). Activation of the UT-II receptor was found to elicit an increase in Ca2+ 
mobilisation (Ames et al., 1999). hU-II-induced vasoconstriction and increase in IP3 
generation in the rabbit thoracic aorta was inhibited by the phospholipase C inhibitor, 
NCDC (Opgaard et al., 2000). These findings suggest that the UT-II receptor is a Gq 
protein-coupled receptor that mediates contraction via the release of Ca2+ from 
internal stores due to phospholipase C activation causing IP3 generation. hU-II was 
shown to be a more potent positive inotropic peptide than ET -1 in human myocardial 
cells. hU-II did not cause arrhythmias in this tissue as readily as ET-l, and hU-II did 
not interfere with the time taken for the myocardium to relax to 50% of the tone of the 
original contraction (Russell et al., 2001). 
Intravenous administration of goby U-II in the rat caused a minor increase in cardiac 
output with a small reduction in regional vascular resistance resulting in a small 
vasodepressor effect (Ames et al., 1999). Endothelium-dependent relaxation of rat 
aortic strips has previously been observed (Gibson, 1987). These results suggest that 
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the hU-II may induce vasodilatation in some vessels in the same way that the 
vasoconstrictor peptide ET -1 can induce vasodilatation via its subpopulation of ET B 
receptors. A previous study on rat arteries showed that hU-II-induced both a 
vasoconstrictor and vasodilator effect in the left anterior descending coronary artery, a 
vasodilator effect in the mesenteric artery, and neither a vasodilator or vasoconstrictor 
effect in the rat basilar artery (Bottrill et at., 2000). hU-II-induced vasodilatation was 
observed in the coronary artery of the perfused rat heart after an initial transient 
vasoconstriction (Katano et at., 2000). 
The recently revealed evidence of a vasodilator effect of hU-II, coupled with the 
failure ofhU-II to constrict human small muscular PRAs without the presence of 
L-NAME, led to the question of whether or not hU-II would vasodilate these human 
PRAs. The vasodilator effect was also investigated in the small muscular resistance 
arteries of a systemic vascular bed, for which the abdominal adipose systemic 
resistance arteries (SRAs) were chosen. 
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4.2. Methods 
Small muscular pulmonary resistance arteries (PRAs) were dissected free from human 
lung tissue resected from patients undergoing thoracotomies for bronchial carcinoma. 
Written consent was obtained from patients to allow the collection of a biopsy of their 
resected lung for our study. As the anatomical position of the tumour varied between 
patients, the area of the lung that the biopsy of 'safety margin' tissue is from also 
varies and cannot be specified. Human small muscular PRAs were dissected free 
from the surrounding parenchyma and set up on an isometric wire myograph as 
described in chapter 2 (Mulvaney & Halpern, 1977). The transmural pressure of the 
vessels was set at ~ l6mmHg. 
Small muscular systemic resistance arteries were dissected from a biopsy of 
abdominal skin and adipose tissue taken from patients undergoing surgery for 
abdominal hernias. Written consent was obtained from patients to allow the 
collection of a biopsy of their abdominal tissue for our study. The area of abdomen 
that the biopsy came from varied as the position of the hernia varied from patient to 
patient. The small muscular systemic resistance arteries (SRAs) were dissected free 
from the surrounding adipose tissue and set up on an isometric wire myograph. The 
transmural pressure of the vessels was set at ~ 90mmHg. 
After the tension was stabilised, the vessels were left to equilibrate for 45 minutes. 
The viability of the vessels was assessed by adding 50mM KCI to the baths. This was 
repeated until two reproducible vasoconstrictions were obtained. There were several 
washes in between and a return to baseline before the next addition. The viability of 
the endothelium was assessed by adding 311M 5-HT to raise tone followed by 1 flM of 
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acetylcholine (ACh) to vasodilate the PRAs. The results of the endothelium function 
tests are shown for each protocol group in Table 4.6. Any vessels which did not 
show a functional endothelium were discarded from the study. Previous studies have 
shown that the endothelium could not be safely removed manually in these vessels 
without damaging the thin smooth muscle layer. Therefore, all vessels in this study 
have an intact and functioning endothelium. 
A submaximal dose of 10nM ET -1 was added to the baths to pre-constrict the PRAs 
in those protocols assessing hU-II-induced vasodilatation after ET-1-induced pre-
constriction. A subset of vessels were pre-constricted with ET -1 and left for the 
duration of the cumulative concentration response curve (CCRC) to hU-II as time 
controls to show that the smooth muscle cell relaxation induced by hU-II is not 
merely a consequence of a fall in ET-1-induced tone. A subset of vessels were pre-
constricted with ET-1 before being relaxed by porcine U-II to investigate the 
difference between isoforms of different species in their ability to relax PRAs and 
SRAs. The vessels of some protocol groups were incubated with one of three 
inhibitors of endogenous endothelium-derived vasodilators to investigate the 
mediator(s) involved in the hU-II-induced vasodilatation. The nitric oxide synthase 
inhibitor, 0.1mM NG-nitro-L-arginine methyl ester (L-NAME), was added to a subset 
of vessels to investigate a possible role of NO in the hU-II-induced vasodilatation 
(Gambone et al., 1997; Parsons et al., 1997; Bottrill et al., 2000; Tare et al., 2000). 
The cyclooxygenase inhibitor, 1!!M indomethacin, was added to a subset of vessels to 
investigate a possible role for PGI2 in the hU-II-induced relaxation (Gambone et al., 
1997; Bottrill et al., 2000; Tare et al., 2000; MacIntyre et al., 2001). The BKca and 
SKca (large and small conductance, respectively) calcium-activated potassium 
112 
channel blockers, 0.1 ~ each of apamin (Ap) and charybdotoxin (ChTX), were 
added to a set of vessels to investigate a possible role for endothelium-derived 
hyperpolarising factor (EDHF) in the vasodilator effect ofhU-II (Garland et al., 1995; 
Zygmunt et al., 1998; MacIntyre et al., 2001). The Kca channel blockers and EDHF 
itself are described more fully in chapter 3. Two subsets of vessels were pre-
constricted with 50mM KCI instead of ET -1, with one set acting as the KCl time 
controls and the other being treated with hU-II to further investigate a possible role of 
EDHF in the hU-II-induced vasodilatation, as KCI-induced tone has been shown to 
inhibit EDHF release (Garland et al., 1995; Shimokawa et al., 1996). 
Due to the availability of tissue, there were only three protocol groups of abdominal 
adipose SRAs, those acting as ET-1 time controls; those treated with hU-II; and those 
treated with porcine U-II. The results of the endothelial viability tests for these 
vessels can be seen in Table 4.9. Any SRAs without a functional endothelial layer 
were discarded from the study. 
The vessels in these studies were used for one CCRC only as both hU-II and ET-1 are 
resistant to washout with ET -1 being more resistant to removal than hU-II (Maguire et 
al., 2000). 
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4.3. Results 
4.3.1. Human PRAs: 
hU-II-induced a vasodilatation in control human small PRAs. The resulting CCRC is 
shallow in nature. The pECso value was 10.78 ± 0.27 (n=10) and the maximum 
relaxation response was 83 ± 4% (of ET-1-induced tone). A summary of the pre-
constriction achieved by 10nM of ET -1 are shown in Table 4.1. A summary of pECso 
values are shown in Table 4.3. The hU-II-induced vasodilatation was significantly 
different from the time control fall off of tone at O.lJlM of hU-II (P < 0.001). 
Therefore, hU-II is a potent vasodilator peptide in human small PRAs. The 
vasodilator responses to hU-II are displayed in Figure 4.2. 
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Figure 4.2: Vasodilator response to hU-II in the control human small PRAs in the 
presence and absence of various vasodilator inhibitors. ET-1 time control (n=13); 
hU-II (n=lO); porcine U-II (n=4); O.lmM L-NAME (n=6); l)lM indomethacin (n=5); 
and O.1JlM apamin (Ap) & charybdotoxin (ChTX) (n=5). Data expressed as 
percentage of ET -I-induced tone (10nM). Each point represents the mean ± SEM. n 
= number of individual PRAs from the same number of individual lung biopsies. 
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Porcine U-II induced a dose-dependent vasodilatation with a shallow CCRC in 
control human small PRAs. The pECso value was 9.85 ± 0.55 (n=4) and the 
maximum relaxation response was 80 ± 11 % (ofET-I-induced tone). A summary of 
the pre-constriction achieved by IOnM of ET -1 is shown in Table 4.1. The porcine 
U-II-induced vasodilatation was significantly different from the time control fall off 
of tone at O.IIlM of hU-II (P < 0.001). Therefore, porcine U-II is a vasodilator 
peptide in human small PRAs. There was no significant difference in the potency of 
hU-II- and porcine U-II-induced vasodilator response. The vasodilator responses to 
hU-II and porcine U-II are displayed in Figure 4.3. 
Protocol ET-1 hU-II Porcine L-NAME Indome- Ap& 
Group Time Alone U-II / thacin / ChTX/ Control hU-II hU-II hU-II 
Vessel 
Size 160 ± 11 153 ± 10 156 ± 12 157 ± 11 133 ± 10 189 ± 14 
(J.tm) 
ET-l- 1.89 2.76 1.88 1.79 2.59 1.35 Induced 
+ ± ± ± ± ± tone -
(mN) 0.31 0.63 0.30 0.41 1.43 0.52 
n 
n= 13 n= 10 n=4 n=6 n=5 n=5 
number 
-------
Table 4.1: Dimensions and measurement of lOnM ET-1-induced tone achieved in 
the various protocol groups. Data expressed as mean ± SEM. n =number of 
individual PRAs. 
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Protocol KCI KCII Time Group Control hU-II 
Vessel 
Size 124 ± 20 123 ± 12 
(JAm) 
KCI- 1.12 1.56 induced 
Tone ± ± 
(mN) 0.21 0.27 
n 
n=4 n=4 
number 
Table 4.2: Dimensions and measurements of 50mM KCI-induced tone achieved in 
the various protocol groups. Data expressed as mean ± SEM. n number of 
individual PRAs from the same number of individual lung preparations. 
hU-II-induced vasodilatation in the presence ofO.1mM of the NOS inhibitor 
L-NAME (n=6), was significantly different from the time control fall off of tone at 
O.lI1M ofhU-II (P < 0.001). A summary of the pre-constriction achieved by 10nM of 
ET -1 is shown in Table 4.1. There was no significant decrease in the potency of 
hU-II in the presence of L-NAME. A summary of the pECso values of hU-II are 
shown in Table 4.3. There was no attenuation of the maximum'relaxation response to 
hU-II nor any significant difference between the vasodilatation effected at any given 
concentration ofhU-II. A summary of these results is shown in Table 4.4 and Figure 
4.2. 
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Protocol Group 
pECsovalue n number 
hU-II 10.78 ± 0.27 n= 10 
Porcine U-II 9.85 ± 0.55 ns n=4 
L-NAMEI 10.45 ± 0.37 ns n=6 hU-II 
Indomethacin I 10.71 ± 0.48 ns n=5 hU-II 
Ap&ChTXI 8.73 ± 0.59 ** n=5 hU-II 
Table 4.3: pECso values for porcine U-II and hU-II ± various vasodilator inhibitors in 
small ACh-sensitive PRAs. Apamin (Ap) & charybdotoxin (ChTX). Data are 
expressed as mean ± SEM. n = number of individual PRAs from the same number of 
lung preparations. Statistical comparisons were made using a one-way ANOV A with 
a Dunnetts' post-test. P < 0.01 ** vs. hU-II control. ns = not significant. 
hU-II-induced vasodilatation in the presence of I/lM of the cydooxygenase (COX) 
inhibitor, indomethacin (n=5), was significantly different from the fall off of tone in 
the time control vessels at O.If.tM hU-II (P < 0.001). The vasodilator response to hU-
II in the presence and absence of 1 f.tM indomethacin is displayed in Figures 4.2 and 
4.4. A summary of the pECso values are shown in Table 4.3. There was no 
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significant decrease in the potency ofhU-II in the presence of indomethacin, however, 
there was a statistically significant attenuation of the maximum relaxation response to 
hU-II from 30pM and above (P< 0.05 then P < 0.01 from 30nM). A summary of 
these results is shown in Table 4.4 
hU-II-induced vasodilatation in the presence of O.l[.tM of the Kca channel blockers, 
apamin (Ap) & charybdotoxin (ChTX) (n=5), was not significantly different from the 
fall off of tone in the ET-l time control vessels at any given concentration ofhU-II. 
The effect hU-II in the presence and absence ofO.l[.tM apamin and charybdotoxin is 
displayed in Figures 4.2 and 4.5. There was a significant decrease in the potency of 
hU-II in the presence ofapamin & charbydotoxin (P < 0.01). A summary of the hU-
II pECso values is shown in Table 4.3. The maximum vasodilator response to hU-II 
was also significantly attenuated (P < 0.01) as was the response to hU-II at any given 
concentration (P < 0.05 at 1pM then P < 0.01 at 3pM and above). A summary of 
these results is shown in Table 4.4. 
The raising of tone in small resistance arteries with 50mM KCl instead has been 
shown to inhibit the release of endothelium-derived hyperpolarising factor (EDHF). 
Therefore, experiments were conducted in which the tone of PRAs was raised with 
50mM KCl instead of 10nM ET-l before a CCRC to hU-II was carried out. A 
summary of the pre-constriction caused by 50mM KCl is shown in Table 4.2. There 
was no significant difference in the hU-II response from the KCl time control (n=4). 
Both KCl protocol groups showed no relaxation which was significantly less than the 
fall ofET-l-induced tone at O.l/lM hU-II (P < 0.01). No graph is shown as the tone 
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had only decreased by a maximum of 5% by the end of the experiment and could not 
be differentiated from the x-axis of the graph. These results are shown in Table 4.5. 
hU-II Bath hU-II alone L-NAMEI Indomethacin Ap & ChTXI 
ConeD (n = 10) hU-II (n = 6) I hU-II (n = 5) hU-II (n = 5) 
-12 15 ±4% 7 ± 3 %ns 7 ± 5 %ns 1 ± 1 % * 
-11.5 29±7% 20 ± 5 %ns 17 ± 3 % ns 3 ± 2 % ** 
-11 39± 6% 31±8%ns 24 ± 4 %ns 3 ± 2 % ** 
-10.5 50± 6% 39 ± 9 % ns 30 ± 4 % * 3 ± 2 % ** 
-10 56±6% 45±10%ns 35 ± 4 % * 8 ± 5 % ** 
-9.5 62±6% 54±10%ns 39 ± 4 % * 8 ± 5 % ** 
-9 67± 5 % 63 ± 8 %ns 44 ± 4 % * 11 ± 6 % ** 
-S.5 70± 5 % 70 ± 6 % ns 47 ± 4 % * 21 ± 8 % ** 
-S 74±4% 72 ± 6 % ns 51 ± 5 % * 23 ± 9 % ** 
-7.5 78 ±4% 77 ± 8 %ns 55 ± 6 % ** 23 ± 9 % ** 
-7 83 ±4% 78 ± 8 % ns 58 ± 6 % ** 24 ± 8 % ** 
Table 4.4: The measurement of vasodilatation as % of lOnM ET-l-induced tone 
effected at each point in the hU-II CCRC. Apamin (Ap) & charybdotoxin (ChTX). 
Data is expressed as mean ± SEM. Statistical comparisons were made usmg 
Student's t-test. P < 0.05*, P < 0.01 ** vs. hU-II control. ns = not significant. 
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Figure 4,3: Vasodilator response to hU-II and porcine U-II in the control human 
small PRAs. ET-l time control (n=13); hU-II (n=lO); and porcine U-II (n=4). Data 
expressed as percentage of ET-l-induced tone (lOnM). Each point represents the 
mean ± SEM. n = number of individual PRAs. 
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Figure 4.4: Vasodilator response to hU-II in the control human small PRAs in the 
presence and absence of l!-.tM indomethacin. ET-l time control (n=13); hU-II (n=lO); 
and indomethacin (n=5). Data expressed as percentage ofET-l-induced tone (lOnM). 
Each point represents the mean ± SEM. n = number of individual PRAs. 
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Figure 4.5: Vasodilator response to hU-II in control human small PRAs in the 
presence and absence of O.l!-tM apamin & charybdotoxin. ET-l time control (n=13); 
hU-II (n=lO); and apamin (Ap) & charybdotoxin (ChTX) (n=5). Data expressed as 
percentage ofET-l-induced tone (lOnM). Each point represents the mean ± SEM. 
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hU-II Bath ET-l I hU-II KCI I hU-II Concn 
-12 15 ±4% O±O%* 
-11.5 29±7% o ± 0%** 
-11 39± 6% o ± 0%** 
-10.5 50± 6% o ± 0%** 
-10 56± 6% o ± 0%** 
-9.5 62±6% o ± 0%** 
-9 67± 5 % o ± 0%** 
-8.5 70± 5 % o ± 0%** 
-8 74±4% o ± 0%** 
-7.5 78 ±4% 1 ± 1%** 
-7 83 ±4% 5 ± 5%** 
Table 4.5: The measurement of vasodilatation as percentage of 10nM ET -1- or 
50mM KCl-induced tone effected at each point in the hU-II CCRC in PRAs (n = 10 
and n = 4, respectively). Data is expressed as mean ± SEM. Statistical comparisons 
were made using Students' unpaired t-test. P < 0.05*, P < 0.01 ** vs. ET-l/hU-II 
control. n = number of individual PRAs from the same number of individual lung 
biopsies. 
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Protocol ET-l Time hU-II Porcine U-II L-NAMEI Group Control (n = 10) (n= 4) hU-II (n = 13) (n= 6) 
5-HT -induced 
tone (ruN) 
& 0.58 ± 0.09 0.87 ± 0.26 0.89 ± 0.24 0.73 ± 0.11 
(% ofKCI-
induced tone) 43 ±5% 57±6% 48 ± 11% 39±9% 
ACh-induced 
relaxation 0.36 ± 0.07 0.39 ± 0.08 0.60 ± 0.20 0.45 ± 0.10 
(ruN) & 
(% of5-HT- 63±6% 55 ±8% 58±8% 59±7% 
induced tone) 
Protocol indomethacin! Apamin& KCI Time KCl/hU-II Group hU-II ChTX I hU-II Control (n=4) (n= 5) (n= 5) (n=4) 
5-HT -induced 
tone (ruN) 
& 0.75 ± 0.21 0.46 ± 0.11 0.40 ± 0.05 0.61 ± 0.06 
(% ofKCI-
induced tone) 39±9% 60±9% 37±6% 40 ± 10% 
ACh-induced 
relaxation 0.50 ± 0.22 0.30 ± 0.08 0.27 ± 0.04 0.40 ± 0.06 
(ruN) & 
(% of5-HT- 60±9% 64±8% 68±7% 67±8% 
induced tone) 
I 
Table 4.6: The measurements of the endothelial viability tests in human PRAs. The 
extent of 5-HT-induced tone is shown in mN and as a % of 50mM KCI-induced tone. 
The extent of the ACh-induced relaxation is shown in mN and as a % of 5-HT-
induced tone. Apamin (Ap) & charybdotoxin (ChTX). Data is expressed as the mean 
±SEM. 
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4.3.2. Human abdominal SRAs: 
hU-II induced a vasodilatation in human abdominal adipose SRAs with a shallow 
CCRC. The pECso was 10.72 ± 0.12 (n=6) and the maximum relaxation response was 
88 ± 6% (of 10nM ET-l-induced tone). The hU-II-induced vasodilatation was 
significantly different from the fall off in tone seen in the time control vessels at 
O.lJlM hU-II (n=6) (P < 0.001). The effect ofhU-II on abdominal adipose SRAs is 
displayed in Figure 4.6. 
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Figure 4.6: The vasodilator response to hU-II and porcine U-II on human abdominal 
adipose tissue small SRAs. ET-l time control (n=6); hU-II (n=6); and porcine U-II 
(n=6). Data expressed as percentage of ET -I-induced tone. Each point represents 
the mean ± SEM. n = number of individual SRAs. 
Therefore, hU-II is a potent vasodilator peptide in human small abdominal adipose 
SRAs. There is no significant difference between the potency ofhU-II in pulmonary 
resistance arteries and abdominal adipose systemic resistance arteries. These results 
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are shown in Table 4.8. There is no significant difference between the maximum 
vasodilatation achieved by hU-II in the pulmonary and systemic resistance arteries. 
Protocol ET-l Time hU-II Porcine Group Control U-II 
Vessel Size 201 ± 10 192 ± 16 206 ± 16 (~m) 
ET-l-
induced 1.81 ± 0.52 3.08 ± 1.00 8.30 ± 2.96 Tone 
(mN) 
n n=6 n=6 n=6 
Table 4.7: Dimensions and measurements of 10nM ET-l-induced tone achieved in 
the various protocol groups of SRAs. Data expressed as mean ± SEM. n = number of 
individual SRAs from the same number of individual abdominal adipose tissue 
biopsies. 
Porcine U-II caused a vasodilator response in human abdominal adipose systemic 
resistance arteries. The effect of porcine U-II on abdominal adipose SRAs is 
displayed in Figure 4.6. The pECso value was 10.64 ± 0.35 (n=6) and the maximum 
relaxation response of 81 ± 6% (of IOnM ET -I-induced tone). A summary of these 
results is shown in Table 4.8. The vasodilatation produced by porcine U-II was 
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significantly different from the fall off of tone observed in the ET -1 time control at 
O.l~M hU-II (P < 0.001). Therefore, porcine U-II is a potent vasodilator peptide in 
abdominal systemic resistance arteries. There is no significant difference between the 
potency of, and maximum vasodilatation achieved by, porcine U-II between the 
pulmonary and systemic resistance arteries. There is also no significant difference 
between the potencies ofhU-II and porcine U-II in the abdominal systemic arteries. 
Protocol Group pECsovalue n number 
hU-II 10.72 ± 0.12 n=6 
Porcine U-II 10.64 ± 0.35 ns n:=::6 
Table 4.8: pECso values for porcine U-II and hU-II in small abdominal adipose 
SRAs. Data are expressed as mean ± SEM. n = number of individual SRAs from the 
same number of abdominal adipose tissue biopsies. Statistical comparisons were 
made using Students' unpaired t-test. ns = not significant. 
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Protocol ET-I Time Group Control hU-II Porcine U-II 
5-HT -induced 
tone (mN) 
& 0.74 ± 0.23 2.56 ± 1.17 2.99 ± 1.59 
(% of KCI-
induced tone) 64 ± 12% 68 ± 15% 41 ±5% 
ACh-induced 
relaxation 0.42 ± 0.14 1.86 ± 0.95 1.50 ± 0.57 
(mN)& 
(% of 5-HT- 60±7% 62±9% 67±8% 
induced tone) 
Table 4.9: The measurements of the endothelial viability tests in human SRAs. The 
extent of 5-HT-induced tone is shown in mN and as a % of KCI-induced tone. The 
extent of the ACh-induced relaxation is shown in mN and as a % of 5-HT-induced 
tone. Data is expressed as the mean ± SEM. 
4.3.3. U-II isoforms in normotensive rat PRAs: 
I investigated the effect of three isoforms of U-II, human; porcine; and rat on control 
rat PRAs. None of the isoforms induced vasoconstriction or vasodilatation responses 
in these vessels under any circumstances (results not shown). Therefore, the 
vasoactive effects ofhU-II in the pulmonary circulation are species specific. 
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4.4. Discussion 
4.4.1. Vasodilator effect ofU-II in human PRAs and SRAs: 
The human and porcine isoforms of U-II are potent vasodilators of human small 
PRAs with an intact endothelium. This study is the first to show an hU-II-induced 
relaxation effect in human vessels. The human and porcine isoforms of U-II are 
equipotent in these arteries. We compared the potency of hU-II with other 
vasodilators in human PRAs. This work was published as a rapid communication in 
the American Journal of Physiology (Stirrat et al., 2001). The order of potency for 
the vasodilators studied was: hU-II (10.78 ± 0.27) = ADM (10.1 ± 0.4) » SNP (7.4 ± 
0.2) = ACh (6.8 ± 0.3) in human small PRAs (Stirrat et al., 2001). hU-II was also 
found to be a potent vasodilator of human abdominal adipose SRAs. These findings 
were different from those revealed in early studies into the effect of hU-II which 
showed a potent vasoconstrictor action of hU-II in the vasculature of various species 
(Itoh et al., 1987; Ames et al., 1999; Douglas et al., 2000, MacLean et al., 2000). 
However, these findings are consistent with those from previous studies that showed 
hU-II-induced vasodilatation in the rat small mesenteric and coronary arteries (Bottrill 
et al., 2000; Katano et al., 2000). These results show that hU-II is able to induce 
vasoconstriction and vasodilatation in the same vascular bed and in a single arterial 
preparation. The rat main pulmonary artery is constricted upon application of hU-II 
while the human small muscular PRAs were dilated and a variable constriction was 
only seen in 30% of vessels incubated with the NOS inhibitor L-NAME (MacLean et 
al., 2000; Stirrat et al., 2001). hU-II-induced vasoconstriction and vasodilatation are 
observed in the coronary artery of the rat (Bottrill et al., 2000; Katano et al., 2000). 
This evidence suggests the existence of UT-II receptors on both endothelial and 
vascular smooth muscle cells similar to the distribution of ET B receptors in pulmonary 
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arteries. When stimulated, the ET B receptors located on the endothelial cells mediate 
ET-l-induced vasodilatation while the ETB receptors located on the vascular smooth 
muscle cells mediate vasoconstriction (MacLean et al., 1994; McCulloch et al., 1996; 
MacLean et al., 1998). These results contrast with radioligand binding assays 
conducted in skeletal muscle which suggested a single, homogeneous population of 
receptors (Ames et al., 1999). hU-II has a similar heterogeneous vasoactive profile to 
ET-l as both of these peptides can elicit vasodilatation and vasoconstriction. hU-II is 
a more potent and efficacious vasodilator of human small muscular PRAs than ACh 
while being a more potent but less efficacious vasoconstrictor of these vessels than 
ET-l (Ames et al., 1999; Maguire et al., 2000; MacLean et al., 2000; Stirrat et al., 
2001). 
4.4.2. Mediators involved in the hU-II-induced vasodilatation in human PRAs: 
These results show that hU-II-induced vasodilatation is mediated by EDHF and a role 
for a cyclooxygenase (COX) product, possibly PGlz. The involvement of EDHF was 
uncovered by the inhibition of the large and small conductance K+ Ca2+ -activated 
channels with charybdotoxin (ChTX) and apamin respectively. These K+ channel 
blockers totally inhibited hU-II-induced vasodilatation. A role for PGh was revealed 
by the COX inhibitor, indomethacin, which resulted in an attenuation of the maximum 
dilation induced by hU-II but not a decrease in its potency. The absence of an effect 
by L-NAME suggests that NO was not involved in the hU-II-induced vasodilatation 
in human small muscular pulmonary resistance arteries. 
Studies into the relaxation effect of well known vasodilators acetylcholine (ACh) and 
bradykinin have shown variations in the second messenger systems mediating their 
129 
relaxation response. Variation was also observed when their relaxation was studied in 
vessels from different vascular beds (Gambone et at., 1997). Therefore, different 
agonists produce their relaxation effects by different signal transduction pathways. 
In the isolated canine main and first order pulmonary arteries, ACh and bradykinin 
elicit vasodilatation via different endothelium-derived mediators. ACh-induced 
relaxation is mediated by NO alone at low concentrations and by NO and EDHF at 
high concentrations. However, bradykinin mediates its vasodilator effect via NO and 
PGrz at low concentrations and by NO; PGI2; and EDHF at high concentrations 
(Gambone et at., 1997). A previous study showed that hU-II-induced vasodilatation 
was mediated by NO alone in the rat left anterior descending coronary artery. 
However, EDHF probably mediates the relaxation induced by hU-II in rat small 
mesenteric arteries with NO playing only a minor role (Bottrill et at., 2000). This 
earlier study revealed an anatomical difference in the signal transduction pathways 
mediating the relaxation effect of hU-II in rat arteries (Bottrill et at., 2000). My 
results suggest the relaxation of human small muscular PRAs by hU-II is mediated 
predominantly by EDHF with a minor role for PGI2. However, electrophysiological 
studies are required to confirm this. The differences in the vasodilator mediators 
behind hU-II-induced vasodilatation in the vessels studied so far could be attributed to 
anatomical variation and more studies are needed in other species to investigate the 
possibility that species variation will affect the signal transduction pathways activated 
by hU-II to produce relaxation. The study investigating ACh-induced vasodilatation 
in chronic hypoxic rats, described in chapter 3, showed that the maximum dilator 
response to ACh was increased in PRAs from chronic hypoxic rats. This study also 
revealed that the vasodilator mediator profile involved in the ACh-induced 
vasodilatation changed in the presence of PHT. It is proposed that EDHF mediates 
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the relaxation in response to ACh in the control rats while NO, PGh and EDHF are 
involved in mediating the relaxation in the chronic hypoxic rats. It would be 
interesting to see whether the potency of hU-II or the maximum vasodilator response 
to hU-II is increased in the PRAs of patients with PHT. The study described in 
chapter 5 involved patients with PHT secondary to different degrees of left ventricular 
dysfunction, but the availability of this tissue would not allow for extra investigation 
into the vasodilator effects of hU-II in these vessels. We can only speculate that, as 
with ACh, the vasodilator mediator profile of hU-II-induced vasodilatation would be 
different from that observed in patients with out PHT. Would this mediator profile 
include a role for NO as observed in the vasodilator response to ACh in chronic 
hypoxic rat PRAs? The study described here, and other studies (Bottrill et al., 2000) 
are consistent with the hypothesis that small calibre arteries are more likely to be 
dependent on relaxations mediated by EDHF than large calibre arteries. This 
hypothesis proposes that as the internal diameter of the artery decreases, the 
importance of EDHF mediated relaxation increases, as witnessed in mesenteric 
arteries (Garland et al., 1995; Shimokawa et al., 1996). 
4.4.3. Possible pathophysiological role of hU-II: 
A possible pathophysiological role for hU-II has been proposed in a variety of 
conditions, especially those in which endothelial dysfunction is thought to playa part 
in the disease process. hU-II may be involved in coronary atherosclerosis; systemic 
hypertension; chronic heart failure; and chronic renal failure (Ames et al., 1999; 
Davenport & Maguire, 2000; Affolter & Webb, 2001; Totsune et al., 2001). 
However, any pathophysiological role for hU-II in these conditions would be as a 
consequence of its vasoconstrictor effects. However, a decrease in the vasodilator 
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response to hU-II may uncover a vasoconstrictor response. This is supported by 
studies showing that L-NAME uncovers vasoconstrictor responses in human PRAs 
and constrictor responses are more prominent in endothelium-denuded human arteries 
(Davenport & Maguire, 2000; MacLean et al., 2000). This new evidence of hU-II-
induced vasodilatation in human vessels may suggest a protector role of hU-II in the 
cardiovasculature. Further in depth investigations of the vasoconstrictor and 
vasodilator profiles of hU-II are needed to clarify the potential cardiovascular 
pathophysiological/protection role of the peptide. These studies should be carried 
out in human vessels as previous studies have shown considerable species variations 
in the hU-II-induced effects which make it difficult to extrapolate results seen in 
another species, such as the rat, to humans. 
4.5. Conclusion 
hU-II is a very potent and efficacious vasodilator peptide in human small muscular 
pulmonary and abdominal adipose systemic resistance arteries. In the PRAs, the 
hU-II-induced vasodilatation is mediated predominantly by EDHF with a minor role 
for a prostanoid, PGb Further investigation with UT-II subtype specific antagonists 
is needed to explore the possibility of whether antagonism of the hU-II-induced 
vasoconstrictor, or stimulation of the vasodilator effect could provide a future 
therapeutic target for the treatment of various cardiovascular diseases. 
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Chapter 5 
The effect of mixed ET AI ET B 
antagonists in the treatment of 
human PHT secondary to left 
ventricular dysfunction 
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5.1.1. Endothelin structure: 
An endothelium-derived contracting factor (EDCF) was identified and isolated from 
vascular endothelial cells. This vasoactive substance was found to be a 21-amino acid 
peptide and was named endothelin (ET). It was soon discovered that, not only was 
ET one of three isoforms (ET-l; ET-2; and ET-3), these isoforms were structurally 
related to other vasoactive peptides, the sarafotoxins (STXs), and vasoactive intestinal 
peptide (VIP). Each of these peptide isoforms contain a pair of disulphide bonds in 
their structure (see Figure 5.1) (Yanagisawa et al., 1988; Fleminger et al., 1989; 
Cody et al., 1991; Rubyani & Botelho, 1991; Rubyani & Polokoff, 1994). 
5.1.2. Endothelin biosynthesis and expression: 
All the members of this family show complete homology of peptide positions 1; 3; 8; 
10; 11; 15; 16; 18; 20; and 21. The amino acids at position 1; 3; 11; and 15 are the 
cysteine residues which are involved in the disulphide bonds, cysteine 1 and 15 form 
one disulphide bridge and cysteine 3 and 11 form the other (Rubyani & Polokoff, 
1994). The chromosomal location of the genes of the three ET isoforms have been 
mapped to chromosome 6 (ET-l), chromosome 1 (ET-2), and chromosome 20 (ET-3) 
in many mammalian species, including humans (Rubyani & Polokoff, 1994). The 21-
amino acid peptide ET is the end product of a three step process from gene product to 
biologically active product. The stimulation of ET -1 mRNA expression in vascular 
endothelial cells can be elicited by interleukin-l B (IL-l B); transforming growth 
factor-B (TGF-B); thrombin; phorbol ester; angiotensin-II; vasopressin; tumour 
necrosis factor-a (TGF-a); and shear stress (Yanagisawa et al., 1988; Ohta et al., 
1990; Resink et al., 1990; Yoshizumi et al., 1990; Rubyani & Botelho, 1991; 
Harrison et al., 1998). 
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I, 
Endothelin-l GBG) I (human, porcine) 
D K F. C V V F C ~ I . n f 1 w -COOH 
~ I Endothelin-2 
8 (human) 
D K E C V Y F C ~ L D 1 f W -COOH 
~ I Endothelin-2 
~0 (mouse) 
D K F C V V F C ~ I. n f 1 W -COOH 
Endothelin-3 
~8 I (human, rat) 
D K F r v Y y r ~ L n 1 f w -COOH 
Figure 5.1. Amino acid heterogeneity of the endothelin isofonns, in their 21 amino 
acid sequence, from various species. Cysteine residues forming disulphide bonds are 
represented by the yellow circles. The pink circles denote changes in the amino acid 
sequence compared with the sequence ofET-l. Illustration adapted from Rubyani & 
Polokoff, 1994. 
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When discussing the biosynthesis of ET -1, human ET -1 will be used as an example. 
The form of ET -1 produced by the ET -1 gene is known as PreproET -1 and is 203 
amino acids long. This peptide undergoes proteolytic cleavage at the 18th amino acid 
by signal peptidase to form proET -1 peptide. The proET -1 peptide (large ET -1) is 
then cleaved at the 53rd and 92nd amino acids by a diabasic amino acid-specific 
endopeptidase cleavage carboxypeptidase to form big ET -1. The third and final step 
is the cleavage if big ET-l at the 73rd amino acid by endothelin-converting enzyme 
(ECE), a furin-like specific endopeptidase to form ET-l (Cys53 to TRP23) (Rubyani & 
Botelho, 1991; Rubyani & Polokoff, 1994; Kido et al., 1998). It is likely that the 
metalloproteinase ECE, will be different for each of the three ET isoforms. 
Expression of ECE has been found intracellulady and on the cell surface of human 
coronary artery preparations. This study also showed that ECE expression is both 
continuous by a constitutive pathway and by a regulated pathway that can be activated 
if needed, analogous to the constitutive and inducible forms of nitric oxide synthase 
(NOS) enzyme (Russel et al., 1998). There is evidence that patients with PHT; 
cardiac disease and damage such as that resulting from myocardial infarction have an 
increased plasma level of ET -1 and that an increase in ECE-l expression and activity 
is responsible for this observation (Bohnemeier et al., 1998). 
5.1.3. Endothelin receptors: 
All of the known ET receptors are found in the cardiovascular system. The ETA 
receptors are found on the vascular smooth muscle cells of both arteries and veins of 
the pulmonary and systemic circulations. The ETA receptors are also found on 
cardiac myocytes of the atria and ventricles (Mulder et ai., 1998; Modesti et ai., 1999; 
Pieske et al., 1999; Kelso et ai., 2000; Love et ai., 2000; Moraes et ai., 2000; 
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Miyuachi et ai., 2000; Telemaque-Potts et ai., 2000; Berger et ai., 2001). The ETBI 
receptors are found on the vascular endothelial cells of the pulmonary and systemic 
circulations of both arteries and veins. The ETBI receptors are also present on the 
cardiac myocytes (Modesti et ai., 1999; Moraes et ai., 2000; Sawaki et ai., 2000). 
The ET B2 receptors are found on the arterial and venous sides of the pulmonary and 
systemic circulations (McCulloch et ai., 1996; MacLean et ai., 1998; Cowburn et al., 
1999; Modesti et ai., 1999; Love et ai., 2000; Moraes et ai., 2000). ET-1 activation of 
ETA receptors mediates vasoconstriction, vascular smooth muscle cell and cardiac 
myocyte proliferation and hypertrophy, a positive inotropic effect in cardiac 
myocytes, and a direct cytotoxic effect on cardiac myocytes (Iwasaka et ai., 1998; 
Pieske et ai., 1999; Kelso et ai., 2000; Love et ai., 2000; Miyauchi et ai., 2000; 
Moraes et ai., 2000). It has been shown that although ETA receptors are upregulated 
in CHF patients, there is evidence of attenuation of various ETA-mediated effects in 
the cardiovascular system such as vasoconstriction and the inotropic effects. This 
suggests that the 'blunting' of ETA-mediated effects in patients with CHF caused by 
desensitization of the ETA receptor by G-protein-coupled receptor kinase mediating 
phosphorylation of the receptors (Pieske et ai., 1999; Love et ai., 2000; Moraes et ai., 
2000). ET-1 activation of ETBI receptors mediates vasodilatation by the release of 
NO and PGI2 and may act as a clearance site ofET-1 (Modesti et ai., 1999; Moraes et 
ai., 2000; Sawaki et al., 2000). ET -1 activation of ET B2 receptors mediates 
vasoconstriction and modulates the renin -angiotensin-II - aldosterone system 
(RAAS) (McCulloch et ai., 1996; MacLean et ai., 1998; Ohnishi et ai., 1998; 
Cowburn et ai., 1999; Love et ai., 2000; Moraes et ai., 2000; Sawaki et ai., 2000; 
Channick et ai., 2001). 
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5.1.4. Endothelin action: 
Endothelin has a variety of actions depending on which isoform is released and which 
tissue they are acting on. As my study is concerned with the role of ET in secondary 
PHT as a consequence of heart failure, we will concentrate on the actions of 
endothelin in the cardiovascular system. 
The i.v. infusion of ET -1 results in a biphasic effect, a transient vasodilatation 
precedes a sustained and potent vasoconstriction in a variety of mammalian species, 
including man (LeMonnier de Gouville et ai., 1990; Rubyani & Polokoff, 1994). 
ET -1 contributes to the basal tone of the blood vessels of the cardiovascular system 
(Haynes & Webb, 1994; Rubyani & Polokoff, 1994; Barnes & Liu, 1995). Small 
amounts of ET -1 in the cardiovascular system would potentiate the effect of other 
vasoconstrictors such as noradrenaline and 5-HT (MacLean et ai., 1993; Rubyani & 
Polokoff; Kita et ai., 1998). A recent study revealed that the presence of ET-l pre-
constriction augmented the vasoconstrictor response induced by 5-CT in small 
pulmonary arteries from control and chronically hypoxic rats. The 5-CT -induced 
contractile response was further enhanced by the incubation of the PRAs with the 
nitric oxide synthase (NOS) inhibitor, L-NAME, as well as ET-l pre-tone (MacLean 
& Morecroft, 2001). 
ET -1 is produced by cultured endocardial cells which suggest that ET -1 could be 
involved in an autocrine mechanism in the heart, with ET binding sites found 
throughout the heart (Rubyani & Botehlo, 1991; Rubyani & Polokoff, 1994). 
ET -1 has a positive chronotropic effect on isolated heart muscle preparations, but 
results in bradycardia in vivo, possibly due to baroreflex stimulation. The duration of 
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the cardiac action potential is also increased due to the increase in Caz+ influx 
accompanying the positive inotropic effect (Rubyani & Polokoff, 1994). 
The cardiac output is decreased when ET-1 is administered by Lv. infusion in vivo. 
This decrease is probably a response to the increase in total peripheral resistance 
(TPR) that is caused by ET-1 so that mean arterial blood pressure is kept within the 
normal range (Rubyani & Polokoff, 1994). In systemic large arteries and veins, ET-1 
was found to be the most potent endogenous vasoconstrictor causing a slow but 
sustained contraction which is more potent in the veins than in the arteries, resulting 
in an increased preload. However, in the pulmonary circulation, the large arteries are 
more sensitive than the large veins. This difference could be attributed to their 
relative blood gas concentrations as systemic veins and pulmonary arteries are low 
POz vessels (POz ~40mmHg) when compared with systemic arteries and pulmonary 
veins (POz ~ 100mmHg). The pulmonary arterial sensitivity to ET -1 is increased 
during hypoxia, along with the sensitivity of the heart (MacLean et al., 1989; Rubyani 
& Polokoff, 1994; MacLean & McCulloch, 1996; McCulloch et al., 1998). 
ET -1 is a potent vasoconstrictor of isolated microvessel beds. The microcirculations 
of hypertensive rats are more sensitive to the vasoconstriction caused by ET-1 than 
those of normotensive rats (MacLean & MCGrath, 1990; Rubyani & Polakoff, 1994). 
ET-1 stimulates the release of nitric oxide (NO) from vascular endothelial cells, 
which would vasodilate the vessels (Warner et al., 1989; Rubyani & Polokoff, 1994). 
ET -1 can also stimulate the release of prostacyc1in (PGIz) from vascular endothelial 
cells, which accounts for the anti-aggregatory effects of ET-1 (Rakugi et al., 1989; 
Rubyani & Polokoff, 1994). 
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ET -1 is a potent bronchoconstrictor of the trachea and bronchi of many mammalian 
species, including humans. The ET -1 is secreted by bronchial epithelial cells. 
However, removal of the epithelium only increased the vasoconstriction caused by 
ET-l (Hay et al., 1993; Rubyani & Polokoff, 1994). As in the blood vessels of the 
cardiovascular system, ET -1 administration causes an initial transient relaxation 
followed by a sustained and potent vasoconstriction of airway smooth muscle cells in 
vivo (Rubyani & Polokoff, 1994). 
Members of the sarafotoxin (STX) family of peptides can also cause these effects on 
the heart and lungs as they can activate the ET B receptors which mediate these 
responses (Rubyani & Polokoff, 1994; MCCulloch et al., 1996; MacLean & 
MCCulloch, 1998; MCCulloch et al., 1998). 
5.1.5. Role of endothelin in chronic heart failure: 
ET -1 has been implicated as having a role in some disease states. Many studies have 
shown increased levels of circulating immunoreactive ET -1 (irET -1) in diseases such 
as heart failure and PHT (Love & McMurray, 1996; MacLean, 1998). An increase in 
the levels of irET-l has been observed in patients with chronic heart failure (CHF). 
This increase in ET -1 could promote the progression of the patient towards CHF in a 
number of ways. ET -1 synthesis has a reciprocal synergistic relationship with the 
renin-angiotensin-aldosterone system which would enhance sodium retention and 
vasoconstriction resulting in the weakened heart being placed under even greater 
stress. ET -1 augments the vasoconstriction elicited by other vasoconstrictors such as 
noradrenaline. Thus, ET -1 can augment the effect of sympathetic innervation on the 
heart. As ET -1 also has the ability to promote mitogenesis in smooth and cardiac 
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muscle cells, ET -1 enhances the process of myocardial and peripheral vascular 
remodelling that occurs with CHF (Rubyani & Polokoff, 1994; Love & McMurray, 
1996; Kita et al., 1998). Therefore, ET-l over-production can augment all the 
processes that eventually lead to CHF. As mentioned earlier, the family of 
sarafotoxins (STXs) are structurally similar to the three ET isoforms. The venom of 
the burrowing asp, Atractaspis Engaddensis is an STX. The venom of the burrowing 
asp has been demonstrated to cause death by heart failure. The resulting heart failure 
is a consequence of the stimulation of coronary vasospasm and atrio-ventricular node 
block. These two effects of STX appear to be mediated via an ETB receptor (Lee et 
al., 1986). 
5.1.6. Role of endothelin in pulmonary hypertension: 
Studies have shown an increase in the irET -1 level in patients with PHT of both 
primary and secondary natures. This increased irET -1 level appears to occur due to a 
decrease in clearance of ET -1 from the circulation and an increase in ET-l 
production. The increase in ET -1 production could be due to the fact that increases in 
ET-l mRNA and ECE-l expression and decreases in ET-l clearance have been 
observed in PHT patients, especially in the small PRAs and right atrium 
(Y oshibayashi et al., 1991; Moraes et al., 2000). There is a statistically significant 
directly proportional relationship between the concentration of ET -1 in the pulmonary 
circulation and the degree of pulmonary vascular resistance in PHT patients. In PHT, 
the elevated plasma ET -1 levels appear to be a consequence of ET -1 spillover from 
the pulmonary circulation (Yoshibayashi et al., 1991; Love & McMurray, 1996; 
MacLean, 1998; Moraes et al., 2000). The evidence suggests that an increased ET-l 
production is a major cause of the development of PHT. Hypoxia of the pulmonary 
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circulation induces an increase in ET -1 production which may sustain the increase in 
mean pulmonary arterial pressure occurring as a result of hypoxia, such as that seen in 
people living at high altitude. An increase in plasma ET -1 levels are seen in patients 
with emphysema, adult respiratory distress syndrome, heart disease, and cystic 
fibrosis (Yoshibayashi et at., 1991; Rubyani & Polokoff, 1994; MacLean, 1998; 
Moraes et at., 2000). 
5.1.7. Endothelin receptor second messenger systems: 
Many studies have been carried out on cultured vascular smooth muscle cells and 
isolated artery or vein preparations in order to determine the 2nd messenger systems 
coupling the different ET receptor subtypes to their physiological effect. Most studies 
have been concerned with how ET-l causes vasoconstriction via the ETA receptor. 
There is evidence that ET -1 induces a biphasic increase in [C~+]i. The initial, rapid, 
transient increase is mediated by release of Ca2+ from intracellular stores. This 
intracellular store overlaps with the caffeine-sensitive intracellular store (Miasiro et 
at., 1988; Kai et at., 1989; Rubyani & Polokoff, 1994). The slow, sustained increase 
in [Ca2+]i is likely to be due to Ca2+ influx from the extracellular fluid (Simpson & 
Ashley, 1989). Other studies have found that ET -1 caused an increase in [Ca2+]i via a 
nifedipine-insensitive Ca2+ channel and not by an L-type Ca2+ VOC (Rubyani & 
Polokoff, 1994). The intracellular Ca2+ is mobilised from the stores by PIP2 
hydrolysis product, IP3. It is proposed that ET-l activates the ETA receptor which is 
coupled to a Gq protein which phosphorylates phospholipase C (PLC) causing the 
breakdown of PIP2 to IP3 and diacylglycerol (DAG). IP3 stimulates the release of 
Ca2+ from an intracellular store (probably the sarcoplasmic reticulum) and DAG 
activates protein kinase C (PKC). PKC activates many target proteins within the cell 
142 
such as Ca2+ VOC's and contractile proteins. Both of these steps increase [Ca2+]i and 
sensitises the myosin light chain kinase (MLCK) to Ca2+, resulting in contraction 
(Resink et al., 1988; Marsden et al., 1989; Suguira et al., 1989; Sunako et al., 1989; 
Rubyani & Polokoff, 1994). The PKC inhibitor, staurosporine, can greatly decrease 
the contraction elicited by ET -1 (Rubyani & Polokoff, 1994). 
There is evidence that ET -1 causes vasodilatation via the ET B receptor which is 
coupled to a different Gq protein than the ETA receptor and stimulates PLA2. PLA2 
activation causes the breakdown of arachidonic acid to PGh in the endothelial cell by 
cyclo-oxygenase then peroxidase, and finally, by prostacyclin synthetase. PGh then 
acts on the IP receptor which stimulates adenylate cyclase (AC) then cAMP via a Gs 
protein. The increased cAMP activates protein kinase A (PKA) which phosphorylates 
various target proteins to decrease [Ca2+]i and renders the MLCK Ca2+-insensitive so 
that any increase in [Ca2+li would not cause contraction. ET-l acting via the ETB 
receptor also stimulates the release of NO which causes vasodilatation via cGMP and 
protein kinase G (PKG) activation (Rubyani & Polokoff, 1994). 
It has also been suggested that ET -1 directly modulates intracellular cyclic 
nucleotides. ET -1 activates ETA receptors in the vascular smooth muscle cells to 
stimulate a Gi protein to decrease AC and cAMP (Rubyani & Polokoff, 1994). 
Hypoxia can modulate the levels of cAMP found in the various arteries of the 
pulmonary system (Mullaney et al., 1998; Mullaney et al., 2000). Hypoxia causes a 
decrease in the basal level of cAMP in all the different pulmonary arteries except the 
small PRAs. ET -1 decreases the cAMP level of the main and first branch of control 
rat extralobar arteries, an effect partially blocked by inhibiting the ETA receptor in 
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control rats. However, all hypoxic pulmonary arteries displayed an increase in cAMP 
with ET -1. This study demonstrates that hypoxia can modulate basal and ligand-
activated levels of cAMP either directly or via cross-talk by G proteins, and that this 
modulation varies depending on what artery is being studied (Mullaney et ai., 1998). 
An earlier study substantiates these findings by looking at the phosphodiesterase 
(PDE) activities in the pulmonary circulation. The cAMP PDE activity and the cGMP 
PDE activity was found to have increased in all hypoxic arteries, except the small 
PRAs. This would account for the decrease in cAMP basal level seen in the later 
study. The increased cAMP PDE activity was due to an increase in PDE 3 
(cilostimide-inhibited PDE). The increased cGMP PDE activity was due to an 
increase in PDE 1 (Ca2+/calmoduli-stimulated PDE) and PDE 5 (zaprinast-inhibited 
PDE). These results reveal that changes in the cyclic nucleotides in response to HPV 
is due to increased PDE activities and that these alterations are differentially 
modulated with respect to artery location and PDE type (MacLean et ai., 1997). 
5.1.8. Another endothelin receptor subtype: 
As discussed above, although the 2nd messenger systems coupling the ET receptor 
subtypes to their physiological actions is complicated and can undergo cross-talk and 
differentiated modulation, the receptor subtypes themselves seemed quite straight 
forward. It appeared that ETA receptors caused stimulation and contraction of tissues 
while ET B mediated inhibition and relaxation of tissues. However, recent studies in 
the different pulmonary arteries of various mammalian species, including man, have 
appeared to expose this classification as over-simplistic using novel ET antagonists. 
A study looking at the receptor mediating vasoconstriction in isolated rabbit and 
human pulmonary arteries found vasoconstriction of the rabbit artery that was not 
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completely inhibited by ETA antagonists. This suggested that ET B receptors were 
capable of mediating vasoconstriction as well as vasodilatation (Fukuroda et ai., 
1994). In that study, the receptors mediating contraction of the pulmonary arteries 
were not the same subtypes. However, studies on the small muscular PRAs of 150-
250!AID in diameter, where most of the increase in pulmonary arterial pressure 
originates, have displayed similar receptor subtypes mediating ET-l-induced 
vasoconstriction in these vessels of rats, rabbits, and humans (MacLean et ai., 1994; 
McCulloch & MacLean, 1995; McCulloch et ai., 1996; Docherty & MacLean, 1998; 
MacLean & McCulloch, 1998; MacLean et ai., 1998a; MacLean et aI., 1998b; 
McCulloch et ai., 1998, Cowbum et ai., 1999). In rabbits, ET-l-induced 
vasoconstriction of PRAs is partly mediated by a heterogeneous population of ET B 
receptors, including an atypical ET B-like receptor (ET B2)' The agonist potency rank 
order for this receptor is: STX6c > ET -1 = ET -3 which is not typical for either the ETA 
or the ETB receptor (Docherty & MacLean, 1998). In addition, responses to ET-l 
were not blocked by either ETA- or ETB-receptor antagonists. Further studies on 
rabbit PRAs looked for differences between receptor subtypes in normal rabbits and 
rabbits with PHT that was secondary to L YD, induced as a result of coronary artery 
ligation. The ET receptor subtype mediating vasoconstriction in the PRAs from 
rabbits with L VD was the atypical ET B2 receptor as only the mixed ET NET B 
antagonist, SB 209670, inhibited the vasoconstriction. However, NO appeared to 
modify the response to ET -1 mediated by these receptors in the PHT rabbits 
(Docherty & MacLean, 1998). 
It has been possible to study a secondary form of PHT by keeping rats in a hypobaric 
chamber for 2 weeks (MacLean & MCCulloch, 1998). Therefore, studies could look 
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at the differences between receptor subtype populations in control and chronic 
hypoxic rat small PRAs. Studies have revealed that rat PRA vasoconstriction is 
mediated via an atypical ET B2 receptor with an agonist rank order of potency of: 
STX6c = ET-3 > ET-l (MCCulloch & MacLean, 1995; MCCulloch et at., 1998). The 
maximum contraction induced by ET -1 is increased in chronic hypoxic (CH) rats. 
This appears to be due to an increase in the typical vasoconstrictor ETA receptor 
activation in CH rat PRAs which could contribute to the increase in ET -1 maximal 
contraction (McCulloch & MacLean, 1995; McCulloch et at., 1998). There could 
also be an up-regulation of ETB2 receptors in CH rat, however, there is no specific 
antagonist which would allow us to confirm this hypothesis as yet. A similar atypical 
ET B2 receptor response appears to mediate ET -1 induced vasoconstriction in human 
PRAs. This ETB2 receptor, as in the rat, needs the mixed ETAiETB antagonist SB 
209670 to inhibit ET-l action in human PRAs (MCCulloch & MacLean, 1995; 
MCCulloch et at., 1998; MacLean, 1998). However, despite the pharmacological 
evidence for 'atypical' ETB-mediated responses, it has to be acknowledged that only 
two genes for ETA and ET B receptors have been identified in the human genome (Li et 
at., 1994a; Li et at., 1994b). 
The 2nd messenger system that couples the atypical ET B2 receptor to its physiological 
effect of vasoconstriction has yet to be fully elucidated. However, recent evidence 
has been gathering to suggest that ET -1 modulates K+ currents in the vascular smooth 
muscle cell to cause depolarisation and, eventually, contraction. It has been 
demonstrated that inhibition of K+ channels in rat main pulmonary artery smooth 
muscle cells cause a depolarisation of the cell membrane which leads to the opening 
of Ca2+ VOC's, resulting in contraction via an increase in [Ca2+]i. The K+ channel 
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involved in this depolarisation is the delayed rectifier K+ channel (Kv) (Salter et ai., 
1998; and Yuan et ai., 1998). 
As well as the vasoconstriction mediated by these receptors, ET -1 has been previously 
shown to inhibit various K+ channels resulting in a depolarization of the vascular 
smooth muscle cells (VSMCs) and subsequent vasoconstriction. Earlier studies have 
shown that ET-l inhibited the voltage-dependent K+ channels (Kv) of the 
intrapulmonary arterial SMCs of the rat; the delayed rectifier K+ current (IKV) Kv 1.5 
in the pulmonary arteries of the rat; and the Ca2+-activated K+ (Kca) channels in 
human pulmonary artery smooth muscle cells isolated from patients with and without 
chronic obstructive pulmonary disease (Larissa et ai., 1998; Peng et ai., 1998; Salter 
et ai., 1998; Larissa et ai., 1999). Therefore, ET-l elicits vasoconstriction by 
inhibiting various K+ currents resulting in membrane depolarization as well as an 
increase in intracellular Ca2+ concentration. 
5.1.9. Characterisation of endothelin receptors: 
The initial characterisation of ET receptors in to ETA receptors mediating contraction 
and ET B receptors mediating relaxation was done only on the basis of physiological 
effects of ET -1. The detailed studies into receptor subtypes only became possible 
when ET antagonists became available. Only by the development of novel selective 
ET antagonists has it become possible to distinguish between vasoconstriction 
mediated by ETA receptors from that mediated by the atypical ET B2 receptors. Most 
of the antagonists developed so far have been ETA antagonists. BQ-123 and BQ-153 
are synthetic analogues of the natural ETA antagonist BE-I8257a isolated from 
Streptomyces misaldensis. Both are selective ETA antagonists (Ihara et ai., 1991; 
Eguchi et ai., 1992; Fukuroda et ai., 1992; Bonvallet et ai., 1994). BQ-123 causes a 
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dose-dependent inhibition ofIP3 generation (Eguchi et al., 1992). BQ-123 can inhibit 
the DNA synthesis involved in vascular smooth muscle cell proliferation seen in PHT 
as well as inhibiting vasoconstriction by its antagonistic effect on ETA receptors. Due 
to the inhibition of DNA synthesis and vasoconstriction, BQ-123 can attenuate the 
development of PHT caused by hypoxic conditions (Bonvallet et al., 1994). The ETA 
antagonists A-127722; PD 156707; and FR l39317 will also inhibit vasoconstriction 
and vascular smooth muscle cell proliferation (Sogabe et al., 1992; Reynolds et al., 
1995; Opgenorth et al., 1996). The ETA antagonists can reduce ET-l-induced PHT to 
some extent, but ETA is not the only receptor to mediate vasoconstriction. The ET B 
antagonist BQ-788 abolished the initial rapid transient vasodilator response of ET -1, 
resulting in augmentation ofa sustained vasoconstriction (Ishikawa et al., 1994). BQ-
788 did not inhibit the ET-l-induced vasoconstriction mediated by the atypical ETB2 
(Docherty & MacLean, 1998; MacLean et al., 1998). No antagonists ofET were able 
to inhibit the ET B2-mediated vasoconstriction until the emergence of novel mixed 
ETAIETB antagonists. SB 209670 was developed as an orally active, mixed ET~TB 
antagonist (Ohlstein et al., 1994). However, it was discovered that this novel 
antagonist inhibited vasoconstriction in the PRAs of various mammalian species 
which are the site of the biggest alterations in response to PHT (Docherty & 
MacLean, 1998; McCulloch et al., 1998; MacLean, 1998; MacLean et al., 1998). 
Three new mixed ET AIET B antagonists have emerged and also appear to inhibit the 
atypical ETB2 receptor response, SB 247083; SB 234551; and SB 217242 (Ohlstein et 
al., 1996; Douglas et al., 1998; MacLean et al., 1998). The inhibition of the ET-l 
response by mixed ETA/ET B antagonists was assessed to reveal which of these is the 
most likely candidate for therapeutic use. 
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5.1.10. Chonic heart failure and secondary PHT: 
The cardiac myocytes in the failing myocardium display a reduced force of 
contractility which leads to a reduction in ejection fraction. The decrease in ejection 
fraction increases the blood volume remaining in the left ventricle, causing stretch of 
the cardiac myocytes leading to a further decrease in contractility. This results in an 
increase in the left ventricular end diastolic pressure and a dilatation of the left 
ventricle. This results in an increase in mean pulmonary artery pressure (MP AP), If 
this situation is sustained for any length of time, PHT secondary to CHF develops. 
Secondary PHT is characterised by an increase in MP AP from < 15mmHg to 
> 19mmHg. An increase in pulmonary vascular resistance (PVR) from 67 ± 30 
dynes.s.cm-5 to 149 ± 14 dynes.s.cm-5 and vascular remodelling where there is a 
progressive muscularisation of the pulmonary vascular tree (Cowbum et at., 1998; 
Maclean, 1998; Moreas et at., 2000: Huang et at., 2001). There is an increase in 
vascular tone of both the systemic and pulmonary circulations secondary to CHF. 
Pulmonary vascular remodelling further enhances PVR and decreases alveolar-
capillary membrane de fusion capacity leading to a decrease in gaseous transfer in the 
alveoli (Puri et at, 1995; Huang et at, 2001). The combination of the increase in PVR 
and the decreased gas transfer correlated with the exercise intolerance seen in patients 
with CHF as PHT increases ventilation - perfusion mismatching. The receptor 
densities of ET receptors in the pulmonary arterial circulation have the ETA to ET B 
ratio of 9: 1, and in the left ventricular cardiac myocytes , the ratio is 84: 16 in favour 
of the ETA receptor. (Modesti et at., 1999; Moreas et at., 2000; Reindl et at., 1998). 
There is an increase in vascular tone of both the systemic and pulmonary circulations 
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in PHT secondary to CHF also. The severity of secondary PHT is directly correlated 
to the prognosis and mortality of patients with CHF (Moreas et al., 2000). CHF is 
treated with a standard triple drug regimen comprising of a diuretic; digoxin; and an 
ACE inhibitor such as enalopril. However, despite this treatment, many patients 
remained symptomatic with little improvement in secondary PHT (Sutch et al., 1998). 
Therefore, new therapeutic approaches are needed to alleviate the symptoms of CHF 
and secondary PHT. 
ET -1 is implicated in the pathophysiology of CHF and in the PHT which occurs as a 
consequence of CHF or congenital heart disease, and in idiopathic or primary PHT 
that has no obvious cause or PHT that occurs as a consequence of sustained hypoxia. 
Plasma concentrations of ET -1 and ET -I-like immunoreactivity in the myocardium 
and pulmonary circulation are raised in patients with PHT secondary to CHF and 
congenial heart defects (Yoshibayashi et al., 1991; Kiowski et al., 1998; Fukachi & 
Giaid, 1998; Cowbum et al., 1998a; Cowbum et al.,1998b; Maclean, 1998; Meada et 
al., 1998; Sutch et al.,1998; Moraes et al., 2000; Huang et al., 2001; Love & 
McMurray, 1996) and is significantly correlated with the haemodynamic changes 
associated with, and the severity of, CHF. ET-l spillover in the lungs is significantly 
correlated with the raised pulmonary and systemic vascular resistances (PVR and 
SVR, respectively) and the increased ratios of PVR : SVR seen in such patients. 
(Yoshibayashi et al., 1991; Love & McMurray, 1996; Kiowski et al., 1998; Fukachi 
& Giaid, 1998; Cowbumet al., 1998a; Cowbum et al., 1998b; Maclean, 1998; Meada 
et al., 1998; Sutch et al.,1998; Moraes et al., 2000; Huang et aI, 2001). ET-l levels 
are increased during exercise and this is inversely correlated with peak exercise 
capacity in CHF patients. This evidence suggests that raised ET -1 levels in secondary 
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PHT may contribute to the exercise intolerance seen in CHF patients (Moraes et al., 
2000). ET-l is a potent and efficacious vasoconstrictor of the arterial and venous 
sides of both the pulmonary and systemic vascular circulations (MacLean, 1998; Love 
et al., 2000). Both ET-1 and endothelin-converting enzyme-1 (ECE-1) have been 
shown to be synthesised in the vascular endothelial cells and macrophages of the 
failing myocardium (Fukuchi & Giaid, 1998). Cowbum et al. (1998a) infused 
exogenous ET-1 (at a concentration observed in CHF patients) into the pulmonary 
artery of patients with CHF subsequent to left ventricular dysfunction. This resulted 
in an increase in the systemic, but not mean pulmonary, artery pressure while cardiac 
index fell (Cowbum et al., 1998 a & b). Therefore, exogenous ET-1 caused systemic 
vasoconstriction without affecting the pulmonary vasculature. This evidence is fuel 
for the continuing debate over whether the increase in plasma levels of ET -1 seen in 
patients with secondary PHT is the cause/mediator of, or is merely a marker of the 
severity of the condition. A definitive answer is still proving to be elusive (Cowbum 
et al., 1998 a & b; MacLean, 1998; Moraes et al., 2000). 
5.1.11. Endothelin antagonists in heart failure: 
Studies have previously shown the effect of ETA selective antagonists on 
haemodynamics in CHF patients. The ETA-selective antagonist, LV 135252, has been 
shown to significantly improve endothelium-dependent, flow-mediated vasodilatation 
that is normally impaired in CHF patients resulting in exercise intolerance (Berger et 
aI., 2001). LV 135252 also significantly lowers systemic systolic BP, increases 
cardiac output, and limits the progressive left ventricular remodelling that causes 
dilatation of the left ventricle leading to a decrease in ejection fraction (Mulder et al., 
1998). BMS-19388 has been shown to reduce the hypertrophy of the cardiac 
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myocytes of the right ventricle, which starts to fail as a consequence of sustained 
PHT. This antagonist also reduces the pre-load to the right ventricle which will 
decrease the right ventricular end diastolic pressure and benefit the right failing 
ventricle (Miyauchi et al., 2000). The ETA-selective antagonists, FR 139317 and 
BMS 182874, inhibited the ET-l-induced vasoconstriction at concentrations> InM in 
human small PRAs (McCulloch et al., 1996). 
A previous study involving the ET B-selective antagonist, BQ-788, has shown that it 
inhibited the first phase of the ET -I-mediated biphasic vasoconstrictor response 
«lnM) observed in human small PRAs (McCulloch et al., 1996). The ETB-selective 
antagonist K-8794 has been shown to increase both systemic BP and SVR as a result 
of inhibition ofETB1-mediated vasodilatation. However, this same study showed that 
K-8794 significantly attenuated the activation of the RAAS, therefore, limiting the 
increase in blood volume and vasoconstriction caused by this neurohumoral system 
(Sawaki et al., 2000). 
The mixed ET AIET B receptor antagonist, bosentan, has been used in several studies 
investigating its haemodynamic effects in patients with secondary PHT as a 
consequence of CHF. Bosentan treatment showed a significant decrease in mean 
arterial pressure, mean pulmonary arterial pressure (MP AP), pulmonary capillary 
wedge pressure (PCWP), SVR, PVR, and right ventricular pressure, whilst increasing 
the CO. These haemodynamic responses were seen within one day of treatment. 
After two weeks of treatment, bosentan further reduced both SVR and PVR, whilst 
CO was further increased. The plasma ET -1 level was increased after bosentan 
administration (Sutch et aI, 1998; and Moraes et al., 2000). Bosentan treatment 
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resulted in an improvement of the haemodynamics of both the pulmonary and 
systemic circulations in patients who had been symptomatic while on the standard 
triple therapy regime (Sutch et ai., 1998). Bosentan is now in phase III trials for CHF 
and has recently been approved by the Food and Drug Administration (FDA) for use 
in primary PHT. The mixed ETA.iETB receptor antagonists, SB 209670; SB 217242; 
and SB 234551, all inhibited the ET-1-mediated vasoconstriction of human small 
PRAs (MacLean et ai., 1998). 
These previous studies have not provided a definitive answer as to which type of ET 
receptor antagonist would be the most therapeutically beneficial in the treatment of 
CHF and secondary PHT. However, as the blockade of ET B2 is beneficial in the 
attenuation of vasoconstriction and in the suppression of the RAAS, ET B blockade is a 
desirable effect, despite the inhibition of ET B I-me-diated vasodilatation. Antagonism 
of both ETA and ET B receptors may be required to fully suppress the 
pathophysiological effects of ET-1 in CHF. Therefore, our group investigated the 
effects of three novel, mixed ET AIET B antagonists on human small PRAs in patients 
with different degrees of left ventricular dysfunction. This study compared the ET -1-
mediated vasoconstriction in the small PRAs of patients with good, moderate, and 
poor left ventricular ejection fractions and control patients to see if there is a change 
in the vasoconstrictor effect of ET -1 as the severity of left ventricular dysfunction 
increases. This study will also characterise the ability of the three novel, mixed 
ETA.iETB antagonists to inhibit the ET-1-induced vasoconstriction in these tissues and 
to compare their effect between the different patient subgroups. 
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5.1.12. Novel mixed ETAIETB antagonists: 
The chemical name of SB 247083 is: ((E)-[1-butyl-5-[2-(2-carboxyphenyl)methoxy-
4-chlorophenyl]-IH-pyrazol-4-yl]-2-[5-methoxydihydrobenzofuran-6-yl]-2-propionic 
acid)). SB 247083 has been characterised as a non-peptide, orally active ETA-
selective antagonist which inhibited the ETA-mediated ET-l-induced vasoconstriction 
of the isolated rat aorta, but was less potent at inhibiting the ET B-mediated STXs6c-
induced vasoconstriction of isolated rabbit pulmonary arteries (Douglas et al., 1998). 
This antagonism profile is due to the greater affinity of SB 247083 for ETA than ETB 
receptor subtypes (Ki 0.41 and 467nM, respectively) (Douglas et al., 1998; Willette et 
al., 1998). 
The chemical name of SB 234551 is: ((E)-alpha-[[I-butyl-5-[2-[(2-carboxyphenyl) 
methoxy-phenyl]-IH-pyrazol-4-yl]methylene ]-6-methoxy-l ,3-benzodioxole-5-
propanoic acid). SB 234551 has been characterised as an orally available, non-
peptide ETA-selective antagonist. Previous studies have shown that SB234551 caused 
a rightward shift of the ETA-mediated ET-l concentration / response curves in the 
isolated rat aorta and large human pulmonary arteries. However, SB 234551 also 
caused a rightward shift in the ETB-mediated STXs6c-induced vasoconstriction of the 
isolated rabbit pulmonary artery (Ohlstein et al., 1998). SB 234551 inhibited the 
ET-l-induced vasoconstriction of isolated human PRAs (MacLean et al., 1998). A 
study investigating the effect of SB234551 on the ET -I-induced decrease in 
glomerular filtration rate and renal plasma flow revealed that SB234551 not only 
inhibited these papthophysiological effects of ET -1 in the renal circulation but 
actually increased the renal plasma flow (Brooks et aI., 1998). As SB 234551 has 
also been shown to have only a weak inhibitory effect on the ETB-mediated STXs6x-
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induced vasodilatation of the isolated rabbit pulmonary artery, SB 234551 has been 
shown to inhibit vasoconstriction by both ETA and ET B receptor subtypes while still 
allowing ETB-mediated vasodilatation (Brooks et al., 1998; Ohlstein et al., 1998). 
This antagonism profile is due to the greater affinity of SB 234551 for ETA than ET B 
receptor subtypes (Ki 0.13 and 500nM, respectively) (Brooks et al., 1998; MacLean et 
al., 1998; Ohlstein et al., 1998; Willette et al., 1998). 
The chemical name of SB 217242 is: (IS, 2R, 3S)-3-[2-(2-hydroxyeth-1-yloxy)-4-
methoxyphenyl]-1-(3 ,4-methylenedoxyphenyl)-5-(prop-1-yloxy)indan-2-carboxylic 
acid. SB 217242 has been classed as a non-peptide, orally active ETA-selective 
antagonist (Underwood et al., 1998; Underwood et al., 1999). In earlier studies SB 
217242 was shown to inhibit the increase in pulmonary artery pressure, the increase in 
right ventricular hypertrophy and medial thickening of PRAs in high altitude-sensitive 
rats resulting from 14 days chronic hypoxia exposure (Underwood et al., 1998; 
Underwood et al., 1999). SB 217242 inhibited the ET-1-induced vasoconstriction of 
isolated human PRAs (MacLean et al., 1998). This antagonism profile is due to the 
greater affinity of SB 217242 for ETA than ET B receptor subtypes (Ki 1.1 and 111nM, 
respectively) (Underwood et al., 1998; MacLean et al., 1998; Willette et al., 1998; 
Underwood et al., 1999). 
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5.2. Methods 
5.2.1. In vivo study: 
Our group teamed up with two cardiothoracic surgeons from the cardiology dept. of 
Glasgow Western Infirmary, Mr. John Lu and Mr. Michael Flynn, to assess the effect 
of various vasoactive substances on the cardiovascular system in vivo and in vitro. 
This was a BHF funded project with local ethical permission granted. The in vivo 
assessment of the vasoconstrictor effects of ET-1 and 5-HT, and the vasodilator 
effects of PGh were carried out by the surgeons involved in the study. Therefore, all 
results of the in vivo study discussed in this chapter have been supplied by Mr. John 
Lu and Mr. Michael Flynn. Patients involved in the study were admitted to the 
hospital for one day a week prior to the coronary artery bypass graft the in vivo 
component of the study which includes thermodilution catheterisation to assess 
cardiovascular haemodynamics and echo cardiographic assessment of left ventricular 
function. Under local anaesthesia, a pulmonary artery flotation catheter was inserted 
into either the femoral, antecubital brachial or internal jugular vein and fed through to 
its destination in the pulmonary artery under fluoroscopy. After a 30 minute period of 
bed rest, the haemodynamic baselines were stabilised and measurements of the right 
heart pressures, pulmonary artery wedge pressure, SVR, PVR and cardiac output were 
taken. The first infusion involved PGI2 at 4, 8, and 12ng/kg/min to assess the 
maximum vasodilator reserve. After a 30 minute washout period, 15pmol/min of 
ET-1, 0.5 ng/kg/min of 5-HT or saline were infused in a random sequence. All 
infusions were followed by a 30 minute washout period during which all 
haemodynamic parameters returned to baseline levels. Heparin (5000 IU) was given 
to all patients before 5 -HT and ET -1 infusion to inhibit platelet aggregation. During 
these infusions, all patients received continuous ECG monitoring. As the in vitro 
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experiments in this chapter only involve ET -1 and the effect of mixed ETA/ET B 
antagonists on this response, I will only discuss the results of the ET -1 component of 
the in vivo study. 
5.2.2. In vitro study: 
Small muscular PRAs were dissected free from human lung tissue biopsies from 
patients undergoing coronary bypass grafts to alleviate coronary artery occlusion and 
left ventricular dysfunction. Written consent was obtained from patients to allow the 
collection of a biopsy of their lung during surgery. As mentioned above, 
cardiothoracic surgeons at Glasgow Western Infirmary had previously assessed the 
function of the left ventricle by echocardiographic measurement of the ejection 
fraction of patients undergoing this surgery. Patients with an ejection fraction of 
>40% were classed as being in the good L VF group. Patients with an ejection 
fraction of between 30-40% were classed as being in the moderate L VF group. 
Patients with an ejection fraction of <30% were classed as being in the poor L VF 
group. Once isolated from the surrounding parenchyma, the small muscular PRAs of 
each of these patient groups were set up on an isometric wire myograph (Mulvaney & 
Halpern, 1997). The transmural pressure of the vessels was set at ~ 16mmHg. 
Another 'group' of vessels was studied. They were small muscular pulmonary 
resistance arteries (PRAs) were dissected free from human lung tissue resected from 
patients undergoing thoracotomies for bronchial carcinoma. Written consent was 
obtained from these patients to allow the collection of a biopsy of their resected lung 
for our study. The patients were given the designation of control left ventricular 
function (control L VF) as these patients did not have coronary artery disease. 
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After an equilibration period of 45 minutes, tension was applied to the isolated vessels 
by the method described in chapter 2. Once the tension had stabilised, the vessels 
were left to equilibrate for a further 45 minutes. 50mM KCI was added to the baths to 
determine the viability of the vessels. KCI additions were repeated until two 
reproducible vasoconstrictions were observed. Between each addition of KCI, there 
were repeated washes of the baths until the tension returned to its baseline level. 
The vessels were incubated for one hour with either I/lM SB 247083, SB 234551, or 
SB 217242. During each experiment, one vessel was not incubated with an ET AIET B 
antagonist and this vessel acted as a control ET -1 response. After the incubation 
period was over, a cumulative concentration response curve (CCRC) to ET-l was 
carried out in all vessels. The vessels were only used for one ET-l CCRC as ET-l is 
resistant to washout (Maguire et at., 2000). The ET -1 response achieved in the 
antagonist treated vessels did not reach a maximum in many cases. However, due to 
the very expensive cost of ET -1, the highest concentration that could be used was 
0.3/lM which did not always allow the ET -1 response to reach a maximum in the 
antagonist treated vessels. 
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5.3. Results 
5.3.1. In vivo study (carried out by surgeons Mr. John Lu and Mr. Michael 
Flynn): 
An infusion of ET -1 at a rate of 15pmollmin was infused into good, moderate, and 
poor L VF group patients. The haemodynamic parameters tested before and after 
infusion were mean PAP, capillary wedge pressure, mean arterial pressure, CI, heart 
rate, SVR and PVR. These parameters were compared between the different patient 
groups before ET -1 infusion. The only parameter to show a significant difference 
between the groups was the PVR at rest which showed a significant increase in the 
poor L VF group compared with the good L VF group. These results are shown in 
Table 5.1. 
LVF Good Poor 
Group (at rest) (at rest) 
PVR 
(dynes.s 139.14 ± 11.40 189.50 ± 13.25* 
.cm-s) 
n 14 6 
Table 5.1: The pulmonary vascular resistance (PVR) values measured in patients 
from the good and poor L VF groups. Data are expressed as mean ± SEM. n = 
number of patients. Statistical comparisons were made using an unpaired Students' 
t-test. P < 0.05* vs. good LVF group. 
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After infusion of ET-1 (15pmollmin), the only parameters to show a significant 
difference between the groups were PVR and mean arterial pressure. Infusion of ET-1 
caused a significant increase in the PVR value of the good L VF group when 
compared to the PVR at rest in this group. These results are shown in Table 5.2. 
LVF Good Good 
Group (at rest) (with ET-l) 
PVR 
(dynes.s 139.l4 ± 11.40 171.29 ± 10.86* 
.cm-s) 
n 14 14 
Table 5.2: The PVR value measured in patients of the good LVF group at rest and 
after infusion of ET -1 (15 pmol/min). Data are expressed as mean ± SEM. n = 
number of patients. Statistical comparisons were made using an unpaired Students' 
t-test. P < 0.05* vs. PVR at rest. 
Infusion of ET -1 caused a significant increase in the mean arterial pressure of the 
moderate L VF group when compared with the good L VF group. These results are 
shown in Table 5.3. 
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LVF Good Moderate 
GROUP (with ET-l) (with ET-l) 
Mean 
arterial 85.57 ± 3.11 96.86 ± 3.14* pressure 
(mmHg) 
n 14 14 
Table 5.3: The mean arterial pressure measured after infusion ofET-l 
(15 pmol/min) in the good and moderate LVF groups. Data are expressed as mean ± 
SEM. n = number of patients. Statistical comparisons were made using an unpaired 
Students't-test. P < 0.05* vs. good LVF group. 
5.3.2. In vitro study 
5.3.2.1. Comparison ofET-l response between groups: 
ET -1 induced a potent vasoconstriction in the human small PRAs from the control, 
good, moderate, and poor L VF groups. The ET -1 CCRC appears to be 
characteristically biphasic in nature with a first slow, shallow component and a 
second fast, steep component. The PRAs in this study are classed with regards to the 
patient's ejection fraction. Patients undergoing a thoracotomy to resect a bronchial 
carcinoma, but have no coronary artery disease, are classed as controls. PRAs from 
patients undergoing a coronary atiery bypass with an ejection fraction of> 40% are 
classed as having a good L VF. PRAs from patients undergoing a coronary artery 
bypass with an ejection fraction of 30-40% are classed as having a moderate LVF. 
PRAs from patients undergoing a coronary artery bypass with an ejection fraction of 
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<30% are classed as having a poor LVF. The vasoconstrictor response to ET-1 in 
these groups is displayed in Figure 5.2. The vessels sizes and maximum contractile 
responses to 50mM KCI from each of the different L VF groups are shown in Table 
5.4. There was no significant difference in the potency of ET -1 between the patient 
groups. These results are shown in Table 5.5. There was no significant difference in 
the maximum constrictor response to ET -1 between the groups. These results are 
displayed in Table 5.6. 
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Figure 5.2: The vasoconstrictor response to ET -1 in the human small PRAs of the 
various LVF groups. Control (n = 12); good LVF (n = 7); moderate LVF (n = 12); 
and poor LVF (n = 8). Data expressed as percentage of 50mM KCI-induced 
vasoconstriction. Each point represents the mean ± SEM. 
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Protocol Control GoodLVF Moderate PoorLVF Group LVF 
Vessel Size 191 ± 21 180 ± 32 213 ± 14 194 ± 25 (Jlm) 
KCI-
Induced 
Tone (mN) 3.17 ± 0.40 1.42 ± 0.45 1.94 ± 0.45 1.52 ± 0.46 
n 12 7 12 8 
Table 5.4: Dimensions and measurements of 50mM KCI-induced vasoconstriction 
in the control ET -1 protocol group of the four different L VF groups. Data are 
expressed as mean ± SEM. n = number of patients. 
LVF Control GoodLVF Moderate PoorLVF Group LVF 
pECso 8.13 ± 0.12 8.53 ± 0.17"5 8.24 ± 0.14"5 8.32 ± 0.07"5 
values 
n 12 7 12 8 
Table 5.5: pECso values for ET-l in the human small PRAs of the control, good, 
moderate and poor L VF groups. Data are expressed as mean ± SEM. n = number of 
patients. Statistical comparisons were made using a one-way ANOVA with a 
Dunnetts' post-test. ns = not significant vs. control group. 
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Protocol Control Good Moderate Poor Group 
ET-l Max. 
Response 
(as % KCI- 152 ± 13 141 ± 1608 135 ± 1608 168 ± 1708 
Induced 
Tone) 
n 12 7 12 8 
Table 5.6: The maximum contractile response to O.3IlM ET-1 as percentage of 
SOmM KCI-induced vasoconstriction in the human small PRAs of the control, good, 
moderate and poor L VF groups. Data are expressed as mean ± SEM. n = number of 
patients. Statistical comparisons were made using a one way ANOVA with a 
Dunnetts' post-test. ns = not significant vs. control group. 
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5.3.2.2. The effect of the mixed ETAIETB antagonists in the control group: 
ET -1 induced a vasoconstriction which had a characteristically biphasic CCRC in the 
small muscular PRAs in the presence and absence of the mixed ETAIETB antagonists 
except for SB 247083 in the control group (Figure 5.3). The vessels sizes and 
maximum contractile responses to 50mM KCl in the control PRAs are shown in 
Table 5.7. 
The vasoconstrictor response to ET -1 in the presence and absence of l/lM 
SB 247083; SB 234551; and SB 217242 in the control group is shown in Figure 5.3. 
A summary of pECso values is shown in Table 5.8. A summary of the maximum 
responses to ET -1 is displayed in Table 5.9. 
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Figure 5.3: The vasoconstrictor response to ET -1 in the human small PRAs in the 
presence and absence of l/lM of a mixed ETAIET B antagonist in the control L VF 
group. Control ET-1 (n = 12); SB 247083 (n = 10); SB 234551 (n = 8); and 
SB 217242 (n 8). Data expressed as percentage of 50mM KCl-induced 
vasoconstriction. Each point represents the mean ± SEM. 
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Protocol Control ET-l SB 247083 SB 234551 SB 217242 Group 
Vessel Size 191 ± 21 202 ± 15 216 ± 18 194 ± 25 ("m) 
KCI-
Induced 
Tone (mN) 3.17 ± 0.40 3.58 ± 0.89 1.23 ± 0.28 1.52 ± 0.46 
n 12 10 8 8 
------ - '-----
Table 5.7: Dimensions and measurements of 50mM KCI-induced vasoconstriction 
in the various protocol groups of the control group. Data are expressed as mean ± 
SEM. n = number of patients. 
SB 247083 significantly decreases the potency ofET-1 (n = 10, P < 0.05). 
SB 247083 significantly attenuates the maximum response to ET-1 (P < 0.01). 
SB 234551 significantly decreases the potency ofET-1 (n = 8, P < 0.05). SB 234551 
significantly attenuates the maximum response to ET-1 (P < 0.01). SB 217242 
significantly decreases the potency of ET-1 (n 8, P < 0.05). SB 217242 
significantly attenuates the maximum response to ET-1 (P < 0.05) (Tables 5.8 and 
5.9). 
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Protocol Control ET-l SB 247083 SB 234551 SB 217242 Group 
pECso 8.13±0.12 7.59 ± 0.15* 7.66 ± 0.12* 7.56 ± 0.18* 
values 
n 12 10 8 8 
Table 5.8: pECso values for ET -1 in the human small PRAs of the control group ± 
1 ~M of a mixed ET NET B antagonist. Data are expressed as mean ± SEM. 
n = number of patients. Statistical comparisons were made using a one-way ANOV A 
with a Dunnetts' post-test. P < 0.05* vs. control ET-l. 
Protocol Control ET -1 SB 247083 SB 234551 SB 217242 Group 
ET-l Max. 
Response 
(as % KCI- 152 ± 13 49 ± 12** 65 ± 10** 87 ± 25* 
Induced 
Tone) 
n 12 10 8 8 
, 
Table 5.9: The maximum contractile response to 0.3/lM ET-1 as percentage of 
50mM KCI-induced vasoconstriction in the human small PRAs of the control group. 
Data are expressed as mean ± SEM. n = number of patients. Statistical comparisons 
were made using a one-way ANOV A with a Dunnetts' post-test. P < 0.05*, P < 
0.01 ** vs. control ET-l response. 
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5.3.2.3. The effects of the mixed ETAIETB antagonists in the good LVF group: 
ET -1 induced a vasoconstrictor response with a characteristically biphasic CCRC in 
the small muscular PRAs in the presence and absence of the mixed ET NET B 
antagonists in the good LVF group, except for in the presence of SB 217242 which 
removed the first component of the CCRC. The vessel sizes and maximum 
contractile responses to 50mM KCl in the good LVF PRAs are shown in Table 5.10. 
The vasoconstrictor response to ET -1 in the presence and absence of 11-lM 
SB 247083; SB 234551; and SB 217242 in the good L VF group is shown in Figure 
5.4. A summary of pECso values is shown in Table 5.11. A summary of the 
maximum responses to ET-1 is displayed in Table 5.12. 
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Figure 5.4: The vasoconstrictor response to ET -1 in the human small PRAs in the 
presence and absence of 11-lM of a mixed ETAIET B antagonists in the good L VF 
group. Control ET-1 (n = 7); SB 247083 (n = 6); SB 234551 (n = 4); and SB 217242 
(n = 4). Data expressed as percentage of KCl-induced vasoconstriction. Each point 
represents the mean ± SEM. 
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SB 247083 significantly decreases the potency ofET-l (n = 6, P < 0.05). SB 247083 
significantly attenuates the maximum response to ET-l (P < 0.01). SB 234551 
significantly decreases the potency of ET -1 (n 4, P < 0.05). SB 234551 
significantly attenuates the maximum response to ET-l (P < 0.01). SB 217242 
significantly decreases the potency of ET-l (n 4, P < 0.01). SB 217242 
significantly attenuates the maximum response to ET-l (P < 0.01). (Tables 5.11 and 
5.12). 
Protocol Control ET-1 SB 247083 SB 234551 SB 217242 Group 
Vessel Size 180 ± 32 190 ± 10 204 ± 14 183 ± 19 (11m) 
KCI-
Induced 
Tone (mN) 1.42 ± 0.45 2.19 ± 0.83 0.89 ± 0.23 1.27 ± 0.09 
n 7 6 4 4 
Table 5.10: Dimensions and measurements of 50mM KCl-induced vasoconstriction 
in the various protocol groups of the good L VF group. Data are expressed as mean ± 
SEM. n = number of patients. 
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Protocol Control ET-l SB 247083 SB 234551 SB 217242 Group 
pECso 8.53 ± 0.17 7.87 ± 0.19* 7.77 ± 0.24* 7.40 ± 0.09** 
values 
n 7 6 4 4 
Table 5.11: pECso values for ET-1 in the human small PRAs ofthe good LVF group 
± 1 flM of a mixed ETAIET B antagonist. Data are expressed as mean ± SEM. 
n = number of patients. Statistical comparisons were made using a one-way ANOV A 
with a Dunnetts' post-test. P<0.05*,P<0.01** vs. controlET-l. 
Protocol Control ET-l SB 247083 SB 234551 SB 217242 Group 
ET-l Max. 
Response 
(as % KCI- 141 ± 16 50 ± 9** 49 ± 19** 61 ± 3** 
Induced 
Tone) 
n 7 6 4 4 
Table 5.12: The maximum contractile response to 0.3flM ET-1 as percentage of 
50mM KCl-induced vasoconstriction in the human small PRAs of the good L VF 
group. Data are expressed as mean ± SEM. n = number of patients. Statistical 
comparisons were made using a one-way ANOVA with a Dunnetts' post-test. 
P < 0.01 ** vs. control ET-1 response. 
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5.3.2.4. The effects of mixed ETAIETB antagonists in the moderate LVF group: 
ET -1 induced a vasoconstriction which had a characteristically biphasic CCRC in the 
small muscular PRAs in the presence and absence of the mixed ETN£,TB antagonists 
in the moderate L VF group, except for SB 247083. The vessels sizes and maximum 
contractile responses to 50mM KCI in the moderate L VF PRAs are shown in Table 
5.13. 
The vasoconstrictor response to ET -1 in the presence and absence of l/-lM SB 
247083; SB 234551; and SB 217242 in the moderate L VF group is shown in Figure 
5.5. A summary of pECso values is shown in Table 5.14. A summary of the 
maximum responses to ET-1 is displayed in Table 5.15. 
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Figure 5.5: The vasoconstrictor response to ET-1 in the human small PRAs in the 
presence and absence of l/-lM of a mixed ET AIET B antagonists in the moderate L VF 
group. Control ET-1 (n = 12); SB 247083 (n = 7); SB 234551 (n = 7); and SB 217242 
(n = 6). Data expressed as percentage of 50mM KCI-induced vasoconstriction. Each 
point represents the mean ± SEM. 
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Protocol Control ET-l SB 247083 SB 234551 SB 217242 Group 
Vessel Size 213 ± 14 168 ± 17 197 ± 22 200 ± 12 (ltm) 
KCI-
Induced 
Tone (mN) 1.94 ± 0.45 1.14 ± 0.46 0.84 ± 0.27 1.09 ± 0.25 
n 12 7 7 6 
Table 5.13: Dimensions and measurements of 50mM KCl-induced vasoconstriction 
in the various protocol groups of the moderate L VF group. Data are expressed as 
mean ± SEM. n = number of patients. 
SB 247083 did not significantly decrease the potency of ET -1 in the moderate PRAs. 
SB 247083 significantly attenuates the maximum response to ET-1 (n = 7, P < 0.05). 
SB 234551 did not significantly decrease the potency of ET-1. SB 234551 did not 
significantly attenuate the maximum response to ET-1. SB 217242 did not 
significantly decrease the potency of ET -1. SB 217242 did not significantly attenuate 
the maximum response to ET-1. (Tables 5.14 and 5.15). 
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Protocol Control ET-1 SB 247083 SB 234551 SB217242 Group 
pECso 8.24 ± 0.14 8.30 ± 0.36llS 8.10 ± 0.18lls 7.67 ± 0.15lls 
values 
n 12 7 7 6 
Table 5.14: pECso values for ET-1 in the human small PRAs of the moderate LVF 
group ± 1 flM of a mixed ETA/ET B antagonist. Data are expressed as mean ± SEM. 
Statistical comparisons were made using a one-way ANOVA with a Dunnetts' post-
test. ns = not significant. 
Protocol Control ET-1 SB 247083 SB 234551 SB 217242 Group 
ET-1 Max. 
Response 
(as % KCI- 135 ± 16 49 ± 16* 106 ± 32llS 110 ± 19l1s 
Induced 
Tone) 
n 12 7 7 6 
Table 5.15: The maximum contractile response to 0.3flM ET-l as percentage of 
50mM KCI-induced vasoconstriction in the human small PRAs of the moderate L VF 
group. Data are expressed as mean ± SEM. n = number of patients. Statistical 
comparisons were made using a one-way ANOVA with a Dunnetts' post-test. 
P < 0.05* vs. control ET-1 response. ns = not significant. 
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5.3.2.5. The effects of the mixed ETAfET B antagonist the poor LVF group: 
ET -1 induced a vasoconstriction which had a characteristically biphasic CCRC in the 
small muscular PRAs in the presence and absence of the mixed ET NET B antagonists, 
except SB 247083 in the poor L VF group. The vessels sizes and maximum 
contractile responses to 50mM KCl in the poor L VF PRAs are shown in Table 5.16. 
There is no significant difference in the tone induced by 50mM KCl between the 
control ET-1 group and either of the mixed ETNETB antagonist groups. 
The vasoconstrictor response to ET -1 in the presence and absence of l/-lM SB 
247083; SB 234551; and SB 217242 in the poor L VF group is shown in Figure 5.6. 
A summary of pECso values is shown in Table 5.17. A summary of the maximum 
responses to ET -1 is displayed in Table 5.1S. 
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Figure 5.6: The vasoconstrictor response to ET-1 in the human small PRAs in the 
presence and absence of l/-lM of a mixed ETAIET B antagonists in the poor L VF group. 
Control ET-1 (n = 8); SB 247083 (n = 6); SB 234551 (n = 6); and SB 217242 (n = 6). 
Data expressed as percentage of 50mM KCl-induced vasoconstriction. Each point 
represents the mean ± SEM. 
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Protocol Control ET-1 SB 247083 SB 234551 SB 217242 Group 
Vessel Size 155 ± 26 175 ± 13 180 ± 10 164 ± 17 (11m) 
KCI-
Induced 
Tone (mN) 1.31 ± 0.31 1.23 ± 0.21 0.66 ± 0.13 0.58 ± 0.09 
I 
n 8 6 6 6 
Table 5.16: Dimensions and measurements of 50mM KCI-induced vasoconstriction 
in the various protocol groups of the poor L VF group. Data are expressed as mean ± 
SEM. n = number of patients. 
SB 247083 significantly decreases the potency ofET-1 (n = 6, P < 0.05). SB 247083 
significantly attenuates the maximum response to ET-1 (P < 0.01). SB 234551 
significantly decreases the potency of ET-1 (n 6, P < 0.01). SB 234551 
significantly attenuates the maximum response to ET-1 (P < 0.01). SB 217242 
significantly decreases the potency of ET-1 (n 6, P < 0.01). SB 217242 
significantly attenuates the maximum response to ET-1 (P < 0.01). (Table 5.17 and 
5.18). 
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Protocol Control ET-1 SB 247083 SB 234551 SB 217242 Group 
I 
pECso 8.32 ± 0.07 7.82 ± 0.17* 7.41 ± 0.12** 7.39 ± 0.07** 
values 
n 8 6 6 6 
Table 5.16: pECso values for ET-1 in the human small PRAs of the poor LVF group 
± 111M of a mixed ET NET B antagonist. Data are expressed as mean ± SEM. 
n = number of patients. Statistical comparisons were made using a one-way ANOVA 
with a Dunnetts' post-test. P < 0.05*, and P < 0.01 ** vs. control ET-1. 
Protocol Control ET-1 SB 247083 SB 234551 SB 217242 Group 
ET-1 Max. 
Response 
(as % KCI- 168 ± 17 68 ± 12** 59 ± 18** 62 ± 16** 
Induced 
Tone) 
n 8 6 6 6 
Table 5.18: pECso values for ET -1 in the human small PRAs of the poor L VF group 
± 111M of a mixed ET AIET B antagonist. Data are expressed as mean ± SEM. 
n = number of patients. Statistical comparisons were made using a one-way ANOV A 
with a post-test. P < 0.01 ** vs. control ET-l. 
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5.4. Discussion 
5.4.1. In vivo study: 
The findings of the in vivo study conducted by Mr Lui and Mr Flynn both agreed and 
disagreed with the results of two previous studies investigating the effect of infused 
ET -Ion the cardiovascular haemodynamics of CHF patients. The results of the 
Moraes et al. (2000) study showed that the presence of CHF was correlated with the 
pulmonary haemodynamic parameters of PVR and mean PAP, but not the systemic 
parameters of CI and SVR. Our group's study found that the only changes in the 
cardiovascular system that the progression of left ventricular dysfunction caused were 
in the pulmonary circulation. The PVR of the poor L VF group at rest was 
significantly increased with respect to the PVR of the good L VF group. This previous 
study also defined PHT as being present when the mean PAP is 0 19mmHg. The 
mean PAP of the poor L VF group was 20.33 ± 1.80mmHg. However, this difference 
was not significantly different from the good L VF group, but this lack of significance 
is possibly due to the small number of patients in this group (n = 6). Our group's 
study also agreed with the study conducted by Cowburn et al., 1999, which found that 
the mean arterial pressure was significantly increased by the infusion of ET -1 in 
patients with CHF. Our group's study found that the mean arterial pressure was 
significantly increased after infusion of ET -1 in the moderate, but not the poor, L VF 
group when compared to the good L VF group. However, this earlier study also found 
a significant increase in the SVR, but not the PVR, after infusion of ET -1 in CHF 
patients. This was not seen in our study in any of the patient groups. The infusion of 
ET -1 only elicited a significant increase in the PVR of patients in the good L VF group 
compared with their PVR at rest. 
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5.4.2. In vitro study 
5.4.2.1. Comparison ofET-l response between different patient groups: 
ET -1 induced a potent and efficacious vasoconstriction in small PRAs from the 
control and all the heart failure groups. The biphasic nature of the ET -1 CCRC is due 
to the presence of both ETA and ET B2 receptors mediating the ET -lresponse in these 
vessels (McCulloch et at., 1996; MacLean et aI., 1998). Previous studies in human 
PRAs have shown that the fIrst component of the ET -1 contractile response is slow 
and shallow « InM), this is mediated by the ETB2 receptor. The second fast, steep 
component of the curve (> InM) is mediated by the ETA receptor (McCulloch et at., 
1995; McCulloch et at., 1996, McCulloch et at., 1998; MacLean et at., 1998a). 
BQ-788 was able to inhibit both vasodilator and vasoconstrictor ETB receptors in 
human PRAs and showed the involvement of a vasoconstrictor ET B receptor in this 
preparartion (McCulloch et at., 1996). There was no signifIcant difference in the 
maximum vasoconstriction elicited by ET -1 between the control and heart failure 
groups. These results show no signifIcant differences in the KCI- or ET-l-induced 
vasoconstrictor responses of the control patients with bronchial carcinoma and 
patients with good L VF. Therefore, this study validates the use of lung tissue taken 
from patients undergoing bronchial carcinoma removal as control tissue for other 
human pulmonary vascular studies as the presence of carcinoma did not appear to 
alter the function of the PRAs in this study. The potency of the ET-l-induced 
constriction was also unaltered by the progression of left ventricular dysfunction. The 
ET -I-mediated vasoconstriction of the dorsal hand vein, and the positive inotropic 
effect induced by ET -1 in the ventricular cardiac myocytes, were both attenuated in 
patients with CHF (Pieske et at., 1999; Love et at., 2000). This 'blunting' of the ET-
I-mediated vasoconstriction was not observed in the small PRAs from the CHF 
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patients compared to controls. Indeed, there was no significant difference in either 
potency or maximum response of the ET-1-induced vasoconstriction between even 
the poor left ventricular function and the control groups. Therefore, there is no 
desentization of the ETA receptors in the small PRAs that is seen in other tissue 
preparations from CHF patients. 
5.4.2.2. Effect of the mixed ETAIETB antagonists: 
SB 247083 significantly decreased the potency of ET -1 in all the patient subgroups, 
except for in the moderate L VF group. SB 247083 did markedly reduce the 
maximum effect of ET -1 in all patient groups. Previous work has shown that this 
component of the CCRC is mediated by the ETA-receptor (McCulloch et al., 1996) 
and, hence, is indicative of the high potency of SB 247083 against the ETA-receptor 
(Kj: 0.41nM) (Douglas et al., 1998; Willette et al., 1998). Previous work has been 
unable to demonstrate inhibition of the first component of the CCRC with a selective 
ETA-receptor antagonist, only with a selective ETB-receptor antagonist (McCulloch et 
al., 1996). Therefore, the reduction of this component by SB 247083 observed in all 
groups (except the moderate L VF group) must be due to its moderate affinity at the 
ETB receptor (Kj: 467nM) (Douglas et al., 1998; Willette et al., 1998). 
SB 234551 significantly decreased the potency of ET-1 in all patient subgroups 
except for the moderate LVF group. SB 234551 markedly reduced the maximum 
effect of ET -1 in all the patient subgroups (except for the moderate L VF group), 
indicative of its high potency against the ETA receptor (Ki: O.13nM) (Brooks et al., 
1998; MacLean et al., 1998; Ohlstein et at., 1998; Willette et al., 1998). The 
reduction of the first component of the CCRC by SB 234551 observed in all groups 
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(except for the moderate L VF group) must be due to its moderate affinity at the ET B 
receptor (Ki: 500nM) (Brooks et a!., 1998; MacLean et al., 1998; Ohlstein et al., 
1998; Willette et al., 1998). 
SB 217242 significantly decreased the potency of ET -1 in all the patient subgroups 
(except for the moderate LVF group). SB 217242 markedly reduced the maximum 
effect of ET -1 in all the patient groups (except for the moderate L VF group), 
indicative of its high potency against the ETA receptor (Ki: 1.1nM) (MacLean et al., 
1998; Underwood et al., 1998; Willette et al., 1998; Underwood et al., 1999). The 
reduction of the first component by SB 217242 observed in all groups (except the 
moderate L VF group) must be due to its moderate affinity at the ET B receptor 
(Ki: 111nM) (MacLean et al., 1998; Underwood et al., 1998; Willette et al., 1998; 
Underwood et al., 1999). 
The reason for the lack of effect of these antagonists in the 'moderate' L VF group is 
unclear. It may have been due to the 'n' values available, and that an increased 
sample size would have increased a trend into a significant difference as seen in the 
other patient groups. 
Alternatively, the pulmonary circulations of the moderate LVF group may be 
undergoing a compensatory physiological mechanism. The PVR is inversely 
correlated with LVF. The moderate LVF group had an ejection fraction of between 
30-40% and an average PVR of 161.14 ± 14.05 dynes·s·cm-5• One hypothesis is that 
once the PVR reaches a certain point, a compensatory mechanism is switched on 
which alters the effects of ETA and ET B activation, or alters the characteristics of 
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these receptors by altering their densities, state of sensitization, or G-protein coupling. 
This mechanism reduces the effect of the mixed ETAIETB antagonists. Once the PVR 
increases further in patients with poor L VF, the mechanism is turned off and the 
effects of the antagonists are restored. As all of the antagonists failed to decrease the 
potency of ET -1 in this group, this suggests that both antagonists failed to antagonise 
ET B2 receptors which mediate ET -I-induced vasoconstriction up to InM (McCulloch 
et al., 1996). As both SB 234551 and SB 217242 failed to attenuate the maximum 
contractile response to ET -1 in this group, this suggests that both antagonists failed to 
antagonise ETA receptors which mediate ET-l-induced vasoconstriction above InM 
(McCulloch et al., 1996). The compensatory mechanism may result from the 
differential regulation of both ETA and ET B receptors. The cause of the disparity in 
the results from the moderate L VF group compared with the other groups requires 
further investigation. However, it should be noted that the moderate LVF group was 
the only group to experience a significant increase in the mean arterial pressure after 
the infusion of ET -1. This effect may result from the compensatory mechanism at 
work in the cardiovascular systems of patients classed as having moderate left 
ventricular function. 
The findings of the study revealed that all three of the novel, mixed ETAIET B 
antagonists used in this study effectively inhibited the ET -I-induced vasoconstriction 
of the small muscular PRAs in the control, good, and poor L VF groups. The increase 
in pulmonary vascular tone observed in patients with CHF and secondary PHT 
contributes to the exercise intolerance experienced by these patients (Maeda et ai., 
1998; Moraes et at., 2000). As ET -1 causes pulmonary vasoconstriction in vivo and 
181 
in vitro, the mixed ET NET B antagonists may be beneficial in increasing the exercise 
capacity of patients with CHF 
5.5. Conclusion 
The results of the in vivo study show that the cardiovascular haemodynamic changes 
subsequent to left ventricular dysfunction vary widely between patients with different 
levels of disease and that the role that ET -1 plays in causing these changes has yet to 
be fully elucidated. 
The results of the in vitro study suggest that the mixed ETAIET B antagonists could be 
beneficial in the treatment of CHF and secondary PHT as they attenuate the 
pathophysiological effects of ET -1 in both the pulmonary and systemic circulations. 
Indeed, the mixed ET NET B antagonist, bosentan is now in phase III trials in the 
treatment of heart failure. Therefore, these three, novel mixed ET NET B antagonists 
could be of similar therapeutic benefit in CHF, with the added benefit of decreasing 
PVR. 
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Chapter 6 
The effect of mixed ET AI ET B 
antagonists in the treatment of 
hypoxia-induced PHT using the 
chronic hypoxic rat model 
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6.1.1. Introduction 
The infrequent occurrence of PHT makes the study of the pathophysiological 
processes involved difficult to ascertain, as tissue from patients with this condition is 
not readily available. However, the chronic hypoxic rat model allows us the 
opportunity to get as close to pathophysiological secondary PHT conditions as 
possible as there are no underlying illnesses or genetic predisposition to hypertension 
or heart failure in the rats used in the study, no surgery such as coronary artery 
ligation involved, and no drugs were used to induce PHT in this animal model 
(McCulloch & MacLean, 1995; MacLean et al., 1995; McCulloch et al., 1998; 
MacLean & McCulloch, 1998). 
6.1.2. ET-l in PHT: 
There is an increase in the plasma levels of ET -1 in patients with, and in animal 
models of, primary and secondary PHT with a directly proportional relationship 
between the level of ET -1 and the severity of the disease state (Russel & Davenport, 
1995; Love & McMurray, 1996; Yang et al., 1997; Cowbum et al., 1998a; MacLean 
et al., 1998; Underwood et al., 1999; Chen & Oparil, 2000; Miyuachi et al., 2000; 
Moraes et al., 2000; Telemaque-Potts et a!., 2000). It is still unclear whether ET-l is 
an important mediator ofPHT or simply a marker of the condition. 
6.1.3. Effect of chronic hypoxia on ET -1 response: 
Chronic hypoxia has shown to increase the maximum response to ET -1 and ET -3 in 
rat pulmonary resistance arteries (PRAs) (MacLean & McCulloch, 1998; McCulloch 
et al., 1998). These studies have shown an increase in the endogenous tone of small 
muscular pulmonary resistance arteries of the chronic hypoxic rat which is equivalent 
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to an in vivo transmural pressure of ~33mmHg (MacLean et at., 1994; McCulloch et 
at., 1998; MacLean & McCulloch., 1998). Chronic hypoxia increases the level of 
cAMP in the small muscular pulmonary resistance arteries (Mullaney et at., 1998). A 
recent study has revealed an increase in the level of immunostaining of a actin in 
chronic hypoxic rat PRAs compared to controls after hypoxia 2, 7, or 14 days in 
duration. The presence of a actin is a marker of vascular remodelling and shows that 
the vessels are undergoing progressive muscularisation associated with the 
development ofPHT in response to hypoxia (Demiryurek et at., 2000). 
6.1.4. ET receptors in control and chronic hypoxic rat PRAs: 
A previous study has profiled the ET receptors mediating ET-1-induced 
vasoconstriction in control and hypoxic rat PRAs (McCulloch et at., 1998). In control 
rats, the contractile response to ET -1 is resistant to blockade by either selective ETA 
or selective ET B receptor antagonists but inhibited by the mixed ET NET B antagonist 
SB 209670. In addition, the rank order of agonist potency was STXs6c = ET-3 > 
ET-1 which indicates an ETB-like profile. The contractile response to ET-1 was 
increased in the chronic hypoxic rat PRAs and this increase was inhibited by an ETA-
selective antagonist as well as by SB 209670 (McCulloch et at., 1998). The 
signalling mechanisms by which the ETA and ET B receptors mediate the effects of 
ET-1 are discussed in chapter 5. 
6.1.5. Novel mixed ETAIETB antagonists: 
SB 209670 has a Ki at human ETA receptors ofO.2nM and at ETB receptors of 18nM 
(MacLean et aI., 1998). Recently, three new mixed ETAIETB antagonists from the 
same chemical family have been developed, SB 247083, SB 234551 and SB 217242. 
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The chemical structure and details of these are discussed in chapter 5. In summary, 
the affinity ofSB 247083 for human cloned ETA and ETB receptor subtypes is Ki 0.41 
and 467nM, respectively, for SB 234551, Ki 0.13 and 500nM, respectively and for 
SB 217242, Ki 1.1 and ll1nM, respectively (Brooks et ai., 1998; Douglas et ai., 
1998; MacLean et ai., 1998; Ohlstein et ai., 1998; Underwood et ai., 1998; Willette et 
ai., 1998; Underwood et ai., 1999). 
These findings meant that further investigation into the ability of novel mixed 
ET NET B antagonists is warranted. 
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6.2. Methods 
Wistar rats were placed in a hypobaric chamber at 30 days old. The chamber was 
depressurized to 550mbars over a period of 48 hours. When the chamber was at 
550mbars, the oxygen concentration was at 10%. The temperature of the chamber 
was maintained at ~ 21°C with a ventilation rate of 45 Llmin. The rats remained in 
these hypoxic conditions for 14 days and sacrificed upon removal from the chamber. 
Age-matched controls were kept in room air for the same time period (MacLean et at., 
1995; MacLean & McCulloch, 1998). The right ventricle was dissected free from the 
left ventricle and septum, blotted carefully with a tissue and then weighed. The ratio 
of right ventricular (R.V.) weight / left ventricular + septum (L.V. + S) weight is 
calculated to assess the presence of PHT (Hunter et at., 1974; Leach et at., 1977; 
MacLean & McCulloch, 1998). 
The rats were killed by an overdose of sodium pentobarbitone by intra-peritoneal 
injection. The thorax was opened and the heart and lungs were dissected free then 
placed in ice cold Krebs. Second order intralobal small muscular resistance arteries 
« 250/-tm) were dissected out of the lung tissue and carefully cleaned of surrounding 
parenchyma with the aide of a microscope. The vessels from both groups of rat were 
taken from the same region of the left lobe of the lung. The vessels were trimmed to a 
length of 2mm before passing two wire (40f.lm in diameter) through the lumen of the 
vessel and mounting it on a wire myograph (Mulvaney & Halpern, 1977). The 
myography bath contained Krebs solution at 37°C and bubbled with 16% O2 / 5% 
CO2 / balance N2 from a gas pipe connected to a Douglas bag. Previous studies have 
measured the gas tensions in the baths using these parameters and found the O2 
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tension to be 120 mmHg and CO2 tension to be 35 mmHg, which is equivalent to the 
gas tensions seen in the alveolar and pulmonary arteries in vivo (MacLean & 
McCulloch, 1998). The vessels were left to equilibrate for an hour after being 
mounted in the baths. Tension was carefully applied to the vessels so that the control 
rat vessels were set at '" 16 mmHg and the hypoxic rat vessels were set at '" 33 mmHg, 
tensions which are equivalent to those experienced by the vessels in vivo (Herget et aI, 
1978; MacLean & McCulloch, 1998). After the tension was stabilised at appropriate 
level, the vessels were left to equilibrate for a further 45 minutes. The viability of the 
vessels was then assessed by the addition of 50mM KCl to the baths. Once the 
vasoconstriction had levelled off, the baths were washed out several times until the 
tension had returned to the baseline. The KCl addition was repeated until two 
reproducible vasoconstrictions were obtained. Vessels in the control ET -1 protocol 
groups were left to equilibrate until a CCRC to ET -1 was costructed. Some vessels 
were incubated for an hour with one of the following mixed ET AIET B antagonists, SB 
247083, SB 234551, or SB 271242 before a CCRC to ET-1 was constructed. In the 
control Wistar rats, only a single concentration of each antagonist (1JlM) was used as 
none of the three antagonists at this high concentration were able to inhibit the ET -1-
induced vasoconstriction in these vessels. However, three different concentrations of 
each antagonist (1, 0.3, and O.1JlM) were used in studies using chronic hypoxic rat 
vessels. 
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6.3. Results 
6.3.1. Development of PHT: 
The right ventricular to left ventricular + septum ratio is a reliable index for the 
presence of PHT (Hunter et ai., 1974; Leach et ai., 1977). Previous studies have 
shown that 14 days of hypobaric treatment was sufficient to cause PHT in rats as the 
ratio was significantly greater in the hypoxic rats when compared with control rats 
(MacLean et ai., 1995; and MacLean & McCulloch, 1998). The results from this 
present study show that the ratio is significantly greater in the hypoxic rats 
(P < 0.001) when compared with control rats (Table 6.1). This demonstrates that the 
hypoxic rats in this study had developed right ventricular hypertrophy associated with 
the development ofPHT. 
R.V.IL.V.+ 
Experimental 
Septum Ratio n= number Group 
Control 0.21 ± 0.01 n= 11 
Hypoxic 0.32 ± 0.01 *** n= 10 
Table 6.1: Measurement of the right ventricle (R.V.) Ileft ventricle + septum 
(L.v. + S) ratio in the control and hypoxic Wistar rat groups. Data expressed as mean 
± SEM. n = number of individual heart preparations. Statistical comparison was 
made using Students' unpaired t-test. P < 0.001 *** vs. control rat ratio. 
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6.3.2. Control rat PRAs in the presence ofthe mixed ETNETB antagonists: 
ET-l-induced a potent vasoconstriction in the normotensive Wi star rat small PRAs 
with a pEC50 of 8.00 ± 0.13 (n = 11) and a maximal contractile response of 134 ± 10% 
(as % KCl-induced contraction). The ET-l CCRC was characteristically biphasic in 
nature with a first slow, shallow component and a second fast, steep component. A 
summary of the maximum contractile response elicited by ET -1 is shown in Table 
6.2. There was no significant difference in the maximum vasoconstrictor response 
achieved by 50mM KCI or 0.31lM ET -1 in any of the protocol groups in the control 
rat. A summary of the pEC50 values of ET-l are shown in Table 6.3. Figure 6.1 
shows the effect of 111M of the mixed ETAIETB antagonists SB 247083, SB 234551 
and SB 217242 on the ET-l response in control Wi star rat PRAs. 
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Figure 6.1: Contractile response to ET-l in the presence and absence of 111M of the 
mixed ETAIET B antagonists in normotensive Wistar rat PRAs. Data expressed as 
percentage of50mM KCI-induced contraction. Control ET-l (n = 11); SB 247083 
(n = 7); SB 234551 (n = 8); and SB 217242 (n = 9). Each point represents the mean ± 
SEM. n = number of PRAs from the same number of individual lung preparations. 
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The maximum vasoconstrictor response to 50mM KCI was significantly smaller in the 
SB 24551 (n = 9) protocol group than in the ET -1 control (n = 11) (P < 0.05). 
Protocol ET -1 Control SB 247083 SB 234551 SB 217242 Group 
Vessel Size 
1.42 ± 11 140 ± 19 125 ± 8 171 ± 12 
(J-lm) 
KCI-Induced 
Maximum 2.43 ± 0.38 2.94 ± 1.12 1.34 ± 0.32 2.90 ± 0.72 
(mN) 
ET-l-
Induced 3.15 ± 0.52 3.83 ± 1.37 1.89 ± 0.41 3.97 ± 0.97 
Max. (mN) 
n number n= 11 n=7 n=9 n=8 
Table 6.2: Dimensions and measurement of 50mM KCI- and 0.311M ET-l-induced 
maximum contraction achieved in the various protocol groups in the normotensive 
Wistar rat PRAs in the presence and absence of 1 f-tM of mixed ET AJ'ET B antagonist. 
Data expressed as mean ± SEM. n = number of individual PRAs from the same 
number of individual lungs. 
The presence of 1flM SB 247083, SB 234551, or SB 217242 did not result in a 
decrease of the potency ofET-1 in the normotensive Wistar rat PRAs. However, 
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SB 234551 and SB 217242 did shift the first component of the CCRC to the right. A 
summary of the pECso values for ET -1 in the presence and absence of l/lM of various 
mixed ET NET B antagonists is displayed in Table 6.3. 
Protocol 
pECso Value n= number Group 
ET -1 Control 8.00 ± 0.13 n= 11 
SB 247083 8.10±0.17ns n=7 
SB 234551 7.74 ± 0.11 ns n=9 
SB 217242 7.99 ± 0.11 ns n=8 
Table 6.3: pECso values for ET -1 in the presence and absence of l!!M of mixed 
ET AIET B antagonists in normotensive Wi star rat PRAs. Data are expressed as mean ± 
SEM. n = number of individual PRAs from the same number of lung preparations. 
Statistical comparisons were made using a one-way ANOVA with a Dunnetts' post-
test. ns = not significant. 
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6.3.3. Chronic hypoxic rat PRAs in the presence of the mixed ETAIETB 
antagonist, SB 247083: 
Figure 6.2 displays the ET-I-induced contractile response in the presence and 
absence of 1,0.3, O.I/!M of the mixed ET,JETB antagonist, SB 247083, in the PRAs 
of the chronic hypoxic Wi star rat. The ET -1 CCRC had a characteristically biphasic 
appearance in the presence and absence of 1, 0.3, and O.I/!M of the mixed ET AIET B 
antagonist, SB 247083. The maximum contractile response to ET-I in the presence 
and absence of SB 247083 is shown in Table 6.4. 
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Figure 6.2: Contractile response to ET-I in the presence and absence of 1, 0.3, and 
O.l/!M of the mixed ETAIETB antagonist, SB 247083, in chronic hypoxic Wistar rat 
PRAs. Control ET-I (n = 11); I/!M SB 247083 (n = 8); 0.3/!M SB 247083 (n = 5); 
and O.I/!M SB 247083 (n = 6). Data expressed as percentage of 50mM KCI-induced 
contraction. Each point represents the mean ± SEM. n = number of individual PRAs 
from same number of individual lung preparations. 
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Protocol ET -1 Control 1JlM O.3JlM 0.1JlM Group SB 247083 SB 247083 SB 247083 
Vessel Size 
122 ± 7 144± 7 159 ± 16 171±11 
(!-tm) 
KCI-
Induced 
2.42 ± 0.43 2.46 ± 0.34 2.78 ± 1.11 2.66 ± 0.71 
Maximum 
(mN) 
ET-l-
Induced 
4.06 ± 0.51 3.60 ± 0.39 3.96 ± 1.82 3.75 ± 1.43 
Maximum 
(mN) 
n= number n=9 n=8 n=5 n=6 
Table 6.4: Dimensions and measurement of 50mM KCl- and 0.3JlM ET -1-induced 
maximum contraction achieved in the various protocol groups in the hypoxic Wistar 
rat PRAs in the presence and absence of 1, 0.3, or 0.1!J.M of the mixed ETNETB 
antagonist, SB 247083. Data expressed as mean ± SEM. n = number of individual 
PRAs from the same number of individual lungs. 
Each concentration of SB 247083 significantly decreased the potency of ET-1 and 
caused a rightward shift of the CCRe. The potency of ET -1 was significantly 
decreased by 1 (P < 0.05, n = 8), 0.3 (P < 0.05, n = 5), and 0.1JlM (P < 0.05, n = 6) 
SB 247083. A summary of the pECso values is shown in Table 6.5. 
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Protocol 
Group 
pECso Value n=number 
ET -1 Control 8.46±o..16 n=9 
1/lM 
SB 2470.83 7.93 ± 0..0.7* n=8 
o..3/lM 7.89 ± 0..10.* SB 2470.83 n=5 
o..1/lM 7.81 ± 0..0.8* SB 2470.83 n=6 
Table 6.5: pEC50 values for ET-1 in the presence and absence of 1. 0.3, and o..1/lM 
of SB 2470.83 in chronic hypoxic Wistar rat PRAs. Data are expressed as mean ± 
SEM. n = number of individual PRAs from the same number of lung preparations. 
Statistical comparisons were made using a one-way ANOVA and a Dunnetts' post-
test. P < 0..0.5* vs. ET-l control. 
SB 2470.83 at concentrations of 1,0..3, and o..l/lM did not cause parallel shifts of the 
whole ET -1 concentration I response curve. There was a rightward shift of the first 
shallow component of the curve by all three concentrations of SB 2470.83 with I/lM 
of the drug causing the greatest shift of this component. Therefore, a pA2 value could 
not be calculated. However, the estimatedpKB value for I/lM ofSB 2470.83 has been 
calculated and is shown in table 6.6. 
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Protocol Group Estimated pkB n = number 
values 
SB 247083 6.37 ± 0.24 n=8 
Table 6.6: Estimated pKB values for l/lM of SB 247083 in hypoxic Wistar rat PRAs. 
Data are shown as mean ± SEM. n number of PRAs from individual lung 
preparations. 
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6.3.4. Chronic hypoxic Wistar rat PRAs in the presence of the mixed ETAIETB 
antagonist, SB 234551: 
Figure 6.3 displays the ET -I-induced contractile response in the presence and 
absence of 1, 0.3, 0.1~ of the mixed ETAIETB antagonist, SB 234551, in the PRAs 
of the chronic hypoxic Wistar rat. The ET -1 CCRC had a characteristically biphasic 
appearance in the presence and absence of 1, 0.3, and O.IIlM of the mixed ETAIETB 
antagonist, SB 234551. The maximum contractile response to ET-l in the presence 
and absence ofSB 234551 is shown in Table 6.7. 
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Figure 6.3: Contractile response to ET-l in the presence and absence of 1, 0.3, and 
0.1 IlM of the mixed ET NET B antagonist, SB 234551, in chronic hypoxic Wistar rat 
PRAs. Data expressed as percentage of 50mM KC1-induced contraction. Control ET-
1 (n = 9); IIlM SB 234551 (n= 7); 0.31lM SB 234551 (n = 5); and O.lIlM SB 234551. 
Each point represents the mean ± SEM. n = number of PRAs from the same number 
of individual lung preparations. 
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Protocol ET-l Control I/lM 0.3/lM O.I/lM Group SB 234551 SB 234551 SB 234551 
Vessel Size 
117±8 133±5 137 ± 17 142 ± 16 
()lm) 
KCI-
Induced 
2.42 ± 0.43 1.46 ± 0.32 2.30 ± 0.75 3.16 ± 1.43 
Maximum 
(mN) 
ET-l-
Induced 
4.06 ± 0.51 2.32 ± 1.07 5.23 ± 2.04 4.51 ± 2.23 
Maximum 
(mN) 
n=number n=9 n=7 n=5 n=5 
Table 6.7: Dimensions and measurement of 50mM KCI- and 0.3/lM ET-l-induced 
maximum contraction achieved in the various protocol groups in the chronic hypoxic 
Wi star rat PRAs in the presence and absence of 1, 0.3, and O.1/lM of the mixed 
ETNETB antagonist, SB 234551. Data expressed as mean ± SEM. n = number of 
individual PRAs from the same number of individual lungs. 
Each concentration of SB 234551 significantly decreased the potency of ET-l and 
caused a rightward shift of the CCRC. The potency of ET -1 was significantly 
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decreased by 1 (P < 0.01, n = 7),0.3 (P < 0.05, n = 5), and O.lI1M (P < 0.05, n = 5) 
SB 234551. A summary of the pECso values is shown in Table 6.8. 
Protocol 
Group 
pECso Value n=number 
ET -1 Control 8.46 ± 0.16 n=9 
111M 7.73 ± 0.10** SB 234551 n=7 
0.311M 7.83 ± 0.13* SB 234551 n=5 
O.lI1M 7.66 ± 0.27* SB 217242 n=5 
~ -
- - - --
Table 6.8: pECso values for ET-1 in the presence and absence of 1,0.3, and O.1!-.l.M of 
SB 234551 in chronic hypoxic Wi star rat PRAs. Data are expressed as mean ± SEM. 
n number of individual PRAs from the same number of lung preparations. 
Statistical comparisons were made using a one-way ANOVA with a Dunnetts' post-
test. P < 0.05*, P < 0.01 ** vs. ET-l control. 
SB 234551 at concentrations of 1,0.3, and O.II1M did not cause parallel shifts of the 
whole ET -1 concentration / response curve. There was a parallel shift of the first 
shallow component of the curve by all three concentrations of SB 234551 with 111M 
of the drug causing the greatest rightward shift of this component. Therefore, the pA2 
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value could not be calculated. However, the estimated pKB value for 11lM of SB 
247083 has been calculated and is shown in Table 6.9. 
Protocol Group Estimated pkB n=number 
values 
SB 234551 6.75 ± 0.26 n=7 
Table 6.9: Estimated pKB values for l!!M ofSB 234551 in hypoxic Wistar rat PRAs. 
Data are shown as mean ± SEM. n number of PRAs from individual lung 
preparations. 
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6.3.5. Chronic hypoxic Wistar rat PRAs in the presence of 1, 0.3, and O.I,..,M of 
the mixed ETAIETB antagonist, SB 217242: 
Figure 6.4 displays the ET -I-induced contractile response in the presence and 
absence of 1,0.3, O.1l-tM of the mixed ETNETB antagonist, SB 217242, in the PRAs 
of the chronic hypoxic Wi star rat. The ET -1 CCRC had a characteristically biphasic 
appearance in the presence and absence of 1, 0.3, and O.ll-tM of the mixed ET NET B 
antagonist, SB 217242. The maximum contractile response to ET -1 in the presence 
and absence of SB 217242 is shown in Table 6.10. The maximum vasoconstrictor 
response to 0.3l-tM ET-1 was significantly smaller in the 1JlM of SB 217242 protocol 
group (n = 9) than in the control ET-1 group (n = 9) (P < 0.05). 
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Figure 6.4: Contractile response to ET-1 in the presence and absence of 1, 0.3, and 
0.1 I-tM of the mixed ET NET B antagonist, SB 217242, in normotensive Wistar rat 
PRAs. Data expressed as percentage of 50mM KCI-induced contraction. Each point 
represents the mean ± SEM. n number of PRAs from the same number of 
individual lung preparations. 
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Protocol ET -1 Control I)lM 0.3)lM O.l)lM Group SB 217242 SB 217242 SB 217242 
Vessel Size 
140 ± 12 128 ± 10 155 ± 13 160 ± 9 
(11m) 
KCI-
Induced 
2.42 ± 0.43 1.64 ± 0.35 1.42 ± 0.57 2.43 ± 0.59 
Maximum 
(mN) 
ET-l-
Induced 
4.06 ± 0.51 2.58 ± 0.39 2.39 ± 1.34 3.27 ± 0.39 
Maximum 
(mN) 
n=number n=9 n=9 n=5 n=6 
Table 6.10: Dimensions and measurement of 50mM KC1- and 0.3)lM ET-l-induced 
maximum contraction achieved in the various protocol groups in the chronic hypoxic 
Wi star rat PRAs in the presence and absence of 1, 0.3, and O.IIlM of SB 217242. 
Data expressed as mean ± SEM. n = number of individual PRAs from the same 
number of individual lungs. 
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Each concentration of SB 217242 significantly decreased the potency of ET-1 and 
caused a rightward shift of the CCRC. The potency of ET -1 was significantly 
decreased by 1 (P < O.OS, n = 9),0.3 (P < O.OS, n = S), and O.lflM (P < 0.01, n = 6) 
SB 217242. A summary of the pEC50 values is shown in Table 6.11. 
Protocol 
Group 
pECso Value n= number 
ET -1 Control 8.46 ± 0.16 n=9 
1flM 
SB 217242 7.90 ± 0.08* n=9 
O.3flM 7.74 ± 0.20* SB 217242 n=S 
O.lflM 7.S2 ± O.lS** SB 217242 n=6 
I 
Table 6.11: pEC50 values for ET-1 in the presence and absence of 1,0.3, and O.l!!M 
of SB 217242 in chronic hypoxic Wistar rat PRAs. Data are expressed as mean ± 
SEM. n = number of individual PRAs from the same number of lung preparations. 
Statistical comparison were made using a one-way ANOVA with a Dunnetts' post-
test. P < O.OS*, and P < 0.01 ** vs. ET-1 control. 
SB 217242 at concentrations of 1,0.3, and O.lflM did not cause parallel shifts of the 
whole ET -1 concentration / response curve. There was a rightward shift of the first 
shallow component of the curve by all three concentrations of SB 217242. All three 
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concentrations of SB 217242 appeared to cause the same degree of rightward shift. 
Therefore, the pA2 value could not be calculated. However, the estimated pKB value 
for 1~M of SB 247083 has been calculated and is shown in table 6.6. 
Protocol Group Estimated pkB n= number 
values 
SB 217242 6.42 ± 0.20 n=9 
-
~-
-
Table 6.12: Estimated pKB values for 1!--tM of SB 217242 in hypoxic Wistar rat 
PRAs. Data are shown as mean ± SEM. n = number of PRAs from the same number 
of individual lung preparations. 
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6.3.6. Comparison of control and chronic hypoxic rat PRAs: 
The potency of ET -1 was significantly increased in response to chronic hypoxia as the 
pECso decreased from 8.00 ± 0.13 (n = 11) to 8.46 ± 0.16 (n = 9) in the normotensive 
and chronic hypoxia Wistar rat PRAs (P < 0.05). A summary of these results is 
shown in Table 6.13. The maximum contractile response was significantly increased 
in response to chronic hypoxia as the maximum contractile response was increased 
from 134 ± 10% to 181 ± 18% (as % KCI-induced contraction) in normotensive and 
chronic hypoxic Wistar rat PRAs (P < 0.05). A summary of these results can be seen 
in Table 6.14. There is no significant difference between the pECso of ET -1 in the 
presence of each individual mixed ETAIET B antagonist at the three concentrations 
studied. 
Experimental pECso value n=number Group 
Control 8.00 ± 0.13 n= 11 
Hypoxic 8.46 ± 0.16* n=9 
Table 6.13: pECso values for ET-l in the absence of the mixed ETN'ETB antagonists 
in the control and chronic hypoxic Wistar rat PRAs. Data are expressed as mean ± 
SEM. n = number of individual PRAs from the same number of lung preparations. 
Statistical comparisons were made using Students' unpaired t-test. P < 0.05* vs. 
control Wistar rat. 
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Maximum 
Experimental contraction 
n=number Group 
(% ofKCl) 
Control 134 ± 10 n= 11 
Hypoxic 181 ± 18* n=9 
Table 6.14: Measurement of ET-l-induced maximum vasoconstriction achieved in 
the control and chronic hypoxic Wistar rat PRAs. Data expressed as mean ± SEM. 
n = number of individual PRAs from the same number of individual lungs. Statistical 
comparisons were made using Students' unpaired t-test. P < 0.05* vs. control Wistar 
rat. 
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6.4. Discussion 
6.4.1 Comparison of control and chronically hypoxic rat PRAs: 
The results of this study agree with those of earlier studies which saw an increase in 
the potency of, and maximum contractile response to, ET -1 in the chronic hypoxic rat 
PRAs (McCulloch & MacLean, 1995; McCulloch et al., 1998; MacLean, 1998; 
MacLean & McCulloch, 1998). This has been shown to be accompanied by an 
increase in plasma levels of ET -1 (Chen & Oparil, 2000). As described previously, 
the response to ET-1 in control rat PRAs is mediated by a heterogeneous ETB-like 
receptor population (McCulloch et al., 1998). The potency ofET-1 was significantly 
increased from 8.00 ± 0.13 (n=l1) in control rats to 8.46 ± 0.16 (n=9) in chronic 
hypoxic rats (P < 0.05). The maximum contractile response to ET -1 was also 
significantly augmented from 134 ± 10% (n = 11) in control rats to 181 ± 18% (n = 9) 
in chronic hypoxic rats (P < 0.05). This augmentation of the maximum 
vasoconstrictor response to, and increased potency of, ET -1 may be due to the up-
regulation of ETA receptors as a consequence of hypoxia as the increased response is 
inhibited by an ETA receptor antagonist, causing a decrease in the maximum 
contraction induced by ET-l in the chronic hypoxic rat PRAs (McCulloch et al., 
1998). Therefore, the potency of, and maximum contractile response to, ET-l were 
increased in the chronic hypoxic Wistar rat PRAs as a result of the up-regulation of 
both ETA receptors as a consequence of hypoxia. My results are consistent with 
previous studies in that the antagonist studied had negligible effect on the contractile 
response to ET -1 in control rat vessels but did inhibit responses to ET -1 in the chronic 
hypoxic rat vessels, consistent with them behaving as selective ETA receptor 
antagonists (see below for further discussion). 
207 
6.4.2. Control normotensive rat PRAs: 
None of the mixed ETAlETB antagonists were able to decrease the potency of the ET-
I-induced vasoconstriction in these vessels. This is consistent with their affinities for 
the ETA receptor and the previous studies showing that, the small muscular PRAs of 
the rat, responses to ET -1 are mediated by an 'atypical ET B' receptor (McCulloch et 
al., 1998). However, Figure 6.1 shows that l~M SB 234551 and SB 217242 caused 
rightward shifts of the first component of the ET-1 CCRC. As an ETB-like receptor is 
predominantly responsible for the ET -I-induced vasoconstriction in these vessels, the 
affinity of these two antagonists for the ET B receptor needs to be considered. The 
dissociation constant for SB 217242 at ET B receptors is lower than that of SB 247083 
and SB 234551 (Ki 111nM, 467nM and 500nM respectively) (Brooks et al., 1998; 
Douglas et at., 1998; MacLean et at., 1998; Ohlstein et at., 1998; Underwood et al., 
1998; Willette et al., 1998; Underwood et at., 1999). At l~M of these antagonists, 
SB 217242 is almost ten fold higher than its dissociation constant and would be able 
to antagonise the population of ET B2 receptors. This would account for the rightward 
shift of the fust component of the ET-1 CCRC by SB 217242. l~M of SB 234551 is 
twice as high as its dissociation constant and would antagonise the population of ET B2 
receptors. However, l~M of SB 247083 is also twice its dissociation constant at ET B 
receptors, yet SB 247083 did not cause a rightward shift of the first component of the 
ET -1 CCRC. Hence, the effect of these antagonists on this very shallow initial 
component of the CCRC cannot be fully explained in terms of their affinity at the ETB 
receptor. There is no evidence to suggest that these antagonists are inverse agonists. 
It has to be remembered, however, that the Ki values reported were against the human 
ET B receptor and differences may be expected against rat ET receptors.. Therefore, as 
these antagonists did not inhibit the ET -I-induced vasoconstriction in these vessels, 
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the results confirm that ET B2-like receptors are the main receptor subtype mediating 
the ET -1 response in control Wistar rat PRAs. A previous study using the mixed 
ET AIET B antagonist SB 209670 showed that the potency of ET -1 was decreased in 
both control and chronically hypoxic rat PRAs (McCulloch et al., 1998). This is 
different to the results observed using these three novel antagonists and is probably 
due to SB 209670 having a greater affinity for the ET B receptor subtype than any of 
the antagonists used in this study (Ki ETA: 0.2nM and ET B: 18nM) (McCulloch et al., 
1998). In summary, the three novel antagonists had negligible effect on responses to 
ET -1 in control rat PRAs. This very different from the observations made in chapter 
5 which demonstrated that all three antagonists inhibited the responses to ET -1 in 
control human PRAs. This is a very good example of species-specific pharmacology 
and justifies the use of human blood vessels to confirm observations made in animal 
models. 
6.4.3. Chronically hypoxic rat PRAs: 
All of the mixed ETAIET B antagonists were able to significantly decrease the potency 
ofET-l at all three of the concentrations studied in the chronic hypoxic PRAs. As the 
antagonists were able to decrease the potency of ET -1, this indicates that there was an 
increase in the ETA component of the response, confirming previous studies. The 
previous study by McCulloch et al., 1998 also showed that the responses to the ET B 
receptor agonist STXs6c was not increased in the chronic hypoxic rat vessels and the 
ET B-selective antagonist, BQ-788, had no inhibitory effect on this response. 
Therefore, these results confirm an increase in the ETA-mediated component of the 
ET -1 response in the chronic hypoxic rat vessels. 
209 
The potency ofET-1 was significantly decreased by 1, 0.3, and O.lflM of SB 247083 
from the pEC50 ofET-l alone, 8.46 ± 0.16 (n = 9), to 7.93 ± 0.07 (P < 0.05),7.89 ± 
0.10 (P < 0.05), and 7.81 ± 0.08 (P < 0.05) respectively (n = 5-8). All three 
concentrations of SB 247083 caused a rightward shift of the first shallow component 
of the ET-1 curve. The lack of any further effect of SB 247083 > O.1flM confirms 
that only a small population of ETA receptors is present and mediating the constriction 
to ET-1 and that the antagonist is saturating these ETA receptors. Only 1flM 
SB 247083 might be expected to exert some effect on the ETB receptor population 
(Ki: O.4lnM) but as the results from the control vessel show, this is not observed 
(Douglas et al., 1998; Willette et al., 1998). Therefore, the effect of this antagonist on 
contractile response to ET -1 in the hypoxic vessels can be attributed to an effect on a 
small population of ETA receptors. 
The potency ofET-1 was significantly decreased by 1, 0.3, and O.lflM of SB 234551 
to 7.73 ± 0.10 (P < 0.01), 7.83 ± 0.13 (P < 0.05), and 7.66 ± 0.27 (P < 0.05) 
respectively (n = 5-7). There was a concentration-dependent shift of the CCRC 
confirming the results observed with SB 247083, that this antagonist is acting as an 
ETA receptor antagonist (Ki: O.l3nM) and saturating a small population of ETA 
receptors. Figure 6.3 does suggest that 1flM of SB 234551 completely removes the 
shallow component of the CCRC which may be due to this concentration being 
sufficient to inhibit 'atypical' ETB receptors (Ki: 500nM) (Brooks et ai., 1998; 
MacLean et ai., 1998; Ohlstein et ai., 1998; Willette et ai., 1998). 
The potency ofET-1 was significantly decreased by 1, 0.3, and O.lflM of SB 217242 
to 7.90 ± 0.08 (P < 0.05), 7.74 ± 0.20 (P < 0.05), and 7.52 ± 0.15 (P < 0.01) 
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respectively (n = 5-9). There was a concentration-dependent shift of the CCRC 
confirming that this antagonist is acting as an ETA receptor antagonist (Kj: 1.1nM) 
and saturating a small population of ETA receptors. Figure 6.4 does suggest that all 
concentrations of SB 217242 completely removes the shallow component of the 
CCRC which may be due to the higher affinity of this antagonist against 'atypical' 
ETB receptors (Ki: 111nM) (MacLean et ai., 1998; Underwood et ai., 1998; Willette 
et ai., 1998; Underwood et ai., 1999). 
The results of this study do not help to answer the question of whether ET-1 is a 
mediator or simply a marker of pulmonary hypertension. However, these results, 
taken with those from previous studies, reveal an important role for ET -1 in PHT 
(MacLean et ai., 1995; Yang et ai., 1997; MacLean, 1998; MacLean et ai., 1998; 
MacLean & McCulloch, 1998; Underwood et ai., 1999; Chen & Op aril , 2000; 
Miyuachi et ai., 2000; Telemaque-Potts et ai., 2000). 
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6.5. Conclusion 
The mixed ET AIET B antagonists SB 247083, SB2345 51, and SB 217242 had no effect 
on the ET -1 response in the small muscular PRAs of the control rat. 
Chronic hypoxia increases both the potency and maximum vasoconstrictor response 
elicited by ET -1 in the small muscular rat PRAs. 
The mixed ETAIETB antagonists SB 247083, SB 234551, and SB 217242 attenuated 
the increased potency of ET -1 observed in response to chronic hypoxia in the small 
muscular rat PRAs probably through their activity against the ETA receptor. The 
ET-l-induced vasoconstriction in these vessels was mediated by a heterogeneous 
receptor population, with the ET B2 receptor being the predominant receptor involved 
in this response. 
Therefore, new therapeutic advances in the treatment of PHT and right-sided heart 
failure may come from inhibiting the ET -1 responses. 
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7.1. The role ofET-l in PHT: 
The studies described in this thesis have shown that there is an increase in the 
pulmonary vascular reactivity to ET -1 in pulmonary hypertension (PHT) induced by 
hypoxia. The rat model of hypobaric hypoxia is a well characterised model ofPHT .. 
This model was used to study the effect of ET -1 and the mixed ET ~T B antagonists 
in chronically hypoxic rats. The study revealed that there is an increase in the potency 
of, and maximum vasoconstrictor response to, ET -1 in the small PRAs of these rats. 
This verifies that ET -1 is a mediator of PHT developed as a consequence of chronic 
hypoxia. Both the potency of, and maximum contractile response to, ET -1 were 
increased by the presence of hypoxia-induced PHT. This increase in the vascular 
reactivity to ET-l was suggested to be the result of an up-regulation of ETA receptors. 
All three of the novel, mixed ETAIETB antagonists, SB 247083; SB 234551; and 
SB 217242, were able to decrease the potency ofET-l in the PRAs of the chronically 
hypoxic rats but did not affect the potency of ET -1 in the control rats. This result 
suggested that these three antagonists were able to inhibit the up-regulation of ETA 
receptors that occurs in the presence of hypoxia-induced PHT. 
The studies described in this thesis have shown that, in humans, there is no increase 
on the pulmonary vascular reactivity to ET -1 in PHT secondary to left ventricular 
dysfunction (L VD). The study involving patients with varying degrees of (L VD) and 
control patients undergoing bronchial carcinoma resection revealed that there was no 
increase in the potency of, or maximum contractile response to, ET -1 within these 
patient groups. The results of this study were surprising as many previous studies 
have shown an increase in the plasma levels of ET -1 in the presence of heart failure 
and PHT. This increase is directly correlated with the severity of disease. However, 
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this may be associated with a down-regulation of ET receptors in the face of a 
sustained elevation of ET -1. The results of this human study are in contrast to those 
observed in the chronic hypoxic rat study which showed that the presence of PHT 
resulted in an increase in the maximum response to, and potency of ET -1. This 
difference may be due to the different pathobiologies involved in rat and human PHT 
and that the chronic hypoxic rats developed more severe PHT. The increased 
sensitivity to ET -1 in the chronic hypoxic rat may be associated with the advanced 
development of PHT. As the results of this study display no increase in the vascular 
reactivity to ET -1 in the presence of PHT, it is suggested that ET -1 is a marker of 
PHT secondary to LVD. All three novel, mixed ETAIETB antagonists were able to 
decrease the potency of ET -1 in all four patient groups, except for the moderate L VF 
group where only SB 217242 was able to decrease the potency. Therefore, these 
antagonists were able to inhibit the ET B2 receptors in these vessels. All three 
antagonists were also able to attenuate the maximum contractile response of ET -1 in 
all four patient groups, except for the moderate LVF group where only SB 247083 
was able to decrease the maximum response to ET -1. Therefore, these antagonists 
were also able to inhibit the ETA receptors in these vessels, if one assumes it is the 
ETA receptor mediating the response to higher concentrations of ET -1 as suggested by 
MacLean et ai., 1995 and McCulloch et ai., 1998. 
The results of these studies suggest that ET -1 may be a mediator of secondary PHT 
induced by chronic hypoxia, while ET -1 may be a marker of secondary PHT as a 
consequence of L VD. These studies also display that the three mixed ETA/ET B 
antagonists may be of therapeutic benefit to patients with secondary PHT of either 
aetiology. This result has been borne out by the fact that the mixed ET AIET B 
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antagonist bosentan is now in phase III trials for the treatment of chronic heart failure 
and has just been given approval by the USA Food and Drug Administration for use 
in primary PHT. Very recent clinical trials involving bosentan in the treatment of 
chronic heart failure and PHT have revealed mixed results. Bosentan was able to 
improve the exercise capacity and cardiopulmonary haemodynamics in patients with 
primary PHT and PHT secondary to connective tissue disease. The patients in this 
study also saw an improvement in their WHO functional class, Borg dyspnea index 
and an increase in the time to clinical worsening (Rubin et ai., 2002). However, 
preliminary findings from another study using bosentan as a treatment for chronic 
heart failure, called the ENABLE trial, reported at a recent American College of 
Cardiologists meeting found that bosentan did not decrease the mortality rate of 
patients in the trial. As well as this disappointing result, patients taking bosentan have 
experienced weight gain along with potentially serious side-effects of a decreased 
haematocrit and abnormal liver function tests (unpublished communication). Whether 
these side- effects were dose-related is unclear and that altering the dose administered 
may eliminate the unwanted effects. However, as bosentan afforded no therapeutic 
benefit to these patients, it may simply be that bosentan is not the mixed ET~TB 
antagonist to use and that other antagonists of this class may be more beneficial. The 
mixed ETAIETB antagonists SB 247083; SB 234551; and SB 217242 could also be 
effective drugs in the treatment of primary and secondary PHT of different 
aetiologies. 
7.2. The mediators of ACh-induced vasodilatation: effect of chronic hypoxia: 
The rat model of hypobaric hypoxia was used to investigate the effects of PHT on 
vasodilator response to ACh in the small PRAs. This study revealed that the 
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maximum ACh-induced vasodilator response was augmented in the presence of PHT 
induced by chronic hypoxia. This study also investigated the mediators involved in 
the ACh-induced vasodilatation and the effect that chronic hypoxia would have on the 
mediator profile. This study revealed that NO and PGIz were not mediators of the 
ACh-induced relaxation in control rat PRAs as the NOS inhibitor, L-NAME, and the 
cyc100xygenase (COX) inhibitor, indomethacin, were unable to inhibit the ACh-
induced response. This lack of involvement by these mediators pointed to the ACh-
induced vasodilatation being mediated by EDHF. Previous studies have shown that 
pre-constriction of vessels with KCl inhibits the release of EDHF. Indeed, this study 
showed that ACh failed to induce any vasodilatation in vessels pre-constricted with 
KCl, suggesting the involvement of EDHF. The inhibitors of large & intermediate 
(BKca & IKca) and small (SKca) Ca2+-activated K+ channels, charybdotoxin (ChTX) 
and apamin respectively, attenuated the maximum vasodilator effect elicited by ACh. 
However, this combination ofK+ channel blockers was only able to significantly 
inhibit the highest concentrations of ACh, concentrations well above those needed to 
produce vasodilatation. The identity of EDHF has not yet been elucidated, but it has 
been hypothesised that EDHF is a family of substances rather than a single entity 
which elicit vasodilatation and hyperpolarization via different mechanisms. Other 
studies have shown a possible EDHF-mediated vasodilatation to ACh via KArp 
channels. Therefore, these results suggest that the ACh-induced vasodilator response 
may be mediated by two different EDHF-like substances in the control rat PRAs. 
However, the involvement of EDHF in the ACh-induced vasodilator response 
requires confirmation through electrophysiological studies. The study revealed that a 
different mediator profile was involved in the ACh-induced vasodilator response in 
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PRAs from the chronically hypoxic rats than was observed in the control rats. In the 
chronic hypoxic rat PRAs, NO; PGI2; and EDHF are all involved in the ACh-induced 
vasodilator response. However, the inhibition of these mediators by L-NAME; 
indomethacin; or a combination of ChTX and apamin, did not alter the potency of 
ACh but did attenuate the maximum vasodilator response to ACh. Each mediator was 
involved in different components of the ACh-induced vasodilatation. At low 
concentrations, the ACh-induced vasodilator response was mediated by NO. PGlz 
mediates the ACh-induced response at higher concentrations than NO and 
significantly attenuates the maximum relaxation response. An EDHF-like substance 
acting via IKca and SKca channels mediates the ACh-induced vasodilatation at the 
highest concentrations. This suggests that there is a general increase in the synthesis 
and release of NO, PGI2, and EDHF in the PRAs in response to PHT induced by 
chronic hypoxia. There is also an increased basal tone observed in these chronic 
hypoxic vessels is attenuated by the basal release of NO. These results suggest that 
there is a basal compensatory vasodilator mechanism which attenuates the increased 
basal tone of these vessels and an agonist-stimulated mechanism which increases the 
vasodilator effect of ACh at work in the PRAs of the chronically hypoxic rats 
attempting to return the pulmonary circulation to its natural low resistance state. 
7.3. The vasodilator role of hU-II in the pulmonary circulation: 
Early studies involving human urotensin-II (hU-II) showed that hU-II was a potent 
vasoconstrictor of the vasculature of various species. A previous study conducted by 
our group showed no vasoconstrictor effect of hU-II in the small muscular PRAs of 
human control patients. However, the addition ofL-NAME revealed a variable 
218 
hU-II-induced vasoconstriction in 30% of vessels studied. Therefore, the hU-II-
induced vasoconstrictor response appears to be inhibited by the release of NO in these 
vessels. Recent studies by others have shown that hU-II elicited a vasodilatation in 
the rat small mesenteric and coronary arteries. Therefore, hU-II can induce either a 
vasoconstrictor or vasodilator effect depending on the vascular bed and species being 
studied. The study described in this thesis revealed hU-II to be a potent vasodilator of 
the human small muscular PRAs, the fIrst study to show hU-II-induced vasodilatation 
in human vasculature. The potency order of vasodilators in the human PRAs was 
found to be: hU-II = adrenomedullan (ADM) » sodium nitroprusside (SNP) = ACh. 
This study also investigated the mediators involved in the hU-II-induced 
vasodilatation. The NOS inhibitor, L-NAME, did not inhibit the hU-II-induced 
vasodilatation at any concentration. Therefore, NO was not involved in mediating the 
hU-II-induced vasodilator response. The COX inhibitor, indomethacin, signifIcantly 
inhibited the hU-II-induced vasodilator response at concentrations of30pM and above 
to attenuate the maximum vasodilator response. Therefore, a COX product, possibly 
PGI2, is involved in mediating the hU-II-induced vasodilator response. The addition 
of the intermediate and small conductance Ca2+-activated K+ channel blockers, 
charybdotoxin (ChTX) and apamin respectively, signifIcantly inhibited the hU-II-
induced vasodilator response at every concentration to attenuate the maximum 
vasodilator response and signifIcantly decrease the potency of hU-II. Therefore, 
EDHF appears to be involved in mediating the hU-II-induced vasodilator response. 
However, to confIrm the involvement of EDHF, electrophysiological studies are 
required. EDHF is also involved in the ACh-induced vasodilatation in rat PRAs. 
EDHF alone mediates the ACh-induced relaxation in control rats and, along with NO 
and PGIz, mediates the ACh-induced vasodilatation in chronic hypoxic rats. These 
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studies agree with earlier studies showing that vasodilatation mediated by EDHF 
becomes more important with decreasing vessel size. 
7.4. Regulation of pulmonary vascular tone: 
ET-l is a potent vasoconstrictor of small muscular PRAs. This potency is increased 
in the presence of PHT induced by chronic hypoxia but not in the PHT secondary to 
LVD. A role for ET-l in 'priming' pulmonary resistance arteries for hypoxic 
pulmonary vasoconstriction (HPV) by sensitising vascular smooth muscle cells to 
Ca2+ has also been observed. Therefore, ET -1 has a pathophysiological role in PHT. 
Future treatments for PHT of different aetiologies could include the mixed ET.JET B 
antagonists, SB 247083; SB 234551; and SB 217242 which are able to inhibit the 
vasoconstrictor effect of ET -1 in these vessels. 
The vasodilator effect of ACh is enhanced in the small muscular PRAs of chronic 
hypoxic rats. This suggests an increase in the agonist-stimulated vasodilator response 
which attempts to compensate for the increased vascular reactivity observed as a 
consequence ofPHT. There is an increase in the basal release of NO in the 
chronically hypoxic vessels which suggests that there is also a mechanism attempting 
to compensate for the increased basal tone observed in these vessels. These results 
suggest that compensatory vasodilator mechanisms are activated by the presence of 
PHT in order to return the pulmonary circulation to its natural low resistance state. 
hU-II was previously thought to have a pathophysiological role in a number of disease 
states such as coronary atherosclerosis; chronic heart failure; chronic renal failure; 
and systemic hypertension. This was due to the fact that only vasoconstrictor effects 
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had been observed. However, since recent studies have shown hU-II-induced 
vasodilatation in various vascular beds of the rat, and the study described in this thesis 
showed the first vasodilator effect ofhU-II in the human vasculature, does hU-II have 
a protective role in some vascular beds? It would be have been interesting to be have 
been able to obtain more PRAs from the different patient groups involved in the 
human LVD study on which to assess the vasodilator effect of hU-II, to see whether 
the potency or maximum vasodilator response to hU-II changed with advancing L YD. 
Unfortunately, the number of vessels obtained from this study did not allow for 
another study to be conducted. If the vasodilator effects could be separated from the 
vasoconstrictor effects, hU-II could become a potent vasodilator for the treatment of 
PHT in the way that inhaled NO and analogues of PGI2 are used at present. 
This thesis has two studies showing the likely involvement of EDHF in mediating 
both ACh- and hU-II-induced vasodilatation. These observations agree with previous 
studies which have shown that EDHF becomes more important in mediating 
vasodilatation as the calibre of the vessel decreases. The inhibition of the Ca2 +-
activated K+ channels inhibited the maximum vasodilator response to, and potency of, 
both ACh and hU-II. Many treatments for PHT at present include inhaled NO and 
the inhilatation of analogues of PGIz, These results suggest that more effective 
pulmonary vasodilators could come as a result of stimulating the release of EDHF or 
from drugs which open Ca2+-activated K+ channels selectively. However, with the 
identity of EDHF under debate, any possible treatments acting through this 
mechanism would be a long way off. 
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7.5. Conclusion 
The maintenance of low pulmonary vascular tone is a balance between 
vasoconstrictors such as ET-1 and vasodilators such as ACh and hU-II (although 
species differences should be considered when looking at hU-II-induced 
vasodilatation), as observed in these studies. The presence of PHT of different 
aetiologies interferes with this balance. Successful treatments for PHT could result 
from restoring this balance by inhibiting the vasoconstrictor effect of ET -1 with a 
mixed ET~T B antagonist or stimulating the vasodilator effects of ACh, and hU-II. 
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